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Abstract 
 
The invasion and spread of cutaneous squamous cell carcinoma of the head and neck 
(CSCCHN) along nerves is an aggressive metastatic form of an otherwise treatable 
condition. Following initial perineural invasion (PNI) of a peripheral nerve, tumour cells can 
spread along cranial and spinal nerves away from the site of the primary skin cancer. 
Queensland, Australia has high recorded rates of skin cancer and this advanced form of 
the disease can be associated with poor prognosis.  
 
Skin cancer with PNI detected only on histology in an asymptomatic patient is termed 
incidental PNI. When there is spread of tumour along the nerve evidenced either clinically 
with symptoms and signs of nerve involvement and/or radiologically this is termed clinical 
PNI or perineural spread (PNS). Awareness of perineural disease amongst clinicians and 
patients is limited and analysis of the disease epidemiology and natural history is required. 
The molecular factors involved in the invasion and spread of tumour cells along nerves 
remain unknown.  
 
This thesis aimed to assess and define the epidemiology and natural history including 
treatment outcomes of CSCCHN with PNS. In addition, molecular analysis through whole 
genome expression profiling with targeted functional analysis of potentially significant 
genes was undertaken. The primary aim of this work was to contribute to the awareness 
and understanding of this disease process to improve patient management and outcomes.  
 
This thesis has described specific epidemiological features of patients with this disease. 
The important findings were that patients can present with PNS of CSCCHN without a 
known primary tumour, and that the initial primary tumour may not necessarily have had 
PNI detected. In addition, the majority of patients did not have regional nodal involvement 
at presentation. A clinical profile including common symptoms and signs and the timeline 
to diagnosis was also defined. Treatment with surgery and post-operative radiotherapy can 
offer reasonable outcomes with limited complications.  
 iv 
Genomic expression profiling demonstrated 6917 genes between CSCCHN, CSSCHN 
with incidental PNI and CSCCHN with clinical PNI that were differentially expressed. 
Analysis suggests that multiple pathways may be involved in the pathogenesis. LOXL2 
was demonstrated to be a gene of interest and was validated on immunohistochemistry. 
LOXL2 was both over-expressed and silenced through gene transfection in various 
epithelial cell lines. Functional analysis did not demonstrate any changes in the neoplastic 
properties of the cell lines with LOXL2 over-expression and silencing.  
 
This thesis has contributed significantly to the understanding of the disease process at 
both a clinical and molecular level. Several findings detailed in this body of work have not 
previously been described. This will ideally raise awareness of this rare disease and guide 
clinicians in its assessment and treatment to culminate in an improvement in patient 
outcomes.   
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Chapter 1 
Introduction 
  
1.1 Background 
Non-melanoma skin cancer (NMSC) is the most common form of cancer worldwide with 
approximately 2-3 million cases each year.1 Australia has the highest reported rates with 
almost 2% of the population affected in 2002, equating to 374,000 people.2 Squamous cell 
carcinoma (SCC) is the second most common subtype of NMSC after basal cell carcinoma 
(BCC) and accounts for approximately 20% of cases.3 Although considered a relatively 
treatable disease, NMSC claims the lives of around 560 Australians each year.4  
 
The condition generates a significant burden on the Australian healthcare system with skin 
cancer being one of the most costly cancers.5 Indeed, more hospital admissions are 
attributable to NMSC than any other form of cancer.6 Between 1997 and 2010, the number 
of annual treatment episodes provided for NMSC significantly increased from 
approximately 413,000 to over 750,000, and this likely reflects an increased incidence of 
disease that is compounded by an ageing population.5  
 
The incidence of cutaneous SCC in Australia is estimated to be 387 per 100,000 person-
years.4 It is more common in males, and the rate increases with age.7 Exposure to 
ultraviolet (UV) light is the strongest risk factor and in keeping with this, the sun-exposed 
head and neck is the most frequent site of disease.2,8 The vast majority of cutaneous 
SCCs of the head and neck (CSCCHN) are successfully treated with surgery and/or 
radiotherapy unless high-risk features associated with aggressive disease are present 
(see Table 1.1).9  
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Table 1.1. Features of non-melanoma skin cancer associated with higher risk 
of aggressive disease (adapted from Veness 2007).9 
•     Large size >2cm 
•     Deeply invasive >4-5mm 
•     Incomplete excision 
•     Recurrent disease 
•     Poor differentiated or undifferentiated 
•     Perineural invasion 
•     Location ear or lower lip 
•     Immunosuppressed patient 
 
 
Perineural invasion (PNI) is regarded as a high-risk feature of cutaneous SCC, and this 
has been accordingly recognised in the 7th edition AJCC staging system (see Table 1.2).10 
An accurate incidence of cutaneous SCC with PNI is unavailable as neither cutaneous 
SCC nor PNI are reportable diseases.11 The detection of PNI in cutaneous SCC is 
associated with more aggressive behaviour and a worse prognosis.12-20 A recent 
systematic review and meta-analysis comprising 36 studies with 17,248 patients analysed 
the risk factors for poor outcomes with cutaneous SCC.21 The presence of PNI was 
significantly associated with higher risk of recurrence (relative risk {RR} 4.30, 95% CI 2.8-
6.6, p < 0.01), metastasis (RR 2.95, 95% CI 2.31-3.75, p < 0.01) and death from disease 
(RR 4.06, 95% CI 3.10-5.32, p < 0.01). PNI is also a poor prognostic indicator in several 
other cancers including prostate, pancreas, cervix, stomach, colorectum and head and 
neck (mucosa).22-27 
 
The definition of PNI is the presence of tumour cells in the perineural space of a peripheral 
nerve.28 PNI is classified into two subtypes, incidental PNI and clinical PNI.11,19,29 PNI that 
is incidentally detected on microscopy in a tumour excised from an asymptomatic patient is 
known as incidental PNI.11 This is estimated to occur in approximately 2-6% of NMSCs 
and is the most common subtype.11 Incidental PNI is typically treated with complete 
surgical excision and consideration given to post-operative radiotherapy (PORT) when 
other high-risk features of the patient and/or primary tumour are present (see Table 
1.1).14,30-33  
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Table 1.2. 7th edition American Joint Committee on Cancer (AJCC) primary tumour (T)a 
and nodal (N) staging for cutaneous SCC 2010.10 
Designation Description Designation Description 
TX 
Primary tumour cannot be 
assessed 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
T0 No evidence of primary 
tumour 
N1 
Metastasis in a single ipsilateral lymph node, 
3cm or less in dimension 
Tis Carcinoma in situ N2 
Metastasis in a single ipsilateral lymph node, 
>3cm but not >6cm in greatest dimension, or in 
multiple ipsilateral lymph nodes, none >6cm in 
greatest dimension, or in bilateral or 
contralateral lymph nodes, none >6cm in 
greatest dimension 
T1 
Tumour 2cm or less in 
greatest dimension with 
fewer than two high-risk 
featuresb 
N2a 
Metastasis in a single ipsilateral lymph node, 
>3cm but not >6cm in greatest dimension 
T2 
Tumour >2cm in greatest 
dimension or 
Tumour any size with two 
or more high-risk 
featuresb 
N2b 
Metastasis in multiple ipsilateral lymph nodes, 
none >6cm in greatest dimension 
T3 
Tumour with invasion of 
maxilla, mandible, orbit, 
or temporal bone 
N2c 
Metastasis in bilateral or contralateral lymph 
nodes, none >6cm in greatest dimension 
T4 
Tumour with invasion of 
skeleton (axial or 
appendicular) or 
perineural invasion of 
skull base 
N3 
Metastasis in a lymph node, >6cm in greatest 
dimension 
aExcludes cutaneous SCC of the eyelid. bHigh-risk features for primary tumour: depth/invasion: >2mm 
thickness, Clark level >IV or perineural invasion; anatomic location: primary site ear, or non-hair bearing lip; 
differentiation: poorly differentiated or undifferentiated. 
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The advanced subtype of perineural disease is known as clinical PNI or perineural spread 
(PNS). This manifests with clinical, radiological and/or histological evidence of tumour 
spread along cranial or spinal nerves.29 Perineural tumour can spread along a peripheral 
nerve within the perineural space away from the initial point of invasion. The spread is 
primarily in an antegrade direction towards the brainstem, yet can also be in a retrograde 
direction towards the skin at nerve branching points.34 PNS is most commonly seen in 
middle-aged males and patients typically present with progressive symptoms and/or signs 
of nerve involvement.29,34,35 The trigeminal (V) and facial (VII) cranial nerves are the most 
commonly involved nerves, reflecting their rich innervation of the head and neck skin and 
muscles.29,34,35 When disease involves the V nerve, facial sensory disturbance is typically 
present in the distribution of one or more of the nerve divisions and this can include 
numbness, paraesthesia, burning, pain or formication (i.e. sensation of crawling ants).34 In 
cases of VII nerve involvement, either partial or complete facial paralysis is evident, which 
is dependent on the degree of spread along the nerve.34 Diagnosis and timely treatment 
can be delayed as awareness of this uncommon disease is limited, and it can be confused 
with benign pathology to have devastating prognostic implications.36,37  
 
The current understanding of the natural history of clinical PNI is that progressive central 
spread of disease along nerves occurs with invasion into the brainstem and/or 
leptomeninges via the cerebrospinal fluid (CSF) with poor prognosis.38,39 This complex 
disease necessitates multi-disciplinary management often involving large scale surgical 
resection and reconstruction and/or radiotherapy to the skin and the involved cranial nerve 
pathways.40-43 Clinical PNI is associated with a worse prognosis than incidental PNI with 5-
year disease-specific survival (DSS) for clinical PNI of 64-75% compared to incidental PNI 
of 84-91%.44,45 
 
Whilst CSCCHN with clinical PNI is rare, an accurate incidence is not available since the 
true incidence of CSCCHN is unknown. An estimation of disease frequency in reported 
series from specialised tertiary centres suggests on average between two and eight 
patients seek treatment annually in these centres.13,46 There are limitations in the available 
literature relating to clinical PNI mainly due to variable terminology and the pooling in many 
case series of tumour types (i.e. BCC and SCC), treatment approaches (i.e. surgery alone, 
radiotherapy alone and surgery and radiotherapy) and PNI subtypes (incidental and 
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clinical).12,13,45,47-49 This has led to outcome data with limited application and inherent 
difficulties in defining management guidelines.  
 
Further characterisation of the epidemiological features and treatment outcomes using 
clearly defined patient groups is needed. This will define the disease natural history, 
increase awareness and guide optimal management. This may also provide insight into 
the disease mechanism which is currently unclear. The molecular factors involved in the 
initial invasion of tumour cells into nerves are unknown and the reason why some tumours 
spread aggressively along nerves to distant locations is uncertain. It remains to be 
elucidated whether incidental PNI and clinical PNI are on a disease spectrum with gradual 
progression of disease along nerves, or whether advanced spread reflects innate 
aggressive tumour biology. Analysis of the genetic factors involved is required as they 
have not been defined, and no biomarkers for disease development or progression have 
yet been identified. Investigation of these epidemiological and molecular factors will ideally 
facilitate an improvement in patient outcomes from a disease that can have devastating 
consequences.   
 
1.2 The peripheral nerve  
The human nervous system is divided into the central nervous system (CNS, brain and 
brainstem) and the peripheral nervous system. The peripheral nervous system consists of 
ganglia and peripheral nerves. Peripheral nerves are the communication between the CNS 
and the limbs and organs. They contain afferent (sensory) and/or efferent (motor) 
myelinated or non-myelinated axons with their cell bodies residing in either the ganglia or 
CNS.50 Ganglia are made up of peripheral collections of sensory or autonomic neuronal 
cell bodies with axons and stroma.50 Eleven of the twelve cranial nerves are considered 
part of the peripheral nervous system. The optic nerve is recognised as part of the CNS. 
Unlike the other peripheral nerves, all ganglia of the cranial nerves reside in the CNS.  
 
The major components of the peripheral nerve are axons (arranged in bundles), Schwann 
cells, blood vessels and fibroblasts.51 These are contained by the peripheral nerve sheath, 
which is composed of three distinct layers (see Figure 1.1). The inner layer is the 
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endoneurium, a loose extracellular matrix of connective tissue that envelopes axons, 
Schwann cells and endoneurial capillaries. The perineurium is the middle layer and it binds 
groups of axons within endoneurium to form a nerve fascicle. It is comprised of multi-
lamellar, concentric layers of tightly-packed perineural cells surrounded by layers of 
basement membrane.52,53 The perineural space is a potential space beneath or between 
the layers of perineurium. It contains extracellular matrix, collagen and fibroblasts, and is 
approximately 100 to 300 x 10-8 cm wide.53 The epineurium is the outer layer and it binds 
multiple fascicles together with fibro-collagenous connective tissue to form the cord-like 
structure of the peripheral nerve. Supporting epineurial capillaries and adipose tissue 
(peri-neural fat) are also contained within this layer.53  
 
 
Figure 1.1. Normal cranial nerve histology. Transverse section of normal cranial nerve 
demonstrating the three layers of the peripheral nerve: epineurium (solid arrow); 
perineurium (broken arrow); and endoneurium (arrow head). Image from unpublished data 
(H&E x10).  
 
The perineurium has highly selective and limited permeability.53 It functions as the major 
component of the blood-nerve barrier (BNB) to contain nerve fibres and protect them from 
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the surrounding environment.52,54 The tight junctions between cells known as ‘zonulae 
occludentes’ (formed by the proteins ZO-1, occludin and claudin), are a major constituent 
of this barrier.55 The perineurium prevents the diffusion and central transmission of 
infectious, inflammatory and toxic substances.53,54,56 It regulates nerve fascicle 
homeostasis of both pressure and content via the perineural cells.53,55 The basement 
membrane in conjunction with the zona occludentes form a structural diffusion barrier, 
necessitating active transport of molecules across perineural cells by transcytosis.53,56,57 
On immunohistochemistry, perineural cells are not reactive to S-100, CD57 or 
neurofilament stains.53 However, S-100 staining is positive in axons and Schwann cells 
and is thus useful in detecting neural tissue.53 
 
The perineural space does not contain lymphatic vessels, with the only local lymphatic 
vessels residing external to the epineurium.52,58,59 In addition, no capillaries are free in the 
perineurium or the perineural space.54,55 In order to supply nerve fascicles yet maintain 
barrier integrity, epineurial capillaries wrapped in a sleeve of perineural cells traverse the 
perineurium and ramify inwards to supply the endoneurium and nerve fibres.54,55 The 
endothelial cells of endoneurial capillaries also have tight junctions to supplement the 
BNB, however it is at these sites that the perineurium is necessarily absent.60 
 
Areas where the perineurium is absent denote areas where the BNB is limited and the 
nerve fascicle is therefore at risk from the external environment. These include: (i) distal 
nerve endings; and (ii) where epineurial capillaries feed endoneurial capillaries after 
traversing the perineurium.53 Indeed, animal models of Mycobacterium leprae infection 
suggest that infection spreads from epineurial to endoneurial capillaries with perineural 
thickening and inflammation, leading to Schwann cell involvement, demyelination and 
axonal degeneration.61,62 
 
The perineurium of a peripheral nerve blends with the pia-arachnoid meningeal layer (the 
commencement of the CNS) and the perineural space becomes continuous with the 
subarachnoid space.53,55 At the peripheral skin, the perineurium gradually thins to become 
sparse and single-layered at the level of the dermis.54 At the distal end of the nerve, the 
perineurium either fuses to be a component of terminal endings of sensory nerves 
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(Pacinian corpuscles, muscle spindles) or forms funnel-like openings at the end-plates of 
motor nerves.53,55 Therefore, the perineurium can be regarded as an open-ended tubular 
structure, creating a potential channel or conduit between the periphery and the CNS. 
 
1.3 Cutaneous squamous cell carcinoma 
1.3.1 Clinical and pathological features 
Cutaneous SCCs predominantly occur in Caucasian populations over the age of 50 and 
are more common in males.63 The majority occur on the head and neck and there are 
often multiple synchronous lesions present.2,63 The true incidence is unclear due to 
cutaneous SCC not currently being a reportable disease.2 A summary of the known 
epidemiological risk factors for SCC is detailed in Figure 1.2.7 UV exposure and fair-skin 
are the strongest risk factors.7  
 
Figure 1.2. Epidemiological risk factors for the development of cutaneous squamous cell 
carcinoma. Taken from Green & Olsen 2017.7   
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The reported high incidence of SCC in Australia is likely the product of both patient and 
environmental factors.2 These include an ageing population, high proportion of fair-skinned 
individuals and habitation in regions with high UV radiation exposure levels.7 In addition, 
human behaviour is recognised as playing an important role, with the recreational pursuit 
of a ‘sun-tan’ (through either direct sun exposure or tanning beds) being the subject of 
preventative campaigns such as SunSmart and ‘Slip!Slop! Slap!’.64,65 Evidence suggests 
that the incidence rates in those aged below 50 years are declining, possibly reflective of 
the uptake of the safe practices championed by these campaigns.65-69 This decline may 
also be related to demographic changes, with increased migration of people with dark skin 
colour associated with lower risk profile to Australia.66 
 
Cutaneous SCC is currently staged according to the 7th edition AJCC staging system (see 
Table 1.2 for tumour and nodal staging).10 It is recognised as the most common cancer 
possessing metastatic potential, with a nodal metastasis rate of approximately 3% and an 
overall risk of death from disease of approximately 2%.20,70,71 A recent systematic review 
and meta-analysis of 36 retrospective and prospective cohort studies with 17,248 patients 
by Thompson et al. assessed the risk factors for worse outcomes with cutaneous SCC.21 
The primary tumour features associated with worse outcomes are summarised in Figure 
1.3.21 The major high-risk features included tumour diameter > 2 cm, poor differentiation, 
depth of invasion > 6 mm and incidental PNI.21 The presence of these features was 
associated with increased risk of recurrence, regional metastasis and/or death from 
disease, as detailed in Figure 1.3. The impact of PNI is discussed further in section 
1.4.1.5.  
 
SCCs typically present as a firm, shallow, irregular ulcer with an elevated border and 
hyperkeratosis or scale.72 They can also present as raised, erythematous, non-ulcerating 
nodules.72 They are most commonly managed with surgical excision, yet other treatments 
can include curettage/cautery, photodynamic therapy, cryotherapy and radiotherapy.74 
Treatment is necessary due to the risk of local invasion, metastasis to regional lymph 
nodes and distant organs and death from disease.15,21,73-75 
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Figure 1.3. Summary of the identified high-risk features of cutaneous SCC on systematic 
review and meta-analysis associated with recurrence, metastasis and disease-specific 
death (taken from Thompson et al. 2016).21  
 
Invasive SCC is recognised microscopically by the invasion of tumour cells through the 
basement membrane.3 The degree of tumour cell differentiation is used to histologically 
grade SCCs. Broder’s grading scheme (Grade I-IV) was the traditional method used, 
however many pathologists today apply an adapted and relatively subjective grading: well, 
moderate, poor or un-differentiated.72,76 Microscopically, a ‘well-differentiated’ SCC is 
composed of lobular nests of polygonal cells with abundant cytoplasm, copious 
keratinisation and horn pearl formation that extends towards the dermis. Poorly-
differentiated SCCs are characterised by atypical or anaplastic nuclei, high nuclear to 
cytoplasmic ratio, areas of necrosis and sparse keratinisation.3 The use of haematoxylin 
and eosin (H&E) and cytokeratin immunohistochemistry (such as AE1/AE3) assist in the 
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histological diagnosis and assessment of SCC.63 There are multiple subtypes of SCC with 
varying histological features and prognostic implications.77  
 
Cutaneous SCC develops from keratinocytes in the spinous layer of the epidermis.78 
Actinic keratosis (AK) can be a precursor lesion to SCC and is characterised by dysplastic 
keratinocytes with atypical nuclei.72 It has been estimated that the rate of SCC 
development from AK may be between 0% and 0.075% per lesion per year, and higher in 
patients with prior history of NMSC at 0.53%.79 Overall, the presence of AKs is recognised 
as a strong predictor of local SCC development.7 Carcinoma in situ (Bowen’s disease) is 
also associated with a risk of progression to invasive SCC and is characterised 
microscopically by the presence of tumour cells that have not invaded through the 
basement membrane of the dermo-epidermal junction.72  
 
1.3.2 Molecular mechanisms of SCC 
SCC tumourigenesis is likely a multistep process. UV radiation exposure is the most 
significant underlying epidemiological cause of SCC development.8,80,81 In general, the 
initial genetic mutations triggered by UV exposure are followed by further driver gene 
mutations that lead to genomic instability and the loss of cell cycle control to result in 
tumourigenesis. 78,82,83 The tumour microenvironment may play a significant role in the 
pathogenesis and progression of disease yet this remains to be defined.83  
 
1.3.2.1 UV exposure and mutation effects 
UV exposure is known to play a significant role in SCC tumourigenesis.7 UV-B radiation is 
the major subtype responsible and has been shown to cause mutations in genes such as 
the tumour suppressor gene TP53 (encoding p53 protein) and the cell cycle control gene 
CDKN2A (encoding the p16INK4a and p14arf proteins).84,85 This may be through the 
generation of photoproducts with base substitution mutations and DNA damage.84 A base 
substitution mutation from CC to TT is the most commonly described mutation signature 
brought about by UV-B exposure.84 UV-A has also been implicated possibly through 
oxidative DNA damage.86 UV radiation exposure in general is also thought to induce 
cutaneous immune dysfunction at the level of the skin, impairing innate immune responses 
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to DNA damage.8,84,86,87 Enhancing these properties is the loss of the stratospheric ozone 
layer and it’s natural protective barrier function in certain regions of the world, resulting in 
higher UV radiation levels at the earth’s surface.88 
 
1.3.2.2 Genetic factors 
There are several genetic factors and pathways that are consistently implicated in 
cutaneous SCC tumourigenesis. These include the p53 pathway, CDKN2A gene, NOTCH 
signalling, WNT/β-catenin signalling and RAS oncogene (particularly HRAS).78,85,89-91 
Following an initial UV-induced gene mutation, further mutations in driver genes encoding 
p53, NOTCH1 and NOTCH2, HRAS, epidermal growth factor receptor (EGFR, a receptor 
tyrosine kinase)  and Fyn (a proto-oncogene tyrosine kinase) may be triggered, which 
induce the development of oncogenic properties to culminate in tumourigenesis.78,92 
Exome level sequencing has recently shown cutaneous SCCs harbour a large number of 
mutations in these driver genes, more than many other cancers (including breast and 
lung), and this implies multistep complex processes are occurring in SCC 
development.85,89 Interestingly, many of the same mutations have also been demonstrated 
in non-malignant, sun-exposed skin which likely reflects a field cancerisation effect from 
UV exposure.93-95 This high background mutation rate adds to the challenges in identifying 
the driver mutations responsible for tumourigenesis.85,93  
 
The p53 protein normally functions as a cell cycle regulator that initiates DNA repair and 
apoptosis when required to preserve genomic stability.80 Over 50% of SCCs demonstrate 
p53 mutations that are the result of UV-B radiation exposure.78,93 CDKN2A is involved in 
cell cycle regulation through retinoblastoma and p53 pathways and inactivating mutations 
or deletions in this gene may be involved in SCC tumourigenesis.83,85,91 NOTCH signalling 
is involved in cellular differentiation, proliferation and survival. Loss of function mutations in 
NOTCH1 have been demonstrated in up to 82% of cutaneous SCCs.85,89 Activation of 
EGFR and Fyn is known to down-regulate p53, and this has been observed in cutaneous 
SCC with downregulation of p53 mRNA.78 
 
WNT/β-catenin signalling has been shown to be involved in BCC development, and a role 
in SCC tumourigenesis could also exist.90 Gene expression arrays of cutaneous SCC 
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samples have shown increased WNT ligands and receptor mRNA.96,97 Ra et al. identified 
WNT/β-catenin signalling as the most significantly altered pathway in their small 
microarray dataset which compared SCC (six specimens) to normal skin (five 
specimens).96 Integrin signalling and p53 were also shown to be significantly deregulated 
in this dataset, again lending weight to a multistep, multifactorial process being 
responsible.96 
 
Activating mutations of the RAS proto-oncogene which induces the RAF/MEK/ERK1/ERK2 
kinase pathway via receptor tyrosine kinases, have also been identified in cutaneous 
SCC.85,98,99 This can lead to the acquisition of neoplastic properties including cell 
proliferation, angiogenesis and inhibition of differentiation.98 Approximately 15-30% of 
patients treated with type I BRAF inhibitors (such as vemurafenib) develop cutaneous 
SCCs and keratoacanthomas, and mutations in the RAS oncogene (particularly HRAS) 
with aberrant activation of the MAPK pathway has been proposed as a possible 
mechanism.99 
 
1.3.2.3 Tumour microenvironment factors 
The tumour microenvironment appears to play a role in other cancers, and its role in SCC 
development remains to be elucidated.92,100 This compartment facilitates complex 
signalling pathways between activated cancer-associated fibroblasts (CAFs), infiltrating 
immune cells (lymphocytes, macrophages) and their products (cytokines), adhesion 
molecules and other stromal components such as connective tissue, nerves and blood 
vessels.92,100-102 The tumour microenvironment may play a role in the pathogenesis of 
tumour metastasis and possibly also PNI (discussed below in section 1.4.2.4).92 In 
neuroblastoma it has been shown that a higher density of stromal CAFs and tumour-
associated macrophages was associated with a more aggressive phenotype, and that in 
vitro interaction between these cell types had a stimulatory effect on neuroblastoma cell 
lines.103 CAFs have been shown to promote prostate cancer and head and neck SCC cell 
line invasion and growth, possibly via remodelling of the ECM.100 This may also require 
coordination with local proteases such as matrix metalloproteinases (MMPs), which have 
also been associated with progression of cutaneous SCC.92,100,104  
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1.3.2.4 Immunosuppression and SCC 
Immunosuppressed patients, particularly organ transplant recipients, are at a 65 to 250-
fold increased risk of cutaneous SCC than the immunocompetent population and the 
incidence increases with the duration of treatment.7,105,106 SCC is the most common 
malignancy in organ transplant recipients and is also more aggressive in this population.107 
Rates of regional metastasis are estimated to be between 5-8% with reported 3-year DSS 
of approximately 56%.108 The influence of immunosuppression on the risk of developing 
PNI remains unclear. Patients with HIV/AIDS, chronic lymphocytic leukaemia and non-
Hodgkin lymphoma are also at an increased risk of SCC.7 Whilst the process remains 
incompletely understood, this is possibly a product of the lack of immune surveillance and 
host response to initial keratinocyte DNA damage.107 Given the observed prevalence of 
certain viruses in immunosuppressed patients (such as the β genus of human papilloma 
virus, β-HPV), it has been theorised that viral-induced DNA damage may enhance or even 
trigger this process.7,109 However, the evidence for this is limited with HPV DNA in SCC not 
being consistently present.7,109 In addition, the pharmacological agents required for 
maintaining immune suppression in organ transplant recipients can predispose to tumour 
formation.107,110 For example, cyclosporine may have p53-inhibiting properties.110  
 
1.4 Perineural invasion 
1.4.1 Epidemiological features 
1.4.1.1 Definition 
There is variability in the definition of PNI in the literature.28,111,112 In 1835, Cruveilhier used 
the term ‘neurotropism’ to describe a tumour’s propensity to invade neural tissue.112 With 
specific regard to mucosal head and neck tumours, Batsakis described ‘neurotropism’ as 
the invasion of tumour “in, around and through peripheral nerves”.111 This definition 
included spread along any of the three peripheral nerve layers and/or “within lymphatics of 
the epineurium and perineural sheaths”, despite acknowledging the absence of lymphatics 
in the perineurium.111 
 
More recently, Liebig et al. defined PNI as “tumour in close proximity to nerve and 
involving at least 33% of its circumference or tumour cells within any of the three layers of 
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the nerve sheath”.112 However, the perineurium has highly effective barrier 
properties.35,52,53 In a histopathological study of 51 clinical PNI cranial nerve specimens, 
Panizza et al. demonstrated that the perineurium was an effective, multi-layered barrier to 
spread and contained tumour beneath the perineurium. Tumour spread into the 
epineurium only occurred in 5.9% of specimens near the skull base and in 3.9% at the 
skull base.35 The rate of epineural spread (which was only seen with concomitant 
perineural spread) was higher in the periphery (43%) near the skin where the perineurium 
is thin and single layered. Although supporting data is lacking in CSCCHN with PNI, 
tumour that abuts or encompasses a nerve (i.e. outside the perineurium) may not have the 
same phenotype or prognostic implications as tumour that has invaded into the 
perineurium or endoneurium. In addition, the spread of tumour along the perineural space 
would not be possible without initial PNI into the perineural space. However, in certain 
difficult cases where the peripheral nerve layers are less well-defined, tumour involving at 
least 33% of the circumference has been regarded as supportive of a PNI diagnosis.28,113 
An accurate definition can guide precise disease recognition as the presence of PNI has 
treatment and prognostic implications.29,34 The definition of PNI used in this thesis is based 
on the histopathological features: the presence of tumour cells in the perineural space of a 
peripheral nerve, either beneath or between the layers of perineurium, with or without 
invasion into the endoneurium.28,114 
 
1.4.1.2 Classification 
PNI is currently classified into two subgroups which have differing management and 
prognosis. ‘Incidental PNI’ describes the detection of PNI in an asymptomatic patient on 
histopathology of a CSCCHN.11,30 ‘Clinical PNI’ describes a clinically evident neurological 
deficit in the distribution of a nerve involved with perineural tumour, radiologically 
detectable perineural tumour and/or histological evidence of perineural involvement of a 
cranial or spinal nerve.29,45 Clinical PNI is synonymous with PNS, representing spread or 
metastasis of perineural tumour along the perineural space to a distant location. Clinical 
PNI carries a worse prognosis than incidental PNI, with reduced recurrence-free survival 
(RFS, 59-62% vs 72-78%) and DSS at 5-years (64-75% vs 84-91%).44  
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The use of a consistent, simplified PNI classification (comprising incidental PNI and clinical 
PNI) is important to enable the ongoing generation of relevant and applicable data to guide 
evidence-based clinical practice. Various terms have previously been used throughout the 
literature to classify PNI. These include ‘named or un-named nerve PNI’,115,116 
‘microscopic, macroscopic or extensive PNI’,14,28,49,117 and ‘large nerve or small nerve 
PNI’.29,118 A standardised PNI definition and classification using incidental and clinical PNI 
has been adopted in more recent studies.11,44,46,119,120  
 
1.4.1.3 Natural history 
Knowledge of the natural history of PNI is limited largely because the disease is rare and 
detailed published series using clearly defined patient cohorts are lacking. The known 
epidemiological features of the disease have largely been determined by case series from 
regions with a high incidence of NMSC such as Queensland (Australia) and Texas and 
Florida (United States).12,15,29,34,45,46 Middle-aged males are the most common patient 
group affected by PNI.15,34,45,121,122 The features of a CSCCHN that are associated with 
PNI being present include large size (> 2 cm), location on the cheek or mid-face, recurrent 
tumour and poor differentiation.15,122-124 PNI is also known to be more common and 
aggressive in SCC than BCC.32,47  
 
Incidental PNI and clinical PNI may exist within a spectrum of disease. Following initial 
PNI, tumour may spread along the perineural space in a plane of relative low resistance, 
with progressive symptoms and signs in the patient.53 Tumour spread appears to be 
predominantly in an antegrade direction towards the brainstem, yet can also be in a 
retrograde direction towards the skin.34,35 Retrograde spread is believed to occur at nerve 
branching points and can manifest as dermal nodules in the skin.29,35 At the end of the 
disease spectrum is central failure, representing perineural disease that has invaded the 
brain, brainstem or leptomeninges.39 Leptomeningeal carcinomatosis is a rare form of 
central failure characterised by spread into the subarachnoid space with disease 
dissemination throughout the leptomeninges via the CSF.39 Treatment options for central 
failure are generally limited to palliative chemotherapy or radiotherapy.39 
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Although data on natural history and disease timelines are limited, progressive symptoms 
and signs have been documented to occur over a variable period with one series of 4 
clinical PNI patients demonstrating a range of 5 months to 3 years.36 The V and VII cranial 
nerves are the most commonly involved nerves.29,34,35,117 In a series of 65 patients with 
clinical PNI, Balamucki et al. demonstrated that the most commonly involved nerve was 
the maxillary division of the trigeminal nerve (V2; 55%) followed by the ophthalmic division 
of the trigeminal nerve (V1; 22%), VII nerve (18%) and the mandibular division of the 
trigeminal nerve (V3; 6%).117 In a histopathological study of 51 specimens from 49 patients, 
Panizza et al. demonstrated that V2 was involved in 55% of patients, V1 29%, V3 27.3% 
and VII 24.5% with 7 patients having involvement of more than one nerve.35 
 
The rate of regional nodal metastases at presentation in patients with clinical PNI appears 
to be low, with reported rates between 0% and 16%.13,125,126 In addition, the reported rate 
of distant metastases at presentation is also low between 0.08% and 0.5%.44,126 This could 
reflect differing tumour biology in clinical PNI cases with a predilection for spread down 
nerves rather than lymphatic or haematogenous spread.18,127 
 
1.4.1.4 Diagnosis 
1.4.1.4.1 Clinical features 
Incidental PNI is diagnosed on histopathology of a skin lesion excised from an 
asymptomatic patient. These patients may have had a prior history of skin cancer, or a 
history of multiple previous treatments to a recurrent cancer.122 Clinical PNI patients 
typically present with progressive symptoms and/or signs of nerve dysfunction depending 
on the particular nerve involved by tumour.29 Nerve dysfunction likely reflects segmental 
axonal degeneration due to invasion or nerve compression by tumour at skull base 
foramina.128 
 
The symptoms and signs of clinical PNI can be present for many years and the diagnostic 
clues overlooked or misinterpreted.34,36,129 Mohs described skin cancers exhibiting “silent 
extensions”, with the time to patient presentation with clinical PNI varying markedly from 
weeks to several years.127 This characteristic can often be compounded by the 
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misinterpretation of PNI clinical features as benign conditions such as trigeminal neuralgia 
or Bell’s palsy resulting in critical delays in diagnosis.36,130 Bell’s palsy is an idiopathic 
condition that typically presents with a sudden onset unilateral complete facial paralysis, 
and patients may also report post-auricular pain, taste disturbance and hyperacusis.130 
Trigeminal neuralgia is trigeminal nerve distribution neuropathic pain and is a diagnosis of 
exclusion, necessitating imaging evaluation to exclude PNS or other pathology.131  
 
In addition, patients with clinical PNI can present many years after treatment for a skin 
cancer.129 Evidence of the primary tumour may be absent and the diagnosis of clinical PNI 
from CSCCHN made following biopsy of involved cranial nerve. Accurate diagnosis 
therefore requires a high index of suspicion in all clinicians, particularly surgeons, 
radiologists and histopathologists.35-37 
 
The V and VII cranial nerves are the most frequently involved, and they can be involved 
simultaneously.34,35 Features of V nerve involvement can include burning, pain, 
paraesthesia, formication and/or numbness.48,126,129 This may be at the site of the primary 
tumour or in the distribution of an involved nerve.29 The affected area progresses from 
being localised to involve the dermatomal distribution of one of the V nerve divisions (V1, 
V2 or V3).29 The affected area then spreads over time to include other V nerve divisions, 
reflecting antegrade invasion into the Gasserian ganglion with or without retrograde 
spread down other divisions.35 This progression of disease helps to differentiate clinical 
PNI from trigeminal neuralgia which is typically not progressive. Also, a local 
subcutaneous mass or nodule may be concurrently present, and can facilitate diagnosis 
through biopsy.29 It is also important to differentiate local numbness caused by previous 
surgical excision and numbness caused by tumour that is present preoperatively.  
 
In cases of VII nerve involvement, partial facial paralysis in the distribution of one of the VII 
nerve branches may initially be evident.29 As disease slowly spreads antegrade to the 
stylomastoid foramen, there is progressive development of a unilateral complete facial 
paralysis.29 This helps to distinguish clinical PNI from Bell’s Palsy, which typically presents 
with a sudden onset complete facial palsy.129,130 In addition, clinical PNI involving the VII 
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nerve should also be differentiated from external nerve compression by tumour anywhere 
along the VII nerve pathway. 
 
1.4.1.4.2 Radiological features 
Patients with symptoms and/or signs of cranial nerve dysfunction should be further 
evaluated with diagnostic imaging. Targeted high-resolution magnetic resonance imaging 
(MRI) neurography has been demonstrated to be a highly effective tool in the 
management of PNS.118 MRI is preferred over computed tomography (CT) due to 
improved soft tissue differentiation.132 To further improve image resolution, MRI with 
neurography protocol utilises a small field of view, thin slices and a high-resolution matrix 
with targeted imaging along cranial nerve pathways over a short acquisition time.118,133 
PNS on MRI neurography is typically characterised by contiguous asymmetrical thickening 
and/or enhancement of involved nerve(s), obliteration of neural foramina fat pads and/or 
erosion/enlargement of skull base foramina.29,118,134 These changes may also be evident in 
the pterygopalatine or infratemporal fossae, cavernous sinus or Meckel’s cave depending 
on the extent of disease.132 Secondary denervation changes in the muscles of facial 
expression and mastication may also be seen.118 
 
The zonal classification system was devised by Williams et al. to grade the extent of PNS 
on imaging and can guide treatment approaches and strategies (see Table 1.3).135 The 
zonal extent has been shown to correlate with survival in a case series of 120 patients with 
PNS of CSCCHN.46 5-year DSS for zone 1 patients was 84%, zone 2 patients 63% and 
zone 3 patients 16% (p < 0.0001).46 This series comprised patients treated with either 
surgery and PORT, surgery alone, radiotherapy alone, chemoradiotherapy or palliation.46 
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Table 1.3. The zonal classification of perineural spread of malignancy in the head and 
neck (adapted from Williams et al. and Gandhi et al).118,135 
Zone Disease extent 
Zone 1 
V1 (ophthalmic nerve) to the superior orbital fissure 
V2 (infraorbital nerve) to the external aperture of the foramen rotundum 
V3 (mandibular nerve) to the external aperture of the foramen ovale 
VII (facial nerve) to the external aperture of the stylomastoid foramen 
Zone 2 
V1, V2, V3: from Zone 1 to the Gasserian ganglion cistern 
VII: from Zone 1 up to the lateral end of the internal auditory canal, including the 
Geniculate ganglion and the labyrinthine segment 
Zone 3 All nerves: proximal to the ganglion, into the cisterns, or into the brain stem 
 
 
MRI neurography is useful for both diagnosis and treatment planning.29,118 It has been 
shown to accurately detect and assess the extent of PNS in the majority of cases.118 Using 
1.5-Tesla (1.5T) MRI neurography, Gandhi et al. correlated the disease extent on imaging 
with the pathological extent in 25 patients undergoing curative surgical resection for PNS 
of tumour (22 patients SCC, 1 BCC, 1 melanoma, 1 adenocarcinoma). The sensitivity of 
MRI neurography detection was 100%, and the anatomic extent was accurately 
determined in 83.3%. MRI neurography is preferably undertaken using a 3T platform which 
possesses a more powerful magnet system and improved image resolution than a 1.5T 
platform.118 The effectiveness of 3T MRI neurography was assessed in a series of 33 
patients treated with surgery for PNS of various pathologies (SCC, melanoma, adenoid 
cystic carcinoma and salivary gland tumour).133 In this study, the extent of disease in 57 
nerves resected from 33 patients on histopathology was compared to the extent on 
imaging to assess definition and accuracy of 3T MRI neurography. The sensitivity and 
specificity was 95% and 84% respectively. The zonal extent of disease was correctly 
identified on imaging when correlated with histopathology in 89%.133  
 
Other studies have also confirmed the high sensitivity of MRI for detecting PNS. Nemzek 
et al. demonstrated a sensitivity of 95% with MRI in PNS from head and neck malignancy 
in 19 patients.136 Hanna et al. demonstrated a sensitivity of 100% and specificity of 85% 
using MRI in the assessment of 38 specimens of PNS from adenoid cystic carcinoma.137 In 
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a recent series of 50 patients with PNS from CSCCHN treated with surgery, 100% of 
patients with trigeminal symptoms confirmed as PNS on histopathology had pre-operative 
positive imaging (43 patients; see section 2.3.4.2).120  
 
Possible causes for negative findings on imaging of PNS patients include low-volume early 
disease and previous surgery or radiotherapy.120 For example, MRI neurography failed to 
detect PNS in a patient with a partial facial palsy due to involvement of a 0.5 mm VII nerve 
branch in an irradiated parotid bed.120 In addition, the use of suboptimal imaging 
approaches with either CT or unfocussed whole brain MRI can hinder detection.118 The 
specificity of MRI neurography for perineural disease is not as strong as the sensitivity.118 
Differentials to be considered include infection (invasive fungal sinusitis, viral neuritis), 
inflammation (sarcoidosis), benign neoplasms (meningioma) and other malignancies 
(salivary gland, lymphoma, BCC, and melanoma).118,131,138 In addition, imaging-positive 
disease in an asymptomatic patient is considered rare as patients generally present with 
slowly progressive symptoms and signs prior to imaging.13,48  
 
CT can detect PNS through the identification of bony changes such as skull base foramen 
erosion or expansion by tumour.49,118,136 CT is not as useful as MRI for assessing PNS, 
with demonstrated sensitivity of up to 85%.137 However, it can be used in patients with MRI 
contraindications or to stage regional lymph nodes.131 It is recommended that in cases 
where the diagnosis following imaging is inconclusive, nerve sampling be undertaken 
through either surgical excisional biopsy or radiologically-guided biopsy prior to embarking 
on large scale surgery or radiotherapy in order to prevent inappropriate treatment.29 
 
1.4.1.4.3 Pathological features 
The detection of PNI on histopathology can be difficult.37 Microscopic disease can be 
overlooked unless a high degree of suspicion is applied with careful histological 
processing.37,113 NMSCs with high-risk features detailed in Table 1.1 and Figure 1.3 should 
raise the index of suspicion in the treating clinician that PNI could also be present.139 Male 
gender, tumour size > 2 cm and recurrent tumour are features that have been 
demonstrated to be associated with PNI being present.122,124,139,140  
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Tumour cells identified beneath or between the perineurium with or without intraneural 
invasion (tumour cells in the endoneurium) constitutes a pathological diagnosis of PNI (see 
Figure 1.4).113 Involvement of at least 33% of the circumference may be supportive in 
cases where the diagnosis is uncertain, particularly in low quality specimens.112,113 Stains 
commonly used for the detection of PNI include haematoxylin and eosin (H&E), and 
markers for broad spectrum cytokeratin (AE1/AE3, MNF116) and neural tissue (S100).49 
Microscopically, PNI is recognised as the presence of tumour cells within the multiple 
layers of the perineurium creating an onion-skin effect.113 The intensity of inflammation 
associated with perineural tumour varies and can be florid with germinal centre 
formation.35,101,113 The underlying significance of this is uncertain. Mimics of PNI on 
pathology include peri-tumoural fibrosis, re-excision PNI, reparative perineural infiltration 
or epithelial sheath neuroma and should be excluded.141,142  
 
 
Figure 1.4. Perineural spread of cutaneous SCC within cranial nerve (H&E x 100). 
Epineurium (arrow) contains multiple lymphoid cells with germinal centres. Perineural SCC 
(broken arrow) between the multiple layers of the perineurium giving an ‘onion skin’ 
appearance. Intraneural invasion into the endoneurium is also present (arrowhead). Image 
from unpublished data. 
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There are currently no standardised histopathological reporting schemes for PNI. The 
assessment of incidental PNI typically includes the maximum nerve diameter involved, yet 
quantification of the number of nerves, nerve proximity to tumour and resection margin 
may be important yet data is lacking.11 A nerve diameter ≥ 0.1 mm has been shown to be 
associated with more aggressive disease and this is discussed further in section 
1.4.1.5.116,139 
 
Routine two-dimensional histological sections may not detect PNI in a given specimen due 
to the three-dimensional structure of tumour within a nerve.143 For example, the course of 
small VII nerve branches within the parotid gland may not be appreciated in two-
dimensional sections. PNI could involve either: (i) only small nerve twig(s); (ii) only one 
fascicle; or (iii) only a fraction of the fascicles. Involved fascicles can have differing 
degrees of axial extension along the perineural space or non-circumferential disease in the 
transverse plane.35,113,143 This is particularly important in Mohs micrographic surgery 
(MMS) which excises tumours by gradual uniplanar horizontal sections guided by regular 
microscopic assessment. This can however lead to disease being missed or the false 
impression of a skip in tumour growth on a particular section (see Figure 1.5).143 
 
 
Figure 1.5. Histological processing artefact as a cause of skip lesions. Certain sections 
could result in the misleading appearance of a skip in tumour growth. Diagram taken from 
Matorin & Wagner 1992.143 
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A skip lesion is the theory of a segment of perineural tumour with an intervening segment 
of disease-free nerve, suggesting a ‘skip’ in tumour growth.35 Warren et al. hypothesised 
that prostate cancer metastasis to vertebrae could be due to embolic metastasis in 
“perineural lymphatics”.144 Rodin et al. also noted the possibility of skip areas based on the 
premise that perineural lymphatics were the conduit of perineural tumour, yet then 
demonstrated that the perineural lymphatics do not exist.58 In 1982 Cottel provided 
anecdotal evidence of apparent skip areas of perineural tumour in MMS cases, which 
necessitated tracing of the nerve for further evidence of disease.145 Many studies that 
report skip lesions are earlier case series treated by MMS.145-150 Matorin acknowledged 
the specific limitations of MMS to assess PNI due to technical processing and surgical 
access difficulties, and this is especially pertinent in cases of clinical PNI.143 The existence 
of perineural space lymphatics has been discounted, and the skip lesion has never been 
proven histologically and most likely reflects artefact from histological processing 35,59,143 
 
Panizza et al. assessed the histopathological features of 51 specimens of cranial nerve 
involved with perineural spread from 49 patients.35 In all cases, tumour spread was 
contiguous and no skip lesions were identified. The perineurium was an excellent barrier to 
spread, with low rates of disease spread beyond the perineurium into the epineurium.35 
With the use of longitudinal and/or perpendicular sectioning with appropriate staining, PNI 
can be more accurately identified and assessed.37  
 
1.4.1.5 Prognostic significance of PNI & staging 
There is convincing evidence available for the negative effect of PNI on patient outcomes 
such as local recurrence, nodal metastasis and death from disease.21 Incidental PNI was 
assessed in a recent systematic review of 36 studies with 17,248 patients by Thompson et 
al. and the findings are summarised in Figure 1.3.21 The presence of incidental PNI in a 
cutaneous SCC was strongly associated with worse outcomes through a higher risk of 
recurrence (relative risk RR, 4.30 95% CI 2.8-6.6, p < 0.01), metastasis (RR of 2.95, CI 
2.31-3.75, p < 0.01) and death from disease (RR 4.06, 95% CI 3.10-5.32, p < 0.01).21 
 
In a cohort study of 1832 cutaneous SCCs comparing PNI-negative (95.7%) and PNI-
positive (4.3%) specimens, Schmults et al. demonstrated that the presence of PNI carried 
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a significantly higher risk of local recurrence (subhazard ratio {SHR} 3.2, 95% CI 1.5-7.0, p 
= 0.004) and death from disease (SHR 3.6, 95% CI 1.1-12.0, p = 0.03).20 In a prospective 
study involving 210 patients with cutaneous SCC (87% located in the head and neck), 
Clayman et al. demonstrated a rate of incidental PNI of 14%.17 This series contained 
patients with seemingly complex disease since 21% of patients underwent a neck 
dissection and 29% required soft tissue or craniofacial reconstruction. The presence of 
PNI was associated with significantly worse DSS at 3 years compared to no PNI (64% vs 
91%, respectively, p = 0.002).17 Kyrigidis et al. reviewed 315 patients with CSCCHN and 
noted that PNI was present in almost 20% of cases.151 On comparing the outcomes of 
PNI-positive cases and PNI-negative cases, reduced 5-year overall survival (OS, 45% vs 
76%, p < 0.001; odds ratio, OR 2.0, 95% CI 1.1-3.8, p < 0.046) and RFS (26% vs 82%, p < 
0.001; OR 3.3, 95% CI 1.5-7.4, p = 0.004) was noted on multivariate analysis.151 
 
In regards to nodal metastasis and incidental PNI, a retrospective series of 193 patients 
with CSCCHN demonstrated that the rate of incidental PNI was higher in patients with 
regional nodal metastases (40%) compared to those without regional nodal metastases 
(18.2%; OR 2.00 on univariate analysis, p < 0.005).152 Schmults et al. noted PNI to be 
associated with increased risk for nodal metastasis on univariate analysis (SHR 14.5, 95% 
CI 7.1 – 29.8, p < 0.001), however this effect was lost on multivariate analysis (SHR 1.4, 
95% CI 0.5-5.8, p = 0.39).20 Broughman et al. analysed 6164 patients with cutaneous SCC 
with a rate of PNI of 1%.153 The nodal metastasis rate was approximately 2.6%, and 
patients with PNI in the primary tumour were noted to be of higher risk for this event on 
multivariate analysis (hazards ratio 5.29, 95% CI 2.50-11.21, p < 0.0001).153  
 
A feature of PNI that has been shown to influence prognosis in incidental PNI cases is 
nerve diameter.116,139 Ross et al. recorded the maximal diameter of involved nerves in 48 
patients with incidental PNI of cutaneous SCC.116 When nerve diameter ≥ 0.1mm (large 
caliber) was compared to a nerve diameter < 0.1mm (small caliber), large caliber nerves 
were found to be associated with significantly worse outcomes in regards to rates of local 
recurrence (50% vs 9%, p = 0.003), nodal metastasis (37% vs 0%, p = 0.001), death from 
disease (32% vs 0% p = 0.003), and all-cause survival (48% vs 17%, p = 0.02).116 Carter 
et al. reviewed 114 cases of cutaneous SCC with incidental PNI and found an increased 
risk of nodal metastasis on univariate analysis with large caliber (17%) compared to small 
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caliber nerves (4%, p < 0.05).139 There was also a trend towards significantly increased 
death from disease in large caliber (13%) compared to small caliber nerves (3%, p = 0.06). 
However, the impact of PNI on prognosis was lost on multivariate analysis. This suggests 
that in the absence of other risk factors (such as tumour size > 2cm, moderate or poor 
differentiation, tumour depth > 4mm), incidental PNI of any caliber was not associated with 
reduced outcomes. However, large caliber PNI was associated with the presence of other 
risk factors that worsen prognosis when compared to small caliber PNI, including size > 
2cm (37% vs 7%, p < 0.001), depth > 4mm (76% vs 62%, p = 0.003), invasion beyond 
subcutaneous fat (41% vs 10%, p < 0.001) and lymphatic (15% vs 2%, p = 0.02) and 
vascular invasion (17% vs 3%, p = 0.01).139 
 
In the 7th edition of the AJCC staging system, NMSC with PNI is classified as T1 or T2, 
depending on tumour size and the presence of other high-risk features (see Table 1.2).10 
PNI of the skull base is classified as T4. Nodal and distant metastasis is staged similarly to 
mucosal head and neck cancer (see Table 1.2 for nodal staging).10 The current 7th edition 
AJCC staging system for NMSC outlined in Table 1.2 includes PNI as a feature associated 
with more aggressive disease. Farasat et al. described the process of developing the 7th 
edition AJCC staging system for cutaneous SCC in their role as ‘The Non-melanoma Skin 
Cancer Task Force of AJCC’.154 This process entailed a review of the available literature to 
formulate an evidence-based staging system. The evidence regarding the inclusion of PNI 
in disease staging comprised case series published between 1984 and 
2005.15,48,122,124,140,155 This outlined the association of PNI with poor prognosis yet there 
are inherent limitations in the literature.  
 
Goepfert et al. retrospectively reviewed 967 CSCCHNs from 520 patients and 
demonstrated a rate of PNI of 14%, however 25% of these were from non-skin 
malignancies.15 60% of patients were asymptomatic suggesting that incidental and clinical 
PNI cohorts were likely pooled. Whilst imaging data was not included, histological data on 
the cranial nerves involved was presented. Middle-aged males were the most commonly 
affected patients, and PNI was more frequent in lesions on the midface. When patients 
with PNI were compared to those without PNI, there was a significantly increased rate of 
both regional nodal (35% v 15%) and distant metastases (15% v 3.3%; p < 0.0005).15 In 
addition, local recurrence at two years minimum follow-up was higher in patients with PNI 
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compared to those without PNI (47% v 7.3%; p < 0.005). The PNI patients were complex 
with 83% being referred for salvage treatment compared to 35% of non-PNI patients. 
Other features of the primary tumours such as size, tumour differentiation and depth of 
invasion were not included in this study, all features that have been shown to 
independently influence outcomes (see Figure 1.3).21,73,75  
 
Leibovitch et al. reported a multi-centre prospective case series of patients in Australia 
treated for cutaneous SCC with MMS between 1993 and 2002.122 This series represents 
MMS cases only, a surgical approach often selected for difficult lesions. In this series of 
1177 patients, 31.4% were recurrent tumour and 15.7% were poorly differentiated. The 
rate of incidental PNI was 5.95%, and this was more common in males, recurrent tumours, 
and those with moderate or poor differentiation. Tumour size > 2 cm was significantly 
associated with increased rates of PNI (p < 0.001). Tumour defect size was higher in the 
PNI-positive cases compared to PNI-negative, and this reflects both the diffuse pattern of 
spread along nerves and also the nature of MMS technique of gradual excision by levels 
using horizontal sections.35,143 After 5 years follow-up, data for 336 patients was available 
and comprised 25 PNI-positive patients and 311 PNI-negative patients. Local recurrence 
was seen in 8% of the PNI-positive group (2 patients) and in 3.7% of the PNI-negative 
group (11 patients; no statistics provided due to low numbers).122    
 
Other studies assessed were retrospective series which demonstrated that PNI was 
associated with worse prognosis.48,124,155 One series of 142 patients showed that PNI was 
associated with higher recurrence rates (23% PNI vs 9% non-PNI, p = 0.02) and higher 
disease-specific mortality at 2 years (54% PNI vs 25% non-PNI, p < 0.001), however this 
series only assessed patients with mucosal SCC of the head and neck.155 Garcia-Serra et 
al. described the outcomes of 135 patients with incidental and clinical PNI of SCC and 
BCC.48 Treatment approaches included surgery and PORT or radiotherapy alone and 
these were pooled for outcome analysis. Local control (LC) at 5 years was 87% for 
incidental PNI, and 55% for clinical PNI (p = 0.006) with 88% of local recurrences 
occurring in patients with positive margins. Lawrence and Cottel described a series of 44 
patients with cutaneous SCC and PNI treated with MMS.124 They inferred a survival 
probability of 88.7% measured indirectly from recurrence data which is inherently 
limited.124  
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There is no data available for systematic review which specifically assesses the risk of 
developing advanced clinical PNI. Retrospective assessment of the primary tumours from 
patients who have subsequently developed clinical PNI could assist in this process. 
Clinical PNI is currently classified as a feature of the primary tumour.10 The limitations with 
this include the concept that whilst incidental PNI is a feature of the primary tumour, 
clinical PNI is a form of tumour metastasis that often presents as disease recurrence. The 
zonal system demonstrates promise as a staging tool as it grades the disease extent of 
clinical PNI based on imaging findings, guides treatment and correlates with prognosis (as 
discussed in section 1.4.1.4.2).126  
 
Using the current 7th edition AJCC staging system, zone 1 clinical PNI (pre-skull base) 
equates to T1 or T2, whilst zones 2 and 3 equate to T4 disease.10 The new 8th edition of 
the AJCC staging system will be implemented in 2018, and changes have been made in 
regards to PNI that more accurately reflect the significant prognostic impact of PNI.156 
Specifically, cutaneous SCC with PNI is staged as T3 if the involved nerve is deeper than 
the dermis or is ≥ 0.1mm diameter or if the patient has clinical PNI. Invasion into the skull 
base or skull base foramina is staged T4b.156  
 
1.4.1.6 Treatment & outcomes 
1.4.1.6.1 Incidental PNI 
Excision of the primary tumour facilitates the diagnosis of incidental PNI and ideally can 
provide definitive treatment. A 4-6 mm margin is ideal in low risk CSCCHN, whilst at least 
6 mm is recommended in lesions with other high risk features (see Figure 1.3).74 The 
current National Comprehensive Cancer Network (NCCN) guidelines for cutaneous SCC 
recommend consideration of PORT if PNI is present, especially when other high-risk 
primary tumour factors (including margin status and degree of PNI) are present.157 The 
presence of other high-risk factors (as described in Table 1.1 and Figure 1.3) can also 
influence the decision to provide radiotherapy.9 Radiation fields typically include the 
primary site with a small margin, yet in cases with a positive surgical margin these may 
need to be extended.34  
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The outcomes of patients with incidental PNI have been discussed previously in section 
1.4.1.5. A recent systematic review of treatment outcomes for CSCCHN with incidental 
PNI assessed 7 studies comprising 381 patients that were predominantly treated with 
surgery and PORT.44 These studies are limited to case series. The mean 5-year RFS was 
76% and DSS 88%, whilst OS was 43% (reported in one study only). The overall risk of 
local recurrence was 17%, and the rates of nodal metastasis and distant metastasis were 
10% and 3% respectively. The overall risk of death from disease was low at 6%. With 
regards to the excision approach, a retrospective analysis of patients with incidental PNI of 
SCC and BCC demonstrated improved 5-year DSS with MMS and PORT (36 patients) 
compared to conventional surgical excision and PORT (82 patients; 84% vs 68%, p = 
0.03).158 However, the selection criteria for MMS and the characteristics of the patients not 
treated with MMS were not included.  
 
1.4.1.6.2 Clinical PNI 
There are currently no guidelines for the management of clinical PNI, and treatment varies 
between institutions and specialist units. When treatment is of curative intent it is typically 
with either surgery and PORT or radiotherapy alone.29,117,126,159 Some patients present late 
or have considerable delays in diagnosis, at which stage palliation may be the only 
option.36 A recent series of 120 patients with clinical PNI of CSCCHN noted that almost 
20% of patients were palliated following diagnosis.126 In this series, 60% of patients 
received surgery and PORT, 12.5% radiotherapy alone, 6.7% surgery alone and 1.7% 
chemoradiotherapy.126  
 
The aim of treatment is to prevent recurrence and central failure and improve survival 
whilst limiting morbidity.29,40,42 Surgical resection for clinical PNI is typically undertaken 
with curative intent and is generally considered in medically suitable patients with zone 1 
and zone 2 disease.40 Surgery is designed to resect perineural disease en-bloc with a 
clear margin whilst maintaining form and function for the patient.29,40 Reconstruction post-
resection is also often required.43 The surgical approaches to perineural disease based on 
the nerve involved and the zonal extent of disease are summarised in Table 1.4.  
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PORT is typically required to treat residual microscopic disease and the peripheral nerves 
within the skin.42 Radiotherapy plays a key role in the management of clinical PNI due to 
the diffuse nature of spread along nerves in the skin and treatment is largely case-
based.34,42 There is no evidence that chemotherapy adds survival benefit to patients with 
clinical PNI yet it is typically considered in certain uncommon circumstances such as the 
presence of extra-capsular nodal extension (i.e. nodal metastasis with tumour spread 
beyond the capsule of the lymph node).123  
 
Table 1.4. Surgical management of perineural spread (adapted from Panizza and 
Warren 2012).29 
Nerve 
involved Zone 1 Zone 2 Zone 3 
V1 
To supraorbital notch: 
resect nerve; ~ 1 cm 
beyond notch: orbital 
exenteration +/- superior 
orbital fissure 
Include ganglion via a lateral 
craniotomy or transorbital 
approach 
Radiotherapy; consider 
subtotal resection 
V2 
Infraorbital nerve resection 
+ pterygopalatine fossa 
contents + maxillary 
division via transfacial 
(endoscopic or sublabial) 
Include ganglion via an 
anterior or lateral craniotomy 
approach  
Radiotherapy; consider 
subtotal resection 
V3 
Ascending 
mandibulectomy + 
infratemporal fossa 
contents via combined 
superior and inferior 
approach 
Include ganglion via a lateral 
craniotomy 
Radiotherapy; consider 
subtotal resection 
VII Radical parotidectomy + mastoid segment of VII 
Include ganglion via temporal 
bone resection  
Radiotherapy; consider 
surgery: Geniculate 
ganglion + surrounding dura 
+ contents of internal 
auditory meatus  
VII + V3 
Radical parotidectomy + 
ascending mandibulectomy 
+ infratemporal fossa 
contents 
Include ganglia via lateral 
approach and temporal bone 
resection  
Radiotherapy; consider 
subtotal resection 
Abbreviations: V1 ophthalmic division trigeminal nerve; V2 maxillary division; V3 mandibular division; VII facial nerve 
 
The applicability of available outcome data is limited largely due to pooling of BCC and 
SCC patients and treatment approaches,12,13,47,48 and varying classification of clinical and 
incidental PNI with potential pooling of subgroups.12,49,117 Overall, there is an inherent lack 
of quality evidence that assesses clearly defined patient subgroups. A recent systematic 
review of treatment outcomes for CSCCHN with clinical PNI summarised available 
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outcome data.44 This included 6 studies comprising 241 patients treated with surgery with 
or without PORT, radiation alone and/or chemotherapy. Only two studies reported survival 
outcomes with 5-year RFS of 59-62%, DSS 64-75% and OS 64-68% and one of these 
studies forms section 2.3 of this thesis.120,125 The overall average risk of nodal and distant 
metastasis was low at 6% and 0.5% respectively, whilst risk of death from disease was 
27%.44  
 
Panizza et al. reported on the outcomes of 21 consecutive patients with clinical PNI from 
CSCCHN (which included operable patients with zone 1 or 2 disease) following treatment 
with surgery and PORT and demonstrated 5-year DSS of 64%.125 An updated series of 50 
consecutive patients demonstrated improved 5-year DSS of 75% and this work constitutes 
section 2.3.120 Further work has shown improved 5-year DSS in patients with single nerve 
involvement (67%) compared to patients with multiple nerve involvement (36%, p = 
0.03).126 Achieving a clear surgical margin is also associated with improved outcomes with 
5-year DSS of 72% with clear margins versus 46% with involved margin (p = 0.04).126  
 
A summary of recent outcome data pertaining to clinical PNI is included in Table 1.5. 
Balamucki et al. reported on the outcomes of 109 patients with clinical PNI from SCC and 
BCC treated with surgery and PORT, radiotherapy alone, chemoradiotherapy or surgery, 
PORT and chemotherapy.13 In the surgery and PORT cohort (52 patients), 5-year 
outcomes were OS 48%, DSS 58%, LC 55% and locoregional control (LRC) 50%. Pooled 
outcomes for the entire cohort are detailed in Table 1.5.  
 
Jackson et al. reported a series of 21 patients treated with surgery and/or radiotherapy 
with improved 5-year LC in imaging-negative clinical PNI (64%) compared to imaging-
positive clinical PNI (38%) yet this was not significant (p = 0.67).12 In this small series there 
was pooling of SCC and BCC patients and treatment approaches, and survival outcomes 
were pooled for imaging-negative and imaging-positive disease. Whether the imaging-
negative cohort represents low grade disease not detectable on imaging or whether these 
patients represent incidental PNI patients is unclear since no details on clinical features 
were provided.12  
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Galloway et al. published a series of 45 patients (both SCC and BCC) treated with either 
surgery and PORT, radiotherapy alone or chemoradiotherapy.49 In this series, patients 
were divided into imaging-negative and imaging-positive with minimal/moderate peripheral 
disease or central/macroscopic disease. They demonstrated significantly improved 5-year 
LC, DSS and OS in imaging-negative patients (76%, 100%, 90% respectively, n = 10) 
when compared to minimal/moderate disease (57%, 56%, 50% respectively, n = 14) and 
macroscopic/central disease (25%, 61%, 58%; n = 21).49 An updated series in 2015 with 
65 patients showed imaging-negative disease was present in 11 patients. As only 1 further 
patient had imaging-negative disease in the period between publications, this may reflect 
improved detection rates over time.117 This update demonstrated consistently improved 
outcomes when imaging-negative patients were compared to minimal-moderate peripheral 
disease and macroscopic/central disease (see Table 1.5). This finding could also be due 
to incidental PNI patients being classed as imaging-negative clinical PNI (as only limited 
clinical details were included), with resultant improved outcomes that are more consistent 
with those reported for incidental PNI. 
 
There are limitations to surgery, particularly the inherent risk of disturbing anatomical 
barriers to spread that can result in iatrogenic tumour spread and poorer outcomes.125 
Zone 3 disease treated with surgery has the potential to cause iatrogenic central tumour 
dissemination via the CSF.29 Surgery for zone 3 disease has a limited role but is 
considered on a case-by-case basis depending on the precise imaging extent and patient 
factors (age, general health and wishes).125  
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Table 1.5. Summary of 5-year outcomes for clinical PNI 
Study Institution Tumour type Treatment 
Imaging 
findings 
No. of 
patients OS DSS RFS LC 
Panizza 
et al. 
2012125 
Princess 
Alexandra 
Hospital, 
Brisbane 
Australia 
 
SCC Surgery & PORT Not reported 21 68% 64% 59% 64% 
Balamucki 
et al. 
201213 
University 
of Florida, 
Gainesville 
1965-2007 
SCC/ 
BCC 
Surgery & 
PORT, 
radiotherapy 
OR surgery 
& chemo-
radiotherapy 
Not reported 109 54% 64% 51% 54% 
Balamucki 
et al. 
2015117 
University 
of Florida, 
Gainesville 
1986-2009 
SCC/ 
BCC 
Surgery & 
PORT, 
radiotherapy 
OR surgery 
& chemo-
radiotherapy 
Negative 11 82% 100% 81% 81% 
Positive 
minimal/ 
moderate 
18 50% 58% 54% 57% 
Positive 
macroscopic 36 52% 65% 47% 25% 
Jackson 
et al. 
200912 
Royal 
Brisbane 
Hospital, 
Australia 
1992-2000 
SCC/ 
BCC 
Surgery & 
PORT OR 
radiotherapy 
Negative 11 
57% 76% 46% 
64% 
Positive 10 38% 
Galloway 
et al.  
200549 
University 
of Florida, 
Gainesville 
1986-2002 
SCC/ 
BCC 
Surgery & 
PORT, 
radiotherapy 
OR chemo-
radiotherapy 
Negative 10 90% 100% - 76% 
Positive 
minimal/ 
moderate 
14 50% 56% - 57% 
Positive 
macroscopic 21 58% 61% - 25% 
Abbreviations: OS, overall survival; DSS, disease-specific survival; RFS, recurrence-free survival; LRC, 
loco-regional control, LC, local control, PORT, post-operative radiotherapy 
 
 
Patients for whom surgery is not a valid option can be treated with radiotherapy alone, 
which is also guided by the disease extent on imaging.159 Patients with zone 3 disease are 
generally offered radiotherapy, either as high-dose radical treatment or with palliative 
intent.125 Although essentially case-based, radiation fields for clinical PNI typically cover: (i) 
the peripheral branches of the involved nerve(s); and (ii) the proximal course of the 
involved nerve(s) back to the ganglion for zone 1, to the pre-pontine aspect of the nerve 
for zone 2, and up to the brainstem for zone 3.42 Given that contralateral spread of 
perineural disease has also been reported, field coverage across the midline may also be 
necessary particularly for midline primary tumours.160 Certain institutions have previously 
advocated irradiation to the brainstem due to the risk of microscopic disease and skip 
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lesions.14,30,31,161 Given the inherent associated morbidity and lack of evidence of skip 
lesions, irradiation to the brainstem is not generally indicated unless disease is evident 
proximal to the ganglion, into the cisterns or into the brainstem.35,42 
 
There is no standardised approach to the management of the regional lymph nodes in PNI 
patients. One reason for elective nodal irradiation being provided to N0 patients includes 
the presence of other high-risk primary tumour features that are associated with a higher 
risk of nodal metastasis, such as diameter > 2 cm or poor differentiation (see Figure 
1.3).21,42 Elective nodal irradiation has been recommended due to reports of lower regional 
nodal recurrence in patients with treatment.13,159 One of these series detailed a trend 
towards significantly better 5-year regional control in incidental PNI patients treated with 
elective nodal irradiation (100%, n = 21) compared to no treatment (82%, n = 37 p = 
0.065).13 Goepfert et al. documented a higher rate of nodal metastases in patients with 
CSCCHN and PNI (pooled incidental and clinical PNI cohorts) compared to CSCCHN 
without PNI, however other primary tumour characteristics such as size and depth of 
invasion were not assessed.15 McCord et al. presented a series of 59 patients with clinical 
PNI from CSCCHN (74%) and BCC (26%) treated with either radiotherapy and/or 
surgery.45 LC at 5-years was 50%, with local recurrence being the most common form of 
recurrence. 55 patients were staged N0 at presentation and 65% of these underwent 
elective nodal irradiation. Overall, nodal recurrence occurred in 11% yet it is unclear if this 
occurred in patients who received elective nodal irradiation or not.  
 
Garcia-Serra et al. reported an updated series of patients with PNI from SCC and BCC 
from the same institution.48 They presented 76 patients with clinical PNI (of which 44% 
received elective nodal irradiation) and 59 patients with incidental PNI (of which 18% 
received elective nodal irradiation). In the clinical PNI cohort the rate of nodal recurrence 
was approximately 12%, whilst in the incidental PNI cohort the rate of nodal recurrence 
was 20%. It is unclear which patients in this series recurred regionally, those who received 
radiation to the neck or those who did not. Overall, the evidence for elective nodal 
irradiation in clinical PNI remains limited.  
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1.4.1.7 Summary  
There remain inherent deficiencies in the evidence base currently guiding management of 
CSCCHN with clinical PNI. Whilst certain basic epidemiological and clinical features have 
been previously described, thorough assessment of a relatively homogenous cohort of 
patients in clearly defined treatment groups is required. This will enable a greater 
understanding of the entire disease process, from the initial characteristics of the primary 
tumours from patients who developed clinical PNI, the natural history timeline from primary 
tumour until clinical PNI, through to clear outcomes outlining the effectiveness of treatment 
approaches.  
 
Primary tumour features from clinical PNI patients (including the presence of incidental 
PNI and the treatment received for the primary) are critical details that have hitherto been 
poorly described. Clear profiling of the characteristics of the typical patient with clinical PNI 
is needed to identify patients at risk of developing clinical PNI. Detailing the common 
presenting symptoms and signs can help identify those who are affected as early as 
possible. In addition, illustrating not only treatment outcomes yet also the timing and 
pattern of recurrence and treatment failure is an important process that can improve our 
understanding of the disease natural history. Other areas requiring further analysis are the 
utility of MRI neurography in diagnosis, the frequency of immunosuppression in patients 
with clinical PNI, the frequency of nodal disease and the management of the neck in these 
patients. It is imperative to utilise the experience of patients with clinical PNI to raise 
awareness and improve our understanding of this otherwise rare disease. 
 
1.4.2 Molecular mechanisms of PNI 
The capability of tumour cells to invade the perineural space and then spread contiguously 
into the CNS has long been recognised, yet the precise mechanism remains 
unknown.18,162 It was theorised over 90 years ago that PNI takes place in the periphery 
where the perineurium is “attenuated as the nerve diminishes in size” and is thin, scant or 
even absent.162 The perineurium with its innate barrier properties (multi-lamellated, tightly 
packed endothelial cells) can prevent external tumour invasion into the nerve fascicle.52,53 
It also functions to keep the majority of tumour that has accessed the perineural space 
within it, thus promoting axial extension of tumour along the nerve rather than radial 
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expansion outside the nerve (i.e. local invasion).39,162 Tumour cells can extend along the 
perineural space in an apparently favourable environment. Although the perineural space 
is only a potential space and therefore not without inherent resistance, it may be of 
relatively low resistance when compared to other parts of the peripheral nerve sheath.53 
However, whether other factors within or acting upon this space are involved remains to be 
determined. Animal models have confirmed the anatomical continuity of the perineural 
space with the subarachnoid space forming a conduit for disease in the periphery to 
spread into the CNS.54,163 
 
The pathogenesis of PNI of CSCCHN is certain. The molecular factors involved in the 
pathogenesis of CSCCHN have been discussed in section 1.3.2. These factors could also 
be involved in PNI yet have not been assessed. Investigation of all elements at the nerve 
and tumour interface including the tumour microenvironment is vital to understand the 
disease pathogenesis. There is an inherent lack of studies specifically assessing 
cutaneous SCC and PNI. Whole genome profiling of CSCCHN with clinical PNI has not 
previously been undertaken and no biomarkers of disease presence or progression are 
known. 
 
1.4.2.1 Models of PNI 
One limitation to the current understanding of PNI is the lack of quality disease models. A 
large proportion of the studies investigating the mechanisms of PNI utilise in vitro models 
of prostate and pancreatic cancer since PNI is regarded as an indicator of poor prognosis 
in these diseases.23,112,164,165 The co-culture model developed by Ayala et al. has 
consistently demonstrated utility as a model to investigate PNI at the in vitro level.166 In this 
system, prostate cancer cells are co-cultured alongside harvested mouse dorsal root 
ganglion (DRG) tissue.165 This has demonstrated simultaneous tumour growth, 
axonogenesis and neurogenesis culminating in neurite invasion by tumour, a process 
likely due to reciprocal tumour-nerve signalling within the tumour 
microenvironment.164,165,167 This seemingly symbiotic process appears to involve 
interaction between tumour, nerve and stroma via indeterminate signalling pathways. The 
benefits of this system include the ability to monitor tumour and neurite growth over time 
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with the option of media and additive modulation to investigate different factors. A 
limitation is the incomplete representation of the tumour microenvironment. 
 
An in vivo model of PNI is ideal so that tumour behaviour within a realistic 
microenvironment can be accurately studied. A sciatic nerve model of PNI has been 
devised which involves the injection of tumour cells directly into mouse sciatic nerve.168,169 
This model is capable of studying tumour spread and progression along a nerve, however 
the factors involved in initial PNI within the tumour microenvironment cannot be assessed.  
 
1.4.2.2 Nerve factors 
Normal nerves are maintained and stimulated to proliferate by neurotrophins, chemokines, 
growth factors and axon-guidance molecules.170,171 These factors gained interest after the 
in vitro co-culture model demonstrated a symbiotic-like relationship between tumour and 
nerve.166 Neurotrophins act to stimulate axon growth and maintain neurons and may play 
a role in PNI.112 Neurotrophins that have been investigated include glial cell-line derived 
neurotrophic factor (GDNF), nerve growth factor (NGF), neurotrophin-3 (NT3) and brain-
derived neurotrophic factor (BDNF) (see Figure 1.6).172  
 
GDNF is a chemo-attractant secreted by nerves and surrounding support cells, and has 
been shown to induce pancreatic cancer cell migration and invasion in co-culture 
models.168 Tumour cells migrated towards GDNF and invasion was impaired by inhibition 
of its receptor (RET).168 Radiation treatment reduced GDNF levels in both pancreatic 
cancer cell lines within a co-culture model of PNI and an in vivo mouse sciatic nerve model 
of PNI.169 This suggests that GDNF may play a role in PNI and could be a target for 
radiation treatment. 
 
Expression of NGF and its receptor TrkA has been shown to correlate with PNI and 
increased local recurrence in adenoid cystic carcinoma specimens.173 NGF has also been 
shown to be highly expressed in pancreas and prostate cancer cell lines, and TrkA is also 
expressed on the perineurium of surrounding nerve tissues.112 NGF and its receptor have 
been demonstrated to have increased expression in oral cavity SCC with PNI when 
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compared to oral cavity SCC without PNI.174 NT3 has been observed to be highly 
expressed in pancreatic cancer tissues and within associated involved nerves.112,172 BDNF 
has been shown to correlate with prognosis in adenoid cystic carcinoma and may mediate 
this via an epithelial mesenchymal transition (EMT) through its TrkB receptor.175 Whilst not 
directly implicated in PNI, BDNF may play a role in tumour progression.175  
  
Axon guidance molecules are involved in axon development and have also attracted 
interest given the concept of nerve-tumour cross-talk in PNI.112 Semaphorin 4F displays 
axon guidance properties and its over-expression in prostate cancer cells stimulated 
neurogenesis, and also correlated with PNI nerve diameter and nerve density.165,176 
Semaphorins may also regulate tumour progression, possibly via tumour 
microenvironment composition modulation.177  
 
1.4.2.3 Tumour factors 
A recent study compared the genomic expression of incidental PNI specimens using DNA 
microarray.178 Cutaneous SCCs that were PNI-positive (n = 21) were compared to PNI-
negative (n = 19), and 24 genes with significantly different expression were identified (p < 
0.001).178 No underlying biological pathways were discovered in the dataset and none of 
the genes have been shown previously to be involved in cancer biology. In addition, this 
study was limited to incidental PNI tumours only.178  
 
Tumour cell migration away from the primary site (i.e. metastasis) has been theorised to 
involve a phenotype switch induced by an EMT event.179,180 This process is vital for normal 
human embryonic development during gastrulation and involves a change in cell 
properties from static to migratory.180 Complex pathways and multiple molecular factors 
are involved in this switch and include cell-cell adhesion molecules (cadherins and 
integrins), growth factors (transforming growth factor-β), transcription factors (Snail, Slug) 
and extracellular proteases (MMPs).180,181 An EMT switch in phenotype could provide 
tumour cells with the necessary properties that enable detachment from the primary 
tumour mass, and migration and spread to a distant site.180,182 The role of EMT in PNI 
pathogenesis remains unexplored. 
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Figure 1.6. Molecular mechanisms of perineural invasion. A summary of potential 
interactions between tumour and nerve with signalling through the tumour 
microenvironment that could result in nerve invasion and spread. Figure taken from Bakst 
& Wong 2016.172 
 
1.4.2.4 Tumour microenvironment factors 
The environment within which the interplay between tumour and nerve occurs and 
culminates in PNI and PNS is a target of ongoing research. Studies in pancreatic cancer 
have demonstrated fibronectin, collagen type IV and laminin produced by perineural 
endothelial cells encouraged pancreatic cancer cell migration and invasion.183 This 
suggests extracellular matrix (ECM) proteins (secreted by tumour cells and/or perineural 
cells) may function as a guide for tumour cells and possibly directing them towards the 
perineural sheath. Other factors within the tumour microenvironment with a potential role in 
PNI include MMPs and CAFs.172 MMPs act to remodel the ECM, which could potentially 
promote and/or facilitate tumour cell migration.100 Meanwhile, CAFs could act to provide 
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the necessary scaffolding through which migration, proliferation and/or local invasion 
occurs.100  
 
A recent study demonstrated nerve-tumour reciprocity may be mediated via the 
neuropeptide galanin, which is involved in nociception. nerve regeneration and nerve 
survival.184 In an in vitro model using mucosal head and neck SCC cells, galanin secreted 
by nerves appeared to stimulate tumour growth via activation of the galanin receptor 2 
(GALR2), which in turn induced neuritogenesis.184 Invasion of tumour into neurites 
appeared to be facilitated by activated GALR2, possibly via local prostaglandin secretion. 
This process could be interrupted by targeting galanin or its receptor.184 This work also 
reinforces the nerve-tumour cross-talk theory of PNI pathogenesis.  
 
Neural cell adhesion molecule (NCAM), a sialoglycoprotein involved in cell-cell 
interactions, was previously thought to play a role in PNI of mucosal SCC of the head and 
neck based on high expression levels in PNI patients.185 Further investigation into the role 
of NCAM did not demonstrate any changes in expression on immunohistochemistry (IHC) 
when in CSCCHN with PNI was compared to CSCCHN without PNI.186 However, recent 
work has suggested that tumour invasion into nerves may be stimulated by local Schwann 
cells and that this was dependent on NCAM-1.187  
 
Galectin-1 is a protein thought to be a mediator of inflammation and the immune response 
within the ECM, and high expression in tumour stroma has been shown to be associated 
with poorer prognosis in prostate cancer.188 Recent work into the role of immune cells 
within the tumour microenvironment in CSCCHN with clinical PNI has also been 
undertaken.101 This demonstrated moderate to marked lymphocytic infiltration of T cells, B 
cells and FoxP3-expressing T cells (regulatory T cells) in 58.8% of specimens. In addition, 
galectin-1 staining was shown to be associated with worse prognosis.101 The role of the 
immune system in this disease is a target for ongoing research.  
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1.4.2.5 Summary 
It is apparent that PNI pathogenesis likely involves complex nerve and tumour signalling 
within a favourable microenvironment. This theory is largely through the effort of studies 
investigating other cancers that associate PNI with aggressive disease such as prostate 
and pancreatic cancer.112 There is inherently limited work investigating CSCCHN with 
clinical PNI at the molecular level. Whilst promising in vitro and in vivo models of PNI have 
been developed, analysis of the genetic factors specifically involved in clinical PNI of 
CSCCHN has not been previously studied and is an ideal starting point.166,169 Genomic 
expression profiling could highlight potential targets for investigation and ultimately targets 
for treatment. In addition, comparing the genomic profiles of normal skin, CSCCHN, 
CSCCHN with incidental PNI and CSCCHN with clinical PNI is ideal to determine if a 
disease spectrum is evident, and whether genetic factors may be involved in disease 
progression.  
 
1.5 Thesis scope 
CSCCHN with clinical PNI represents an aggressive form of skin cancer that can have a 
poor prognosis. It is a rare disease with limited general awareness and can be confused 
for benign pathology, contributing to costly delays in diagnosis and treatment. The 
underlying factors involved in the disease process at both the clinical and molecular level 
remain to be fully explored.  
 
This thesis will undertake a descriptive epidemiological analysis of the features of 
CSCCHN with clinical PNI through a detailed assessment of the patient, primary tumour 
and perineural tumour factors involved. Retrospective and prospective data analysis of a 
series of 120 patients with CSCCHN and clinical PNI will be performed. The outcomes of a 
subset of 50 patients with CSCCHN and clinical PNI treated with surgery and PORT will be 
described as a sub-analysis. Detailed analysis of the features of the patients affected by 
this condition can generate a profile of the typical patient with clinical PNI and this may 
provide insight into the mechanism of the disease. This information could be used to assist 
in identifying those patients at higher risk of clinical PNI. The findings from this will ideally 
assist in both raising awareness of the disease and guiding clinicians in the assessment 
and treatment of this condition.  
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To investigate the genetic factors involved and define potential markers of disease 
development and/or progression, gene expression profiling of normal skin, CSSCHN 
without PNI, CSCCHN with incidental PNI and CSCCHN with clinical PNI will be 
undertaken. This will demonstrate any differences in gene expression, and potentially 
provide insight into why certain tumours progress to clinical PNI. Significant genetic factors 
will be assessed with functional assays of transfected tumour cells to further characterise 
the impact of target genes on cell properties. This will contribute to our understanding of 
the disease process, guiding further research and potentially identifying targets for 
treatment that will ideally lead to improved management and ultimately patient outcomes.  
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Chapter 2 
Epidemiology and treatment outcomes of cutaneous 
squamous cell carcinoma with perineural spread 
 
2.1 Introduction 
The epidemiological features of patients with PNS of CSCCHN have not been previously 
well characterised. Detailed assessment of the features of the primary tumour in patients 
with PNS is lacking. Also, determining the typical pattern of presentation is important, as 
many patients are misdiagnosed or diagnosed following significant delays that can result 
in poorer outcomes.  
 
Current available outcome data is limited in its clinical application. The disease is rare, and 
many studies are comprised of mixed patient populations who have received different 
treatments. This is compounded by varying definitions of PNI between studies. The overall 
aim of this section is to improve awareness and understanding of the natural history of 
PNS of CSCCHN. Furthermore, determining treatment outcomes can guide ideal 
treatment approaches and help to inform patients better on prognosis.  
 
This chapter comprises two published manuscripts. Firstly, a descriptive epidemiological 
analysis of 120 patients with PNS of CSCCHN was undertaken (Section 2.2).46 Secondly, 
a sub-analysis describing the outcomes of 50 patients with PNS of CSCCHN who were 
treated with surgery and PORT was performed (Section 2.3).120 This subset was drawn 
from the cohort of 120 patients and comprised the first 50 sequential patients with PNS of 
CSCCHN who received surgery and PORT as treatment. All patient and disease details 
were recorded in an active prospective electronic database managed through the Princess 
Alexandra Hospital Brisbane, Australia.  
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2.2 Insight into the epidemiology of cutaneous squamous cell 
carcinoma with perineural spread 
Warren TA, Whiteman DC, Porceddu SV, Panizza B. Insight into the epidemiology of 
cutaneous squamous cell carcinoma with perineural spread. Head Neck. 38(9):1416-1420. 
2016 
 
2.2.1 Abstract 
Background 
PNS of CSCCHN can be associated with poor outcomes. Disease understanding and 
awareness is limited leading to delayed diagnosis and treatment. This study aimed to 
identify epidemiological features of patients with PNS of CSCCHN. 
 
Methods 
Tumour characteristics and demographics of patients with PNS of CSCCHN managed 
through a single institution were collected between 1998 and 2013.  
 
Results 
120 patients were included. The majority had a skin cancer history (85.8%). The median 
time from primary tumour treatment to PNS symptom onset was 16 months (range 1 - 86). 
34.2% had no PNI detected in the primary. 22.5% had no known primary tumour. Only 
5.8% of patients had nodal involvement at presentation. 
 
Conclusions 
Patients can present with PNS from CSCCHN with no known primary tumour or with 
primary tumours without PNI. The majority of patients presented without regional nodal 
involvement.  
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2.2.2 Introduction 
Following initial PNI of a primary skin tumour into adjacent peripheral nerves, tumour cells 
spread contiguously within the perineural space into cranial nerves and eventually reach 
the brainstem. Whilst the majority of primary CSCCHNs are treatable and do not develop 
PNS, little is known about the features of the primary tumours that lead to PNS. 
Queensland, Australia has the highest recorded rates of CSCCHN in the world.2,189 The 
exact proportion of CSCCHNs that develop PNS is uncertain, yet given the high frequency 
of skin cancer observed in Queensland it is anticipated that the incidence of PNS is 
accordingly high.189  
 
This report describes the epidemiology of PNS from CSCCHN using a large series 
managed through a single institution in Queensland. Focus is given to the precise 
characteristics of each patient’s cutaneous primary, the timeline from primary tumour to 
PNS and the clinical features of PNS at presentation. Improving awareness and 
understanding of the epidemiology of PNS can improve outcomes by identifying affected 
patients early to minimise delays in diagnosis and treatment.190  
 
2.2.3 Materials and Methods 
Patients diagnosed with PNS of CSCCHN who were treated between 1998 and 2013 
through the Princess Alexandra Hospital Queensland, a tertiary referral centre servicing a 
population of approximately 2 million people, were included. Informed patient consent and 
ethics approval from the Metro South Human Research Ethics Committee was obtained 
(2003/197). Patients with PNS of other tumour types were excluded from this analysis. 
 
Data were collected prospectively using a structured data abstraction form and entered 
into an electronic database. Retrospective data collection was also used for any missing 
data. Patient characteristics recorded included age at diagnosis of PNS, sex, prior history 
of skin cancer (as a surrogate marker of sun exposure history) and immunosuppression. 
The details of primary tumour location, size, differentiation, presence of incidental PNI and 
LVI, margin status and treatment details were obtained from hospital chart records, 
primary care physician records and pathology department electronic databases. Primary 
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tumours were classified according to AJCC TNM 7th edition criteria, and were staged 
separately to PNS to emphasise the types of primaries that lead to PNS.10  
 
Disease characteristics of PNS for each patient were analysed. Clinical features assessed 
were symptoms and signs at presentation, time from treatment of the primary to onset of 
symptoms of PNS, and time from onset of symptoms of PNS until diagnosis of PNS. The 
radiological features assessed were imaging modality, detection rate on imaging and 
nerve(s) involved. In those treated with surgery, the pathological features included were 
tumour differentiation, nerves involved and maximum cranial nerve diameter. The zonal 
extent on imaging was used for PNS staging.118 Nodal and distant metastatic disease 
staging was as per AJCC TNM 7th edition criteria.10 The surgical approach to CSCCHN 
with PNS at our institution is based on the nerve(s) involved and the zonal disease extent, 
and has been described previously.29,120  
 
2.2.4 Results 
2.2.4.1 Patient characteristics 
120 patients with PNS from CSCCHN were included and their general characteristics are 
detailed in Table 2.1. Men were affected more than 5 times more frequently than women. 
The mean patient age at PNS diagnosis was 66 years (range 34 - 91 years). The most 
common age group at presentation was 51 - 80 years. The majority of patients (85.8%) 
had a prior history of additional skin cancers indicating significant previous sun exposure, 
and 7.5% had no prior history. In addition, the majority of patients were immuno-competent 
(96.7%). 
 
2.2.4.2 Primary tumour characteristics 
The characteristics of each patient’s primary cutaneous tumour were analysed 
independently of PNS (see Table 2.2). The most common primary tumour stage 
associated with PNS was T2 (33.3%). 22.5% presented with PNS from an unknown 
primary tumour (T0). 21.7% were classed as un-assessable due to either treatment with 
cryotherapy (no histology), a history of multiple potential primary lesions in the region of 
concern or incomplete/missing pathology reports (TX). If specific details of TX primary 
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tumours were available (i.e. location, treatment), these details were included in the 
dataset. Primary tumours were located on the cheek in 15.8%, and other common sites 
included the temple (10%), nose (10%), forehead (8.3%) and pre-auricular skin (8.3%; see 
Table 2.2).  
 
Table 2.1. Patient characteristics 
Patient characteristics No. of patients (n = 120) % 
Age at diagnosis     
21-40 3 2.5% 
41-50 13 10.8% 
51-70 58 48% 
71-80 31 25.8% 
81-100 15 12.5% 
Mean 66 years 
Range 34 - 92 years 
Gender     
Male 101 84.2% 
Female 19 15.8% 
History of skin cancer     
Yes 103 85.8% 
No 9 7.5% 
Unknown/missing 8 6.7% 
Immunosuppression     
Yes 4 3.3% 
No 116 96.7% 
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Table 2.2. Primary tumour features 
Primary features No. of patients (n = 120) % 
Stage*     
TX 26 21.7% 
T0 27 22.5% 
T1 27 22.5% 
T2 40 33.3% 
T3 0 0% 
T4 0 0% 
      
Primary location     
Unknown 45 37.5% 
Cheek 19 15.8% 
Nose 12 10% 
Temple 12 10% 
Forehead 10 8.3% 
Pre-auricular 10 8.3% 
Lip 3 2.5% 
Scalp 3 2.5% 
Eyelid 3 2.5% 
Chin 1 0.8% 
Post-auricular 1 0.8% 
Ear 1 0.8% 
      
Treatment     
No 27 22.5% 
Unknown 11 9.2% 
Yes 82 68.3% 
Surgery 76 92.7% 
Cryotherapy 6 7.3% 
Post-operative radiotherapy 31 37.8% 
Dose (range) 40-60 Gray, 15-30 Fractions 
      
Incidental PNI     
No 26 34.2% 
Unknown 8 10.5% 
Yes 42 55.3% 
Mean nerve diameter (range) 0.29 mm (0.03 mm - 2 mm) 
Abbreviations: PNI perineural invasion: *Nominal classification of the primary tumour if there were 
no perineural spread using American Joint Committee on Cancer 7th edition, 2010.10 
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Surgery was the most common treatment modality for primary tumours (92.7%). The 
majority had clear (46.1%) or close margins (22.4%, < 5 mm), and 22.4% had involved 
margins (in 6.6% margin status was unknown). The proportion of patients that received 
cryotherapy as treatment for the primary tumour was 7.3%. PORT to the primary tumour 
site was given in 37.8% of patients.  
 
In patients with known and assessable primary tumours, 34.2% did not have incidental PNI 
reported in the histology of the primary tumour. 55.3% of patients with known/assessable 
primary tumours had incidental PNI reported on histology. Of these patients, 52.4% 
received PORT. The mean diameter of the maximum involved nerve was 0.29 mm (range 
0.03 mm - 2 mm). The presence or absence of incidental PNI was omitted in the pathology 
report in 10.5% of patients. Primary tumours were well-differentiated in 10.5%, moderate in 
42.1% and poorly differentiated in 39.5%. In 7.9%, the tumour differentiation was unknown 
or not reported. The average maximum tumour dimension was 17.7 mm (range 4 mm - 50 
mm). The mean depth of invasion was 7.4 mm (range 1 mm - 30 mm), however this was 
infrequently reported (31.6%). In 59.2%, the presence of LVI was unknown or not 
reported, whilst 35% were LVI-negative and 5.8% LVI-positive. 
 
2.2.4.3 Perineural spread characteristics 
2.2.4.3.1 Clinical features 
The median time from primary tumour treatment to onset of PNS symptoms was 16 
months (range 1 - 86 months). The median time from onset of PNS symptoms to date of 
diagnosis of PNS was 6 months (range 2 weeks - 5 years). The clinical presentation of 
patients with PNS was variable, and dependent on the nerve involved (see Table 2.3). The 
most common presenting symptoms were numbness (56.7%), neuropathic pain (43.3%) 
and paraesthesia (30.8%). In addition, 34.2% presented with a subcutaneous mass, 
typically overlying or adjacent to cranial nerve exit foramina (most frequently V2 and V1). 
Formication was reported in 15%. Unilateral facial palsy was evident in 39.2%, of which 
59.6% presented as a partial palsy and 40.4% presented complete (all branches). A 
complete facial palsy of progressive onset (89.5%) was the more frequent reported pattern 
compared to sudden onset (10.5%; which can be confused with a diagnosis of Bell’s 
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palsy). Regional nodal involvement was identified at presentation in 5.8% of patients (N0). 
Only one patient presented with distant metastatic disease.  
 
2.2.4.3.2 Radiological features  
The radiological features of PNS are summarised in Table 2.3. Imaging detected PNS in 
93.3% of patients, and was reported negative in 6.7%. The detection rate using MRI 
neurography was 97%. In 3 patients, plain MRI accurately identified PNS. CT was 
performed in 4 patients, and 2 of these were imaging-positive. Disease was detected on 
imaging in Zone 1 in 31.5%, Zone 2 in 42.3% and Zone 3 in 25.2%. On imaging, 64% of 
cases had single nerve involvement and 36% had multiple nerves involved. The most 
frequently involved nerve was V2 (28.8%), followed by V1 (24.3%). Simultaneous 
involvement of V3 and VII was present in 18%, reflecting the known cross-branches that 
exist between cranial nerves V and VII.191  
 
2.2.4.3.3 Pathological features  
The nerves involved in PNS specimens from patients treated with surgery (n = 80 patients) 
are summarised in Table 2.3. The majority of tumours were moderately (45%) or poorly 
differentiated (45%), with less being well-differentiated (7.5%) or undifferentiated (2.5%). 
Single nerve disease was the most common finding (73.8%) and V2 was the most frequent 
nerve involved (35%), followed by V1 (25%). The average maximum diameter of involved 
cranial nerve was 2.86 mm (range 0.15 - 7 mm).  
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Table 2.3. Features of perineural spread 
Clinical features No. of patients         % 
Presentation     
Numbness 68/120 56.7% 
Neuropathic pain 52/120 43.3% 
Paraesthesia 37/120 30.8% 
Formication 18/120 15% 
Burning 4/120 3.3% 
Subcutaneous mass 41/120 34.2% 
Facial palsy 47/120 39.2% 
Partial palsy 28/47 59.6% 
Complete palsy 19/47 40.4% 
progressive onset 17/19 89.5% 
sudden onset 2/19 10.5% 
Nodal stage (TNM)     
N0 113/120 94.2% 
N1 4/120 3.3% 
N2b 3/120 2.5% 
Imaging detection     
Imaging-positive 111/119 93.3% 
Imaging-negative 8/119 6.7% 
No imaging 1/120 0.8% 
MRI neurography imaging-positive 106/109 97% 
Imaging Zone classification     
Zone 1 35/111 31.5% 
Zone 2 47/111 42.3% 
Zone 3 28/111 25.2% 
N/A* 1/111 0.9% 
Nerve(s) involved on imaging     
Single nerve 71/111 64% 
Multiple nerves 40/111 36% 
V1 alone 27/111 24.3% 
V2 alone 32/111 28.8% 
V3 alone 5/111 4.5% 
V multiple branches 11/111 9.9% 
VII alone 6/111 5.4% 
VII and V3 20/111 18% 
VII and V multiple branches 9/111 8.1% 
Great auricular nerve 1/111 0.9% 
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Table 2.3. continued 
Nerve(s) involved on pathology No. of patients % 
Single nerve 57/80 71.25% 
Multiple nerves 22/80 27.5% 
Nil involved 1/80 1.25% 
V1 alone 20/80 25.0% 
V2 alone 28/80 35.0% 
V3 alone 0/80 0% 
V multiple 5/80 6.3% 
VII alone 7/80 8.8% 
VII and V3 11/80 13.8% 
VII and V1 1/80 1.3% 
VII and V2 1/80 1.3% 
VII and V multiple 4/80 5.0% 
Great auricular nerve 2/80 2.5% 
Abbreviations: V trigeminal nerve, V1 trigeminal ophthalmic division, V2 trigeminal maxillary 
division, V3 trigeminal mandibular division, VII facial nerve, *N/A not applicable, as great 
auricular nerve is not accounted for in the zonal classification system. 
 
 
2.2.5 Discussion 
PNS of CSCCHN represents an advanced form of tumour spread with potentially poor 
outcomes that is frequently misunderstood. Unlike lymphatic and haematogenous 
metastasis of cancer cells to lymph nodes and solid organs, many patients and clinicians 
are unfamiliar with this form of cancer spread. It is often confused with other benign 
causes of cranial nerve dysfunction such as Bell’s palsy or trigeminal neuralgia.36 This 
contributes to delays in diagnosis, which are further compounded by a slowly progressive 
disease process. Adding complexity to reaching a diagnosis of PNS is the finding that PNS 
patients can have no known primary tumour, prior history of skin cancer and/or incidental 
PNI in the primary.  
 
Between one in every four to five patients presented with no identifiable index primary 
lesion in the region representing the dermal distribution of the involved nerve (22.5%). This 
may reflect sub-clinical disease or even immune-mediated tumour regression.192 The 
ramifications are that patients with progressive cranial nerve neuropathies should be 
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considered to have PNS until proven otherwise, even in the absence of a skin cancer 
primary or history. Unknown primaries in the head and neck of SCC histology presenting 
with cervical lymph node malignancy occur in less than 3% of head and neck cancer 
patients, and if the primary is identified approximately 90% are mucosal and located in the 
oropharynx.193 The patients in this report represent an entirely different disease entity, with 
an apparent biological predilection for perineural invasion not lymphatic spread.  
 
Clinical PNI or PNS is not always preceded by incidental PNI. Over one third of patients 
did not have incidental PNI detected in their primary tumour, a process generally 
considered an antecedent to PNS. Incidental PNI is often difficult to detect on 
histopathology and can be overlooked.37 The process is dependent on accurate 
processing, staining and assessment of transverse and longitudinal sections, as a given 
tissue section may miss microscopic nerve involvement due to artifact.35,145 This also relies 
on a high index of suspicion in the pathologist and treating surgeon. 
 
Of those with incidental PNI in the primary, the mean maximum diameter of involved nerve 
was 0.29 mm. For incidental PNI, the diameter of nerve involved has been suggested to 
be a prognostic indicator, with a nerve diameter of > 0.1 mm associated with worse 
outcomes including increased local recurrence and nodal metastases.116,139 Of those with 
incidental PNI in this series, 52.4% received PORT to the primary site. There remain no 
clear guidelines on the use of PORT for incidental PNI, and this warrants further 
investigation.  
 
Delays in reaching the diagnosis of PNS are common and in this series the median delay 
was 6 months, yet in some patients the delay has been up to 5 years. The disease process 
and the symptoms and signs it induces are slowly progressive and the median time from 
primary tumour treatment and PNS symptom onset was 16 months. Indeed, the hallmark 
presentation features of PNS are progressive facial palsy and/or trigeminal nerve 
dysfunction, with a steady increase in the affected distribution from one branch to multiple 
as centripetal invasion into the ganglion takes place. 
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The typical patient presenting to our institution with PNS is a male in the sixth to eighth 
decade of life with a prior history of skin cancers (reflecting significant past sun exposure) 
and an intact immune system. Despite being associated with more frequent and 
aggressive cutaneous SCCs, immuno-compromise did not appear to have a strong 
association with PNS.75 Of the known primary tumours, the majority were staged T2 and 
were typically large (average maximum dimension 1.77 cm). There was a preponderance 
of moderate and poorly differentiated primary and perineural tumours. This compares with 
a prospective study of over 600 patients with cutaneous SCCs that showed typical tumour 
differentiation distribution at 53% well-differentiated, 22% moderate and 25% poorly 
differentiated.33  
 
Approximately 1 in 5 primary tumours were un-assessable (TX) with many patients having 
a history of multiple previous skin cancers requiring multiple treatment episodes, at times 
with cryotherapy or laser (and thus no histology). In addition, standardised pathology 
reporting for NMSC is important for disease prognostication.33 Although utilised in some 
countries it is not universal and details such as PNI, LVI and depth of invasion can be 
frequently omitted as seen in this study.194 One finding of concern was that of patients with 
PNS, almost a quarter had involved margins following excision of the primary tumour 
(22.4%), demonstrating the importance of a clear margin. 
 
Nodal involvement was uncommon which suggests: (i) PNS is the sole route of tumour 
spread in some cancers, likely a reflection of inherent tumour biology; and (ii) elective 
treatment using surgery and/or radiotherapy to the neck staged N0 should be 
unnecessary. The low rate of nodal metastasis in this series (5.8%) is consistent with other 
similar series.47,117  
 
2.2.6 Conclusion 
This study contributes to the understanding of the epidemiology and natural history of 
perineural spread from CSCCHN. Over 20% of patients with PNS had an unknown primary 
skin tumour. In addition, over one-third of patients with a known primary tumour did not 
have PNI detected in the primary. Therefore, PNS should always be considered in patients 
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with a progressive cranial nerve neuropathy (particularly V or VII nerve), even in the 
absence of a primary skin neoplasm or incidental PNI history.  
 
The median time from primary tumour treatment to the development of PNS symptoms 
was 16 months and delays in diagnosis occur with a median delay of 6 months. Increasing 
awareness amongst patients and clinicians will help limit diagnostic delays and improve 
outcomes. The majority of patients present with PNS in the absence of regional nodal 
metastasis and this likely reflects tumour biology.  
  
 82 
2.3 Outcomes following surgery and post-operative radiotherapy for 
perineural spread of head and neck cutaneous squamous cell 
carcinoma.  
Warren TA, Panizza B, Porceddu SV, Gandhi M, Patel P, Wood M, Nagle CM & Redmond 
M. Outcomes after surgery and postoperative radiotherapy for perineural spread of head 
and neck cutaneous squamous cell carcinoma. Head Neck. 38(6):824-831. 2016 
 
2.3.1 Abstract 
Background 
Queensland, Australia has the highest rates of cutaneous SCC. PNI is associated with 
reduced local control and survival.  
 
Methods 
A retrospective review of a prospective database of patients with clinical PNI from 
CSCCHN treated with surgery and PORT between 2000 and 2011 and a minimum of 24 
months follow-up. Patients were excluded if immunosuppressed, had non-SCC histology 
or were treated palliatively.  
 
Results 
Fifty patients (mean age 60 years) with median follow-up of 50 months were included. 
54.8% of known primary tumours had incidental PNI. Ten percent had nodal disease at 
presentation. MRI neurography was positive in 95.8%. RFS at 5-years was 62%. 5-year 
DSS and OS were 75% and 64%, respectively. There were no peri-operative deaths.  
 
Conclusion 
This report demonstrates that long-term survival is achievable in patients with clinical PNI 
from CSCCHN following surgery and PORT.  
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2.3.2 Introduction 
Clinical PNI is associated with higher rates of local recurrence and reduced overall survival 
when compared to incidental PNI.12,13 The American Joint Committee on Cancer (AJCC; 
2010 7th edition) classifies all PNI into the skull base as T4 disease.10 Currently, no 
consideration is given to the precise zonal extent of PNS, which has been shown to 
influence patient outcome.195 Zonal extent of PNS can be used for classification (see 
Table 1.3).135 Generally, zone 1 or 2 disease is operable, whilst zone 3 disease is 
considered not, due to the perceived higher risk of iatrogenic spread of tumour via the CSF 
during surgery. However, surgery is considered on a case-by-case basis. 
 
The management of clinical PNI varies between institutions yet surgical resection followed 
by PORT can lead to improved patient outcomes in selected patients.125 Previously 
reported outcome data is restricted in its clinical application through the use of varying 
treatment approaches,12,47 and pooling of either incidental PNI and clinical PNI cohorts15 or 
different tumour types (i.e. SCC and BCC).13 The purpose of this study is to describe the 
long-term survival of patients with clinical PNI from CSCCHN treated with surgery and 
PORT.  
 
2.3.3 Materials and Methods 
50 consecutive patients with clinical PNI from CSCCHN treated with curative intent surgery 
between 2000 and 2011 with a minimum 24 months follow-up for alive patients identified 
from a prospective database were included. Immuno-suppressed patients (n = 2) and 
patients with PNI of other tumour types (melanoma {n = 2} and BCC {n = 6}) were 
excluded. Informed patient consent and ethics approval from the Metro South Human 
Research Ethics Committee was obtained (2003/197). Details of primary tumours were 
obtained from pathology archives. Primary tumours and perineural spread was classified 
according to AJCC 7th edition criteria (see Tables 2.4 and 2.5).10 An ‘r’ notation was 
applied to the staging if a patient presented with PNS from recurrence of a previously 
treated primary skin cancer.  
 
 
 84 
Table 2.4. Patient and primary tumour features 
Patient and primary features No. of patients (%) 
Age  
Mean 60 years 
Range 34-91 years 
  
Gender  
Male 41 (82) 
Female 9 (18) 
  
 
Follow-up  
Median 50 months 
Range 9 - 151 months 
  
Primary tumour classification, 
AJCC  
TX 14 (28) 
T0 6 (12) 
T1 10 (20) 
T2 20 (40) 
T3 0 (0) 
T4 0 (0) 
  
 
Primary site  
Unknown 14 (28) 
Cheek 10 (20) 
Nose 8 (16) 
Temple 7 (14) 
Forehead 4 (8) 
Pre-auricular 4 (8) 
Post-auricular 1 (2) 
Ear 1 (2) 
Eyelid 1 (2) 
  
Primary margins (if treated)  
Clear 11 (32) 
Close 8 (24) 
Involved 12 (35) 
Unknown 3 (9) 
  
 
Incidental PNI in primary 
tumour  
No 11 (36.6) 
Yes 19 (63.3) 
Nerve diameter (no. of 
patients=12; range) 0.03mm - 0.9mm 
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Table 2.5. Features of perineural spread 
Feature of PNS No. of patients (%) 
Classification of PNS, AJCC Clinical Pathological 
TX 14 (28) 14 (28) 
T0 6 (12) 6 (12) 
rT1 10 (20) 10 (20) 
T2 1(2) 1(2) 
rT2 19 (38) 19 (38) 
N0 47 (94) 46 (92) 
N1 2 (4) 2 (4) 
N2 1 (2) 2 (4) 
M0 50 (100) 50 (100) 
M1 0 (0) 0 (0) 
Imaging diagnosis   
MRI neurography: PNS positive 46/48 (95.8) 
CT: PNS positive 1/2 (50) 
Imaging zonal extent   
Zone 1 16/50 (32) 
Zone 2 30/50 (60) 
Zone 3 2/50 (4) 
N/A* 2/50 (4) 
Nerve involved   
Single nerve 34 (68) 
Multiple nerves 16 (32) 
V1 18 (36) 
V2 21 (42) 
V3 14 (28) 
VII 18 (36) 
VII and V3 12 (24) 
Great auricular nerve 2 (4) 
Neck dissection   
Yes 5 (10) 
No 45 (90) 
Nerve margin status   
Clear 35 (70) 
Close (<5mm) 5 (10) 
Involved 10 (20) 
Tumour differentiation   
Well 3 (6) 
Moderate 22 (44) 
Poor 22 (44) 
Undifferentiated 3 (6) 
Post-operative radiotherapy   
No  3 (6) 
Yes  47 (94) 
Dose, range 50-63 Gray 
Fractionation, range 25-30 fractions 
Footnotes: *Two patients with great auricular nerve involvement were N/A 
as spinal nerves are not currently provided for in the zonal system. 
Abbreviations: perineural spread (PNS). 
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All patients underwent pre-operative diagnostic imaging with MRI neurography evaluated 
by a skull base radiologist, or CT when MRI was contraindicated. All management plans 
were discussed in specialised multidisciplinary head and neck and/or skull base tumour 
boards. Surgical resection was planned with imaging findings and all tumours were 
resected en-bloc with frozen section margin control via a skull base or sub-cranial 
approach as described in Table 1.4.29,35,125 Surgery was of curative intent in all patients. 
Neck dissection was performed if: (i) nodal disease was evident or suspected on pre-
operative assessment; or (ii) surgical access to the neck was required to enable 
reconstruction.  
 
PORT was offered to all eligible patients. Treatment was individualised depending on each 
patient’s suitability and disease extent (skin, nerve, nodal involvement). In the latter half of 
the 2000’s, prescribed volumes were typically dependent on the zonal extent of disease on 
imaging and pathology: zone 1 up to ganglion; zone 2 to the pre-pontine aspect of the 
nerve; and zone 3 up to brainstem.135 Fields encompassed the peripheral branches of 
involved nerves, and the regional nodes were addressed only if pathologically involved. 
Bolus was generally considered over the skin corresponding with the nerve distribution. 
Post-operative concurrent chemo-radiotherapy was only used if extra-capsular nodal 
extension was present.  
 
Post-operative follow-up consisted of regular outpatient review (quarterly until 3 years, 
then biannually until at least 5 years post-treatment) in conjunction with baseline and serial 
MRI neurography for surveillance (biannually until 3 years, then annually to 5 years). 
Follow-up was taken from the date of surgery until date of last follow-up or date of death. 
Recurrence was classified as local (further sub-classified as peripheral at skin or central at 
meninges/ brain/brainstem), regional (nodal) or distant metastasis. Local recurrence was 
defined as either an in-field, or out-field of radiotherapy.  
 
The primary outcomes measured were LRC, RFS, DSS and OS. Variables assessed 
included age, gender, nodal involvement, nerve(s) involved, single/multiple nerves 
involved, disease zone, margin status, PORT, salvage intent (i.e. failed previous 
treatment) versus definitive intent (initial treatment) and tumour differentiation. Since there 
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were only two patients with zone 3 disease, zone 2 and 3 were combined for analysis. 
Crude survival probabilities were estimated and plotted using the Kaplan-Meier technique 
and analysis undertaken to assess for significant associations with the variables detailed 
above. A p value of ≤ 0.05 was deemed statistically significant. Analyses were conducted 
using SAS software Version 9.2 (SAS Institute Inc. Cary, NC).  
 
2.3.4 Results 
2.3.4.1 Patient and primary tumour characteristics 
Patient and primary tumour characteristics are described in Table 2.4. Mean age at the 
start of treatment for clinical PNI was 60 years (range 34-91 years), and the overall male-
to-female ratio was approximately 4:1. Median follow-up period following surgery was 50 
months (range 9-151 months).  
 
All tumours with PNS to the skull base are staged as T4, however as most cases present 
some time after the primary has been excised we assessed the primary cutaneous SCC. 
Of these, 60% had an obvious primary and the majority were staged as T2 (40%, 20/50). 
12% of patients presented with PNS having had no cutaneous primary tumour (6/50, T0). 
In 28% of patients the primary tumour was un-assessable (TX) due to either: (i) 
incomplete/missing pathology reports or cutaneous malignancies treated externally without 
formal histological diagnosis (i.e. cryotherapy, laser or shave excision through primary 
care provider); or (ii) the exact primary index lesion was uncertain as multiple cutaneous 
malignancies were present in the region of interest.  
 
The frequencies of all known primary sites are detailed in Table 2.4. The cheek was the 
most common location of a cutaneous primary (20%). In 28% of patients, the location of 
the primary was unknown yet the approximate location of certain TX primary tumours was 
known and therefore included. Of the patients treated with surgery for the primary tumour 
(34 patients), 12 had involved margins, 8 had close margins, 11 had clear margins and 3 
had unclear margin status. Of the patients with a known primary tumour, 63.3% had 
incidental PNI reported. From the histopathology reports of primary tumours that included 
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a measurement of involved nerve diameter (n = 12), the maximal diameter ranged from 
0.03 mm – 0.9 mm (median 0.2 mm).   
 
2.3.4.2 Assessment 
The features of perineural spread are described in Table 2.5. MRI neurography was 
performed in 96% (48/50) and was positive for PNS in 95.8% (46/48). Two patients were 
assessed with computed tomography only (CT) due to MRI contra-indications, and this 
was positive in one patient. All patients with clinically evident PNS of the V nerve at 
presentation had disease evident on MRI neurography (43/43). The extent of PNS was 
zone 1 in 32% (16/50), zone 2 in 60% (30/50) and zone 3 in 4% (2/50). Spinal nerve 
involvement is rare and not currently represented in the zonal classification system. Two 
patients with great auricular nerve involvement are included in this series. 
 
There were two patients with negative MRI neurography. One patient, who had a pre-
auricular SCC with incidental PNI previously treated with surgery and post-operative 
radiotherapy, presented with a partial facial nerve palsy and no detectable PNS on MRI 
neurography. The VII nerve branch was 0.5 mm diameter on histopathology. The second 
patient presented with a parotid mass and local sensory changes, and a past history of a 
cheek SCC. Great auricular nerve PNS was detected intra-operatively and confirmed on 
histopathology (nerve diameter 1 mm), yet disease was not detectable on MRI 
neurography.  
 
94% of patients were clinically staged as N0 at presentation. 4% (2/50) were staged N1 
and 2% (1/50) staged N2 pathologically. All patients were classified as M0. Eighteen 
patients (36%) presented with a subcutaneous tumour mass overlying or adjacent to the 
involved cranial nerve exit foramina. The majority of these were in the V1 or V2 distribution 
yet masses were also detected under the pre-auricular skin. 
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2.3.4.3 Treatment 
All patients underwent en-bloc surgical resection of involved nerve(s) with curative intent 
(for approaches see Table 1.4).29,35,125 28% received prior treatment for perineural spread 
(surgery and/or radiotherapy) and were treated as salvage intent in this series. 5 patients 
(10%) underwent a neck dissection: 3 for apparent clinical N1 disease or greater 
(confirmed pathologically); 1 to permit access for reconstruction (N0); and 1 due to clinical 
suspicion (clinical N0, pathological N2b). 32% (16/50) of patients required an orbital 
exenteration for V1 involvement.  
 
There were no peri-operative deaths. Surgical complications included: free-flap failure 
requiring return to theatre (n = 1), deep-vein thrombosis (n = 1), extradural haemorrhage 
requiring evacuation in theatre (n = 1), CSF leak treated with lumbar drain (n = 1), and 
wound infection (n = 1) treated with washout and antibiotics. In addition, one patient 
sustained an intra-operative myocardial infarction necessitating a change in reconstruction 
plan (undertaken with local flap instead of free flap). This patient developed peri-operative 
pneumocephalus and a CSF leak with poor neurological recovery requiring rehabilitation, 
and subsequently died from pneumonia 9 months post-treatment. Also, one patient 
developed an oro-antral fistula after a sub-labial approach to V2 and PORT, and had 
successful local flap repair.  
 
Clear central nerve margin was obtained in 35 patients (70%) and 5 patients (10%) had 
close margins (i.e. < 5 mm clearance). Two patients required a two-stage operation to 
clear a nerve margin, whilst one patient required a three-stage operation. Clearance of 
potential peripheral nerve margin in skin was not pursued due to the risk of disfigurement, 
and PORT was relied upon for treatment of potential peripheral nerve distribution spread. 
The detail of nerves involved is included in Table 2.5. V2 was the most common nerve 
(42%), followed by V1 (36%) and VII (36%). The majority of patients had single nerve 
involvement (68%). Multiple nerve involvement occurred in 32%, with the most common 
scenario being VII and V3 co-involvement. The great auricular nerve (C2 spinal nerve) was 
involved in 2 patients, with disease peripheral to the dorsal root ganglion.  
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94% (47/50) received PORT with dose range of 50-63 Gray in 25-30 fractions daily 5 
days/week. Five patients received nodal irradiation for regional nodal disease present on 
histopathology, and five patients elective nodal irradiation. Two patients who failed 
previous radiotherapy alone were treated with salvage surgery and not offered further 
PORT. One died from disease after local recurrence 53 months post-treatment, and the 
other remains disease free 75 months post-treatment. One further patient with zone 1 
disease initially not offered PORT due to age (91 years), subsequently developed 
subcutaneous peripheral recurrence 7 months later which was treated with salvage 
surgery and local PORT. This patient remains disease free 30 months since last treatment. 
Complications following PORT included wound breakdown (n = 2), radionecrosis (n = 4; 3 
affecting bone, 1 affecting anterior temporal lobe), corneal irritation necessitating orbital 
exenteration (n = 2) and visual impairment (radiation microangiopathy, n = 2) treated 
conservatively. One patient received chemotherapy (cisplatin) for nodal disease with extra-
capsular nodal extension.   
 
2.3.4.4 Outcomes 
OS at 5-years was 64% with 14 deaths in this series (see Figure 2.1). 10 patients died 
from disease, with DSS at 5-years of 75% (see Figure 2.2). Mean time to death from 
disease was 39 months (range 10-90 months; median 30 months). The ultimate cause of 
death was predominantly central failure (12%), none being in the brainstem, with 
composite peripheral failure in 4% and distant metastasis in 4% (see Table 2.6).  
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Figure 2.1. Kaplan-Meier curve of overall survival for patients with perineural spread from 
cutaneous squamous cell carcinoma treated with surgical resection and postoperative 
radiotherapy.  
 
Figure 2.2. Kaplan-Meier curve of disease-specific survival for patients with perineural 
spread from cutaneous squamous cell carcinoma treated with surgical resection and 
postoperative radiotherapy. 
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Patterns of recurrence are described in Table 2.6. RFS at 5-years was 62% (see Figure 
2.3). There were 18 patients with recurrence of disease, and 6 patients had a second 
recurrence. Mean time to any recurrence was 24 months (range 4-75 months; median 21 
months), with 81% occurring within 4 years and 95% within 5 years post-treatment. 
Recurrence was significantly associated with worse OS (p = 0.002). Local recurrence was 
the most common pattern, particularly peripheral in-field (14%). Three patients had central 
recurrence of disease (two with simultaneous peripheral and central recurrence), and all 
died from disease. One patient recurred with regional nodal disease (on the outer edge of 
the treatment field) and one recurred with local, regional and distant disease.  
 
 
Table 2.6. Patterns of recurrence and failure 
First recurrence pattern Total no. of patients (%) 
% of recurrences 
(no. of patients) 
Local in-field (total) 10 (20) 56% (10/18) 
Peripheral 7 (14) 39% (7/18) 
Central  1(2) 6% (1/18) 
Peripheral and central  2 (4) 11% (2/18) 
  
  
Local out-of-field (peripheral)  6 (12) 33% (6/18) 
Regional nodal in-field 0 (0) 0% (0/18) 
Regional nodal out-field 1 (2) 6% (1/18) 
Distant metastasis 0 (0) 0% (0/18) 
Local in-field, regional out-field and distant 1 (2) 6% (1/18) 
  
  
Failure pattern   
Peripheral failure 2 (4)  
Central failure (all non-brainstem) 6 (12)  
Distant metastasis 2 (4)  
Death from disease 10 (20)  
Death from other causes 4 (8)  
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LRC at 5-years was 62% (see Figure 2.4), and successful surgical salvage of loco-regional 
recurrence was achieved in 33% (6/18). Two patients had out-of-field local recurrence on 
the contralateral side with eventual central failure (one at 75 months post-treatment, 
possibly representing a second yet unknown primary). One patient developed out-of-field 
loco-regional recurrence at 20 months post-surgery in the distal branches of V2 and V3, 
and following salvage surgery remains alive and disease-free at 118 months since last 
treatment.  
 
 
 
 
Figure 2.3. Kaplan-Meier curve of recurrence-free survival for patients with perineural 
spread from cutaneous squamous cell carcinoma treated with surgical resection and 
postoperative radiotherapy. 
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Figure 2.4. Kaplan-Meier curve of loco-regional control for patients with perineural spread 
from cutaneous squamous cell carcinoma treated with surgical resection and 
postoperative radiotherapy. 
 
RFS at 5-years by zonal disease extent demonstrated a significant difference when zone 1 
(88%) was compared to zone 2 and 3 combined (51%, p = 0.05, see Figure 2.5). DSS at 
5-years by zonal disease extent was 93% for zone 1 disease and 73% for zone 2 and 3 
combined (p = 0.17). OS at 5-years by zonal disease extent was 75% for zone 1 disease 
and 63% for zone 2 and 3 combined (p = 0.2). Age, gender, nodal involvement, nerve 
involved, single versus multiple nerves involved, PORT, salvage versus definitive intent, 
and tumour differentiation were not associated with recurrence or reduced survival. Margin 
status did not demonstrate a significant association with recurrence or survival, yet a trend 
towards significantly better 5-year OS was evident when patients with clear/close margins 
were compared to those with involved margins (p = 0.13; see Figure 2.6). 
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Figure 2.5. Kaplan-Meier curve of recurrence-free survival by zonal disease extent for 
patients with perineural spread from cutaneous squamous cell carcinoma treated with 
surgical resection and postoperative radiotherapy (p = 0.05). Zone 1 has been compared 
to zone 2 and zone 3.  
 
Figure 2.6. Kaplan-Meier curve of overall survival for patients with perineural spread from 
cutaneous squamous cell carcinoma treated with surgical resection and postoperative 
radiotherapy by margin status comparing clear/close and involved margin (p = 0.13).  
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2.3.5 Discussion 
This case series details the outcomes of patients with perineural spread from CSCCHN 
treated with surgery and PORT. This treatment approach offers patients a reasonable 
survival benefit with a limited rate of complications. This is contingent on careful pre-
operative planning, including appropriate imaging, and treatment within a specialised 
multidisciplinary unit.  
 
The most common location of primary tumour was the cheek, and V2 disease extending to 
zone 2 is the most common site and extent of clinical PNI. Almost 40% of known primary 
tumours did not demonstrate PNI, and this may reflect the inherent difficulties in detecting 
PNI in an asymptomatic patient.37 Importantly, the absence of either PNI in a primary 
tumour or an obvious index lesion does not exclude a patient from having clinical PNI, and 
can lead to diagnostic delays as the symptoms and signs may be wrongly attributed to 
Bell’s palsy or trigeminal neuralgia.36  
 
The prognostic significance of nerve diameter in the primary tumour remains unclear, yet it 
has been proposed that a diameter ≥ 0.1 mm is associated with aggressive disease.116,139 
Standardised pathology reporting that includes the high-risk features is important to permit 
accurate staging of each primary and to guide appropriate adjuvant treatment. Only 12/30 
pathology reports of primary tumours included an involved nerve diameter measurement 
(median 0.2 mm; range of 0.03 - 0.9 mm), and robust analysis in this study is therefore not 
possible. 
 
MRI neurography compliments all aspects of patient management from diagnosis and 
treatment planning through to follow-up and surveillance. MRI neurography is useful for 
disease staging with the zonal classification system, which in turn guides surgical planning 
and resection extent and should be offered to all eligible patients. Of note, all patients in 
this series with V nerve involvement had positive MRI neurography. The two cases in this 
series with MRI-negative disease represented either rare disease (one patient with great 
auricular nerve involvement) or early disease (one patient with partial VII involvement in a 
previously irradiated parotid bed).  
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Some centres report imaging-negative PNS at rates of 22-47% and this may reflect the 
use of unfocussed whole-brain MRI or an absence of disease.12,49 In our experience 
imaging-negative disease in a symptomatic patient is uncommon as evidenced by 94% of 
patients in this series being imaging-positive. This is enhanced with the use of 3T MRI with 
neurography protocol interpreted by a skull base radiologist, with 95.8% being positive. 
Imaging-positive disease in an asymptomatic patient is rare, and may warrant nerve 
biopsy prior to large-scale resection. CT is recommended if MRI is contra-indicated but 
lacks sensitivity.  
 
The rate of regional nodal involvement in patients with clinical PNI is estimated at 
approximately 9-16%.13,47,117 The rate of regional nodal disease in this series was low at 
10%, and only two patients had regional nodal recurrence (one as first recurrence, one as 
a second recurrence). This is consistent with the premise that PNS is likely a function of 
both tumour biology and proximity to nerve, and is a unique form of metastasis largely 
independent of lymphatic metastasis. Some centres advocate elective nodal irradiation 
due to a risk of subclinical disease.34 Presently at our institution, nodal irradiation is 
generally only offered if nodal disease is evident clinically or pathologically. A neck 
dissection would be undertaken for the same reason, or if required for reconstruction.  
 
Surgical resection for perineural spread is typically only undertaken with curative intent 
and the surgical approach to PNS is dictated by the nerve(s) involved as outlined in Table 
1.4.29 This is followed by PORT in all eligible patients. Surgery is offered to patients with 
zone 1 and zone 2 disease, whilst surgery for zone 3 disease is considered on a case-by-
case basis. Resection of bulky zone 3 disease has the potential to cause tumour seeding 
and dissemination via the CSF and at our institution patients with zone 3 disease are 
generally offered radical or palliative radiotherapy.  
 
Complications from surgery were limited and related to the large-scale nature of the 
surgery required for disease clearance. Importantly, there were no peri-operative deaths. 
Radiotherapy was also associated with limited treatment effects, however two patients 
required an orbital exenteration for delayed eye complications. At our institution, it is now 
largely routine to undertake an orbital exenteration for V1 disease approximately 1 cm 
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beyond the supraorbital notch. This is not only performed for disease clearance, but also 
since the sequelae from the necessary PORT to the globe are severe. In patients with V2 
and/or V3 involvement requiring ganglion resection, an attempt is made to preserve 
corneal sensation by preserving the V1 component of the ganglion. However, in those 
patients where the whole ganglion was resected to obtain a clear margin, no patient 
subsequently experienced ophthalmic issues necessitating ongoing management.  
 
A summary of recent outcome data for clinical PNI of NMSC is outlined in Table 1.5 and 
this series compares favourably to other reports. Previous studies have limited applicability 
as many have heterogeneous patient cohorts treated with different modalities.12,13,15,47 This 
series demonstrates that long-term survival is achievable in patients treated with 
appropriate surgery and PORT, with almost 65% of patients alive at 5 years. Improved 
outcomes including 75% DSS at 5 years are evident, compared to previous reports of 58-
65% in patients with BCC and SCC receiving radiotherapy with limited surgery.13,117 
Similarly, when compared to another series with a similar patient cohort from the state of 
Queensland and limited surgery, RFS was 62% in our series compared to 39%.47 
 
The median time to death from disease in this series was 30 months. One patient died 
from contralateral spread of disease at 90 months follow-up, 15 months after it was 
detected. This reflects the often slow spreading nature of PNS, and the inherent ability of 
tumour to spread to contralateral nerve branches.160 Local recurrence is the most common 
mode of treatment failure. 95% of all recurrences occurred within 5 years of treatment, 
reiterating the need for long-term follow-up. At our institution, patients are followed up for 
at least 5 years.  
 
Recurrence was also noted to be significantly associated with worse 5-year OS. This 
reflects both aggressive tumour biology and the limitations in salvage options following 
treatment failure, however up to a third of patients were salvaged with surgery in this 
series. Of the 3 patients who recurred centrally none occurred in the brainstem, suggesting 
that the central spread of disease was controlled by appropriate surgery and targeted 
PORT. The zonal extent of disease was shown to be significantly associated with risk of 
recurrence, with RFS at 5-years of 88% in zone 1 and 51% when zone 2 and 3 were 
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combined (p = 0.05). These findings demonstrate that improved disease control can be 
achieved with timely diagnosis and management.  
 
2.3.6 Conclusion 
This case series demonstrates improved outcomes with relatively low morbidity for 
patients with CSCCHN with clinical PNI treated with surgical resection and PORT. Careful 
surgical candidate selection, pre-operative planning with MRI neurography and 
management through a specialised multidisciplinary team is recommended. Early 
intervention is paramount and dependent on a timely diagnosis, and this is expected to 
improve with advancing imaging technology and increasing clinician and patient 
awareness of this disease. 
 
 
 
2.4 Synthesis 
The published manuscripts included in this chapter describe the epidemiology and 
treatment outcomes following surgery and PORT for CSCCHN with clinical PNI. The novel 
findings are that more than 1 in 3 patients with clinical PNI did not have PNI detected in 
their primary tumour, and that almost 1 in 4 patients had clinical PNI from an unknown 
primary tumour, which has never been previously described. Consistent with previous 
reports, the majority of patients with clinical PNI of CSCCHN do not have nodal 
involvement.13,125 In addition, treatment with surgery and PORT can offer patients long 
term survival with minimal complications. DSS at 5-years of 75% achieved in this series 
compares favourably to other series in the literature (see Table 1.5).  
 
A profile of the typical patient can be generated, including the common symptoms and 
signs present. Males are more frequently affected, and the disease is most likely to 
present in middle age, consistent with previous studies.15,34,122 Most patients had a history 
of skin cancer indicative of previous sun exposure, and the majority of patients in this 
cohort were immune-competent. This profiling can assist in early identification and 
therefore management, which can translate into improved patient outcomes. This is 
evidenced here by improved RFS in zone 1 patients (88% at 5-years) compared to zone 2 
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and 3 patients combined (51%, p = 0.05).120 This concept has since been further 
demonstrated in a case series of 120 patients with PNS of CSCCHN with DSS at 5-years 
in zone 1 patients being 84%, zone 2 63% and zone 3 16% (p < 0.0001).46 
 
This is the first report detailing the timeline from primary tumour to clinical PNI symptom 
onset and the time to diagnosis. The slowly progressive nature of the disease was 
evidenced by the median time from primary tumour treatment until PNS symptom onset 
being 16 months, yet with a wide range of 1 to 86 months. This information can guide 
primary care providers in their follow-up of patients with high-risk skin cancers to monitor 
for clinical PNI following initial primary tumour treatment. Also, the median time from 
symptom onset to diagnosis was 6 months, also with a wide range of 2 weeks to 5 years. 
This reinforces the need to improve disease awareness amongst patients and clinicians in 
order to limit diagnostic delays. The common symptom profile at presentation is useful to 
inform clinicians on the typical pattern in clinical PNI. Numbness, neuropathic pain, 
paraesthesia and partial facial palsy were the most common clinical symptoms/signs. 
Importantly, the majority of patients with a complete facial palsy reported it to be of 
progressive onset (89.5%%) compared to sudden onset (10.5%), consistent with the 
progressive spread of disease along nerves and also helping differentiate it from Bell’s 
palsy with a characteristic sudden onset facial palsy.130  
 
Clinical PNI patients presented with single cranial or spinal nerve involvement (64%) more 
frequently than with multiple nerve involvement (36%). The V and VII nerves were the 
most frequently involved cranial nerves, with V2 being the most frequent division of the V 
nerve involved, consistent with previous reports.34 Involvement of the great auricular nerve 
is rare and was noted in 2 patients in this series with few reports in the literature.15,196,197 
The most common combination when multiple nerves were involved was V3 and VII, 
reflecting the close communication between these cranial nerves, and this typically 
requires a more extensive surgical approach (see Table 1.4).191  
 
The features of the primary tumours from patients who subsequently developed clinical 
PNI have provided interesting insights into disease epidemiology and biology. The primary 
tumours of clinical PNI patients were most commonly staged as T2. Almost 1 in 4 patients 
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presented with clinical PNI from an unknown tumour and whether this represents 
subclinical disease or immune-mediated tumour regression is uncertain.192 These patients 
had PNS of malignancy with epithelial cells that extended from the level of the dermis, 
suggesting a cutaneous origin of disease despite an obvious cutaneous malignancy being 
absent. More than 1 in 3 patients with clinical PNI from a known primary tumour had no 
incidental PNI reported in the primary. It is unclear from the pathology reports if this 
represents initial PNI that was overlooked and no comment made in the report or whether 
PNI was assessed for and not identified. This strengthens the argument for standardised 
reporting of skin pathology that would necessitate a comment on PNI on each report. 
Almost 1 in 4 patients with clinical PNI had involved margins at the time of treatment for 
their primary tumour, reiterating the importance of a clear margin. In addition, 37.8% 
received PORT for the primary tumour yet still went on to develop clinical PNI. The 
reasons why 62.2% did not receive PORT for the primary tumour is unclear yet clear 
treatment guidelines could assist in minimising under-treatment. Consistent with previous 
series, the majority were moderate or poorly differentiated (> 80%), and tumours were 
typically large (mean 1.7 cm) and deeply invasive (mean 7.4 mm).15,122-124,139 The cheek 
was the most common primary tumour location, followed by the nose, temple, forehead 
and pre-auricular skin, all regions well-innervated by the V and VII nerves.  
 
MRI neurography has demonstrated utility for both initial diagnosis and guidance of 
management of clinical PNI with detection of disease in 96-97% of patients. The zonal 
classification system uses the imaging findings to categorise the disease based on extent 
of spread and therefore the extent of treatment required using either surgery and/or 
radiotherapy. It also has a role in post-treatment surveillance to detect disease recurrence. 
This is particularly useful in patients with pre-existing cranial nerve dysfunction that may 
not present with any new symptoms of disease recurrence. This series of patients, as an 
extension of the previous work by Gandhi et al. who demonstrated the usefulness of MRI 
neurography with clinical PNI, reiterates the vital role of this radiological tool.118  
 
The finding that nodal disease was uncommon in this series is consistent with previous 
reports, and strengthens the notion that tumour biology may be driving the predilection for 
spread down nerves rather than lymphatics.13,125 This feature could also have 
consequences for management in that treatment of the neck electively with surgery or 
 102 
radiotherapy may not be necessary. This is important as it may spare patients 
unnecessary treatment-associated morbidity, however more dedicated investigation is 
necessary before specific guidelines on treatment can be offered.  
 
The analysis of treatment outcomes in section 2.3 was undertaken to generate clinically 
useful outcome data that could help guide management in other units and better inform 
patients on expectations and prognosis. Surgery and PORT can provide improved patient 
outcomes with OS of 64% and DSS of 75% at 5-years compared to other reports as 
summarised in Table 1.5. Other series are difficult to interpret due to pooling of patient 
groups and pathologies.12,44,47,117  
 
In regards to follow-up post-treatment, the mean time to any recurrence in our series was 
2 years, highlighting the need for close follow-up and surveillance in this early period. In 
addition, 95% of recurrences occurred in the first five years post-treatment, necessitating 
at least 5 years of follow-up. Recurrence of disease was significantly associated with 
worse OS (p = 0.002). Local recurrence was the most common mode of disease 
recurrence, and this has been described previously.34 This may reflect the diffuse nature of 
the disease within small nerves, and the limitations of surgery to resect large amounts of 
facial skin.  
 
This body of work contributes to the current understanding of the epidemiology and natural 
history of CSCCHN with clinical PNI. Given the rarity of the disease and complex 
treatment required, CSCCHN with clinical PNI is best managed in an experienced 
specialised institution in a multidisciplinary setting. These novel findings in conjunction with 
increasing disease awareness have the potential to improve the outlook for affected 
patients.  
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Chapter 3 
Materials and Methods 
 
3.1 Genomic expression profiling  
3.1.1 Specimen collection 
This study involved patients with CSCCHN treated between 2003 and 2011. Informed 
consent was obtained from all participants and the study protocol was approved by the 
Metro South Human Research Ethics Committee (HREC 2003/197). Specimens from 
patients stored as formalin-fixed paraffin-embedded (FFPE) tissue blocks were retrieved 
from the Princess Alexandra Hospital Department of Pathology (Brisbane) and Sullivan 
Nicolaides Pathology (Brisbane). To confirm tumour type and the presence and location of 
PNI, each specimen was first assessed by one independent pathologist (not blinded).  
 
The four groups for assessment were: (i) normal skin; (ii) CSCCHN; (iii) CSCCHN with 
incidental PNI; and (iv) CSCCHN with clinical PNI. The aim was for 6 samples per group 
minimum. ‘Normal skin’ specimens were obtained from the skin of patients who underwent 
breast reduction surgery or from donated neonatal foreskin tissue obtained following 
circumcision. This tissue was selected as normal skin control as opposed to head and 
neck skin due to the possibility of sun exposure and the impact of a field change effect 
(see discussion in section 4.5).93-95  
 
3.1.2 RNA extraction  
Six sections of 5 μm thickness were cut from each FFPE block and placed on superfrost 
slides (QIMR Berghofer Histology Unit, Brisbane). One slide was stained with 
haematoxylin and eosin using standard protocol (H&E). Using the H&E slide as reference, 
tumour was macro-dissected from each slide with a scalpel and placed into a 1.5 mL 
microfuge tube. Total RNA was extracted and purified with the RNeasy® FFPE Kit 
(Qiagen, Hilden, Germany). FFPE specimens were de-paraffinised using xylene, and 
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extracted in ethanol. Cells were lysed by incubation in proteinase K, followed by heating to 
80°C for 15 min to reverse formalin-induced crosslinking. Samples were treated with 
RNase-free DNase I (Roche, New South Wales, Australia) to digest all genomic DNA. The 
resulting lysate was mixed with ethanol and guanidine salt buffer to optimise RNA binding 
conditions, and the sample applied to an RNeasy MinElute® spin column (Qiagen) to 
remove contamination and preferentially retain RNA. RNA from each sample was then 
eluted in 30 μL of RNase-free water (Life Technologies, Carlsbad, USA) and stored at -
20°C. RNA yield (ng/μL) was determined by measuring absorbance at 260 nm (A260) and 
280 nm (A280) with a spectrophotometer (NanoDrop® ND-1000, Thermo Scientific, 
Waltham, USA). The A260:A280 ratio was used as a marker of protein contamination, and 
RNA samples with ratios ≥ 1.70 were included in further analysis. The volume per sample 
required to provide two aliquots of 200 ng RNA was determined, and one aliquot was used 
in pre-qualification analysis, and the remaining aliquot reserved for genomic expression 
profiling.  
 
3.1.3 Reverse transcription and RT-PCR  
Reverse transcription was undertaken to generate cDNA from RNA using a DASL® Single 
Use cDNA Synthesis Kit (Illumina®, San Diego, USA) as per the manufacturer’s 
instructions. 200 ng of RNA for each sample was normalised to 5 μL with RNase-free 
water prior to use. Pre-qualification and quantification of RNA was performed with real 
time-PCR (RT-PCR) using primer sets designed to amplify a fragment of RPL13A, a highly 
expressed ribosomal protein (F: 5ʹ-GTACGCTGTGAAGGCATCAA-3ʹ; R: 5ʹ-
GTTGGTGTTCATCCGCTTG-3ʹ; Sigma-Aldrich®, St Louis, USA). Each cDNA product was 
amplified using the Qiagen QuantiTect® SYBR® Green PCR Kit and a RotorGene 6000 
real-time cycler (Corbett Life Science, Australia). Each reaction contained 1 μL of cDNA 
product, 1 μL of 10 μM of each primer and 2 x SYBR Green PCR Master Mix at a final 
volume of 15 μL. PCR reaction conditions were: 95°C for 15 min, followed by 40 cycles of 
95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec. The cycle threshold (CT) was 
calculated with the accompanying software (version 1.7), and used as an estimate of 
target cDNA abundance with a CT value ≤ 28.5 accepted as sufficient. Primer set 
specificity was confirmed by visualisation of a single PCR product of the expected 
molecular weight using DNA gel electrophoresis at 100 V (1% agarose gel in Tris-acetate-
EDTA).    
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3.1.4 Microarray 
Microarray genomic expression profiling was undertaken using the Illumina® Whole-
Genome DASL® HT Assay as per the manufacturer’s instructions (see Figure 3.1). This 
assay hybridises to the Illumina® HumanHT-12 v4.0 Expression BeadChip to assess and 
compare the expression profile of more than 47,000 transcripts within the study groups. 
This BeadChip was limited to a maximum of 12 samples for each chip (2 chips per pack).  
 
 
 
Figure 3.1. Whole Genome DASL® HT Assay. Abbreviations: cDNA, complementary DNA; 
DAP, DASL Assay Pool; PCR, polymerase chain reaction. Image from Illumina® 
(https://www.illumina.com/technology/beadarray-technology/whole-genome-dasl- 
assay.html) 
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200 ng of total RNA per sample was reverse transcribed to cDNA using biotinylated 
primers with a DASL® Single Use cDNA Synthesis Kit (Illumina®). This step generates 
sufficient RNA for single use in the DASL HT Assay. RNA samples were normalised to 100 
ng/μL with RNase-free water, and incubated with provided MCS3 reagent to generate 
biotinylated cDNA. The biotinylated cDNAs were annealed to two DASL® Assay Pool 
(DAP) oligonucleotides (oligos; one upstream-specific and one downstream-specific) and 
combined with hybridisation reagent. This mixture was then bound to streptavidin-
conjugated paramagnetic particles to capture cDNA-oligo complexes. Following 
hybridisation, unbound oligos were removed by washing, and the hybridised cDNA 
extended and ligated at 45°C to create a PCR template. This template was used in a PCR 
reaction with two universal primers (one biotinylated, one fluorescent) to create a labelled 
product, which was then hybridised to the BeadChip overnight at 58°C. The BeadChip was 
then washed with buffer and scanned for intensity data using a BeadArray™ Reader 
(Illumina®).  
 
3.1.5 Microarray data and pathway analysis 
Microarray expression data was analysed with GeneSpring (v12.5, Agilent Technologies, 
Santa Clara, USA). Fluorescent intensities were normalised using quantile normalisation, 
and then to the mean expression level in each array. One-way analysis of variance 
(ANOVA) was applied to identify differential gene expression between all study groups. 
Pairwise Wilcoxon Mann-Whitney tests were also used to compare between two groups. 
The data was then assessed with Ingenuity® Pathway Analysis (IPA®, online software, 
Qiagen) using each pairwise analysis (without multiple testing criteria to maximise data 
capture). This process identifies the significant canonical pathways (and their mediators) 
associated with clinical PNI that are embedded within the PNI microarray dataset.  
 
3.1.6 Gene selection 
We targeted genes that were at least five-fold up-regulated in clinical PNI compared to 
CSCCHN and incidental PNI and of statistical significance (p < 0.05). These genes were 
further investigated using the Entrez Gene database and literature searches of EMBASE 
and Medline to correlate with gene function (NCBI, Bethesda, USA) and the genes with 
known or proposed roles in cancer progression and spread were targeted.  
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3.2 Immunohistochemistry 
Genes of interest were validated with IHC to assess protein-level expression using at least 
20 different FFPE specimens per group, through the QIMR Berghofer Medical Research 
Centre Histology Unit. 5 μm tissue sections were each sectioned separately using fresh 
blades used for RNA work only and sections were soaked in RNAlater® (Thermo Scientific, 
Waltham MA, USA) between each block to prevent contamination. Sections were then de-
waxed, rehydrated and then incubated in 2% hydrogen peroxide for 10 min to block 
endogenous peroxidase activity. After washing in water, antigen retrieval was undertaken 
by incubation in 10 mM citrate buffer in a de-cloaking chamber for 8 min at 121°C. 
Sections were then cooled, washed in TBS, and then blocked with Background Sniper 
(Biocare Medical, Concord, USA) for 15 min at RT. The primary antibody was then applied 
to one slide for each overnight at RT separately to prevent contamination. The primary 
antibodies utilised are detailed in Table 3.1. Sections were then washed in TBS, and 
MACH1 Universal Polymer (Biocare Medical) applied for 45 min and then washed in water. 
Control slide signals were developed in Vector Nova Red for 8 min. Sections were then 
counterstained in Haematoxylin, washed in water, dehydrated, cleared with xylene and 
then cover-slipped and mounted. IHC was optimised for each antibody with a positive and 
negative control utilised to ensure accuracy of interpretation.  
 
Slides were analysed by an independent histopathologist (non-blinded). The intensity of 
staining within tumour cells in each slide was graded as: 0 nil; 1 mild; 2 moderate; 3 
strong. The percentage of cells involved per slide was also graded. Each slide was given a 
total staining score (represented by a ‘H-score’), which was calculated from the product of 
the staining intensity and the percentage of tumour cells involved.198 In the sections with a 
variable staining pattern, a major and minor H-score was given, and the sum of these gave 
an overall H-score. H-score values were graphed and statistically analysed with Prism 
(v6.0, GraphPad Software, California, USA), applying one-way ANOVA and unpaired t-
tests. Images were captured on an Aperio® ScanScope® XT (Vista, USA) with 
ScanScope® software v101.0.0.18. 
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Table 3.1 Antibodies used in immunohistochemistry and Western blotting. 
Protein Company Species Application Dilution 
ATF3 Sigma Rabbit IHC-P 1:200 
CXCL9 Bioss Rabbit IHC-P 1:300 
EphA3 Abgent Rabbit IHC-P 1:400 
ESM1 Sigma Rabbit IHC-P 1:100 
FN1 Sigma Rabbit IHC-P 1:60 
FOXC2 Sigma/Abcam Mouse/Rabbit IHC-P/WB 1:200/1:500 
IL6 R&D Mouse IHC-P 1:100 
LOXL2 Bioss/Abcam Rabbit IHC-P/WB 1:150/1:500 
MDK Abgent Rabbit IHC-P 1:100 
SPHK1 Sigma Rabbit IHC-P 1:60 
S100 Dako Mouse IHC-P 1:300 
Myc Tag Cell Signalling Rabbit WB 1:1000 
tGFP Origene Mouse WB 1:5000 
E-Cadherin Cell Signalling Rabbit WB 1:1000 
N-Cadherin Cell Signalling Rabbit WB 1:1000 
Snail Cell Signalling Rabbit WB 1:1000 
Slug Cell Signalling Rabbit WB 1:1000 
GAPDH Trevigen Rabbit WB 1:5000 
Actin Sigma Goat WB 1:1000 
Abbreviations: IHC-P, immunohistochemistry paraffin embedded blocks; WB, Western blots 
 
3.3 Cell culture 
3.3.1 Cell line resuscitation 
Cryovials containing 1 mL cell line suspension were transferred from liquid nitrogen 
storage to dry ice. Vials were thawed by immersion in water at 37°C and cells were 
resuspended in 4 mL RPMI-1640-10% FCS-PS media at 37°C. Cells were centrifuged at 
1500 rpm at RT for 5 min and the supernatant discarded to remove DMSO (Sigma 
Aldrich). The cell pellet was resuspended in media and transferred to a T25 cm2 flask for 
culture. The cells lines used included A431 (tumourigenic SCC line), Colo16 (tumourigenic 
SCC line), HaCat (non-tumourigenic keratinocyte line) and KJD (non-tumourigenic 
keratinocyte cell line). 
 109 
3.3.2 General cell care 
All cell lines were incubated in RPMI-1640-10% FCS-PS media at constant conditions of 
37°C, 5% CO2 and 95% humidity. Each cell line was treated in the same manner. Media 
changes were conducted as required to maintain cell line growth. All cell lines were 
passaged twice weekly if required or once each cell line reached approximately 80% 
confluence. To achieve this, each flask was washed with PBS and cells lifted with 0.075% 
trypsin and then resuspended in RPMI-1640-10% FCS-PS media. Cell lines in T25 cm2 
flasks with 100% confluence were split into two T75 cm2 flasks for expansion.  
 
3.3.3 Freeze down 
For freezing of cell lines, cells were grown in a T75 cm2 flask in RPMI-1640-10% FCS-PS 
media until at least 80% confluence. Media was discarded, and the cells were lifted from 
the flask by incubation in 2 mL of 0.075% trypsin for at least 15 min, followed by 
resuspension in 8 mL RPMI-1640-10% FCS-PS. Cells were pelleted by centrifugation at 
1500 rpm for 5 min at RT. The cell pellet was resuspended in 2 mL of media and 2 mL of 
20% DMSO in RPMI-1640-10% FCS-PS. 1 mL of each cell line was aliquoted into 
cryovials and transferred to a Nalgene™ Cryo 1° freezing container (Thermo Scientific, 
Waltham MA, USA) for freezing to -80°C prior to long-term liquid nitrogen storage. 
 
3.3.4 Cellular protein preparation 
For cell lysis, cell lines were grown in a T75 cm2 flask in RPMI-10% FCS-PS until greater 
than 80% confluence. Cells were washed in 10 mL PBS, harvested by scraping in 5 mL 
PBS at 4°C and transferred to a 10 mL tube. Cells were pelleted by centrifugation at 1500 
rpm for 5 min at 4°C and the supernatant discarded. The cell pellet was resuspended in 1 
mL of PBS at 4°C and transferred to a 1.5 mL microfuge tube. This suspension was 
centrifuged at 13,200 rpm for 1 min at RT and supernatant discarded. The cell pellet was 
then stored at -20°C until required.  
 
Protease Inhibitor Cocktail (PIC, 1X, Roche) was added to cell lysis buffer (CLB) just prior 
to use. The cell pellet was resuspended in 200 μL CLB-PIC and sonicated for 30 pulses at 
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4°C using a sonicator (Branson, Connecticut, USA). This suspension was centrifuged at 
13,200 rpm for 10 min at 4°C with insoluble cell contents discarded. The soluble 
supernatant protein was transferred to a 1.5 mL eppendorf tube and stored at -20°C until 
required.  
 
3.3.5 Protein estimation 
Protein concentration for each sample was estimated with the Pierce BCA (bicinchoninic 
acid) Protein Assay Kit (Thermo Scientific) using standards of albumin of known 
concentration. Cell lysate samples were diluted in DNase free water H2O (1:10) to a 
volume of 10 μL, which was plated in duplicate into a flat-bottomed 96-well plate (Costar®, 
Corning, New York, USA). Stock solutions of BSA were prepared at 100, 200, 400, 600, 
800, 1000 and 1200 μg/mL and plated in duplicate alongside the cell lysate samples. 100 
μL aliquots of BCA reagent (50 parts of reagent A and 1 part of reagent B as per the 
manufacturer’s instructions) were added to each well. The plate was incubated for 30 min 
at 37ºC. Raw absorbance was read at A562 on the VersaMax™ microplate reader 
(Molecular Devices, California, USA) and a standard curve produced using SoftMax Pro 
(Molecular Devices). The protein concentrations of cell lysates were then estimated from 
the standard curve. 
 
3.3.6 Western blot  
Cellular proteins of interest were detected with Western blot using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad, California, USA). A 
10% loading gel and 5% stacking gel were used. 30 μg of each cell lysate sample was 
made up to 20 μL volume with loading buffer, and then heated at 65°C for 5 min for protein 
denaturation. Samples were loaded onto gels alongside a low molecular weight marker, 
immersed in running buffer, and run at 200 V for 45 min at RT. Protein was transferred to 
nitrocellulose membrane by running apparatus in transfer buffer at 100 V for 1 hour at 4°C. 
Non-specific proteins on membrane were blocked with 5% blotto for 1 hour. The 
membrane was incubated at 4ºC overnight in primary antibody at optimal working dilution. 
The following day, the membrane was washed in 1 x PBS Tween-20, and then incubated 
at RT with species-specific secondary antibody for 1 hour. After further 1 x PBS Tween-20 
washes, membranes were then incubated for 1 min with Western Lightning® 
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Chemiluminesence Reagent Plus (PerkinElmer, Massachusetts, USA) to generate a 
horseradish peroxidase (HRP)-substrate-derived detectable signal which was developed 
and imaged on X-ray film using an X-OMAT film processor (Kodak, New York, USA). The 
primary antibodies used in Western blotting are detailed in Table 3.1. 
 
3.4 Primary perineural cell line  
There are no commercially available cell lines derived from cutaneous SCC with perineural 
invasion. Therefore, the generation of a primary cutaneous SCC perineural cell line was 
attempted. This was undertaken using fresh tissue from patients with clinical PNI 
harvested at the time of surgery with informed consent. A 50-100 mm3 piece of tumour was 
collected (typically contained within a segment of cranial nerve) and placed in RPMI-1640 
FCS-10% PS media at 4ºC for transport. 
 
A number of techniques were trialled with the aim of achieving adequate cell proliferation 
and culture for passage. Tumour was homogenised by: (i) macro-dissecting it from any 
surrounding tissue with a scalpel using aseptic technique to fragment tissue to the cellular 
level; and/or (ii) incubation in collagenase B (2 mg/mL, Roche) in 5 mM calcium chloride 
for 30 min, followed by pipette mixing for homogenisation.  
 
The tumour was then seeded onto 6-well plates in media and incubated at 37ºC 5% CO2. 
The media used for incubation also varied: (i) RPMI-1640 FCS-10% PS; (ii) DMEM (Life 
Technologies); or (iii) keratinocyte serum-free media (Life Technologies). Media was 
changed twice weekly and the plates were monitored for cell proliferation and colony 
formation. In addition, following incubation in collagenase B and macro-dissection with a 
scalpel, tumour suspension was centrifuged at 5000 rpm for 5 min at RT. The supernatant 
was removed, the cell pellet resuspended in 200 μL of RPMI-1640 FCS-10% PS media, 
and 50 μL of this suspension was then injected into the dorsum of a NOD-SCID mouse for 
in vivo tumour culture.   
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3.5 Transfection of cell lines 
Human Myc-DDK-tagged ORF LOXL2 cDNA clone was used for over-expression of 
LOXL2 (Cat#: RC200455; OriGene Technologies, Maryland, USA) and Myc-DDK-tagged 
ORF FOXC2 cDNA clone for FOXC2 (Cat#: RC223412; OriGene). A Myc-DDK-tagged 
pCMV6-Entry Vector was used as control (Cat#: PS100001; OriGene; see Figure 3.2a). 
The LOXL2 and FOXC2 cDNA clones have the same base structure as the Entry Vector 
control, yet have been modified by the insertion of the relevant gene (see Figure 3.2b). 
The pCMV6-Entry Vector possesses kanamycin and G418 resistance markers for 
antibiotic-mediated selection, a Myc-DDK cassette for detection of vector presence and 
has a CMV promoter.  
 
 
 
 
 
Figure 3.2(a) 
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Figure 3.2 (b) 
Figure 3.2. (a) Vector map and sequence for Myc-DDK-tagged pCMV6-Entry Vector 
Control demonstrating insertion points for LOXL2 and FOXC2 gene segments for vector 
customisation. Image courtesy of OriGene (b) The sequences for the Myc-DDK-tagged 
ORF LOXL2 and FOXC2 cDNA clones. Images from OriGene (www.origene.com). 
 
FOXC2 LOXL2 
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LOXL2 gene silencing was also undertaken using four separate constructs of HuSH 
pGFP-V-RS plasmid vector containing LOXL2 short-hairpin (sh)-RNA (Cat#: TG311699; 
see Figure 3.3; Origene). Two control vectors were also used both based on the pGFP-V-
RS plasmid, one scrambled control (Cat#: TR30013) and one negative control (Cat#: 
TR30007). The pGFP-V-RS plasmid possesses kanamycin and puromycin resistance 
markers for antibiotic-mediated selection, a tGFP cassette for detection of vector presence 
within cells and has a CMV promoter.  
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Vector map and sequence for HuSH pGFP-V-RS plasmid vectors (1-4) 
containing LOXL2 short-hairpin (sh)-RNA, scrambled control and negative controls. Image 
from OriGene (www.origene.com). 
 
3.5.1 Transformation of E. coli 
Destination vector selection was achieved by incubating each vector with DH5α 
subcloning efficiency chemically competent Escherichia coli (E. coli) on agar antibiotic-
impregnated media. In a fresh 1.5 mL microfuge tube, 0.5 μL of reconstituted cDNA vector 
was added to 30 μL of E. coli suspension, and stored on ice for 30 min to encourage 
transformation, followed by heat shocking for 45 seconds at 42°C to arrest transformation. 
Tubes were placed on ice for 2 min, and then incubated in 1 mL SOC media with rotary 
 
1. AGCAACGCCTTCCAGGAGACCTGGTATTG 
2. TGCCACATAGGTGGTTCCTTCAGCGAAGA 
3. CAGTGTGCCATGGAGGAGAACTGCCTCTC 
4. TCTGCTTGGAGGACACAGAATGTGAAGGA  
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agitation at 150 rpm for 1 hour at 37°C. cDNA vector-E. coli solution (200 μL) was plated 
onto 2% Luria Broth (LB) agar treated with 100 μL kanamycin (100 mg/mL) and incubated 
overnight at 37°C for colony growth and selection. The following day, three viable colonies 
for each cDNA vector were selected and incubated in 10 mL LB media with kanamycin 
(100 mg/mL) with rotary agitation at 180 rpm at 37°C overnight. 
 
3.5.2 Plasmid DNA extraction and purification 
Plasmid DNA extraction and purification was then undertaken using the QIAprep® Spin 
Miniprep Kit (Qiagen). After incubation overnight, 1.5 mL of the selected colonies in media 
was centrifuged at 13,000 rpm at RT for 3 min to generate a cell pellet. The cell pellet was 
resuspended in buffer and alkaline cell lysis undertaken according to the manufacturer’s 
instructions. The cell lysate was neutralised, cleared by centrifugation at 13,200 rpm at RT 
for 10 min, and then purified and absorbed onto a QIAprep silica membrane. The plasmid 
DNA was washed and eluted using a QIAprep spin column.  
 
3.5.3 Enzyme digestion and electrophoresis 
Purified plasmid DNA concentration and quality was assessed with enzyme digestion and 
gel electrophoresis. Plasmid DNA (10 μL) was incubated with 0.5 μL of appropriate 
restriction enzyme (stabilised in 2 μL buffer, 0.2 μL BSA and DNase-free H2O to volume of 
20 μL; New England Biolabs, Massachusetts, USA) at 37°C for 1 hour. Restriction 
enzymes utilised included XhoI, EcoRI and Sal1. For gel electrophoresis, 20 μL of 
digestant product in loading buffer was loaded onto a 1% agarose gel alongside 10 μL of 1 
kb DNA marker at 80 V for 1 hour at RT. The gel was imaged using MiniBIS Pro and 
GelCapture software (DNR Bio-imaging Systems, Jerusalem, Israel). 
 
3.5.4 Destination vector stock 
To generate destination vector stock, 1 mL of transformed E. coli was added to 100 mL of 
LB media treated with kanamycin (100 μg/mL) and incubated at 37ºC overnight with 
agitation at 220 rpm. The following day, this stock was split into two 50 mL aliquots and 
centrifuged at 4000 rpm for 15 min at RT. The supernatant was discarded and the cell 
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pellet retained. Stock plasmid DNA was then purified and extracted using the QIAprep 
Spin Kit according to the manufacturer’s instructions (Qiagen). Briefly, the pellet of 
transformed bacteria was subjected to alkaline lysis, and the lysate cleared by 
centrifugation. Plasmid DNA was bound to a resin membrane, washed and eluted. DNA 
was precipitated with isopropanol, and the pellet washed in ethanol and air-dried. The 
DNA pellet was resuspended in buffer and concentration determined at A260/A280 
absorbance with a Biomate™ 3 spectrophotometer (Thermo Scientific). Plasmid DNA was 
then stored at -20ºC until further use. 
 
3.5.5 Sequencing validation 
Plasmid cDNA sequencing was undertaken for validation of the destination vector product 
in plasmids that were not sequence-verified by the manufacturer. Plasmid cDNA was first 
amplified with PCR and then sequenced using BigDye® Terminator v3.1 (Life 
Technologies). The reaction mix contained BigDye Terminator with reaction buffer and 1.5 
mM primer. The reaction was first denatured at 95ºC for 5 min, followed by 27 cycles of 
denaturing at 96ºC for 10 sec, annealing at 50ºC for 5 seconds and extension at 60ºC for 3 
min. The reaction was then held at 4ºC. The sequencing reaction was cleaned by 
isopropanol precipitation. The PCR product was incubated in 72 μL of 70% isopropanol for 
15 min, followed by centrifugation at 13,200 rpm for 30 min at RT. The supernatant was 
removed, and 150 μL of 70% isopropanol added to the pellet. This was then centrifuged 
for 10 min, the supernatant removed and the pelleted PCR product air-dried. The PCR 
product was run on the Applied Biosystems 3130 Genetic Analyser (Life Technologies) 
and sequences analysed using BioEdit sequence alignment editor (v7.5.0.3, Ibis 
Biosciences, CA, USA) and Chromas software (Technelysium, Brisbane, Australia).  
  
3.5.6 Cell line transfection 
Each cell line was grown on a six-well plate in 2 mL of RPMI-1640-FCS-10% PS media 
until reaching 60-80% confluency. Lipofectamine® 2000 transfection reagent (Life 
Technologies) was used to enable transfection as per the manufacturer’s instructions. 
Lipofectamine was incubated with Opti-Mem® serum-free media for 5 min (Life 
Technologies). This mix was combined with each plasmid DNA in Opti-Mem® serum-free 
media and incubated for 20 min. Each final mix was then added to each cell line and 
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incubated overnight at 37ºC. A lipofectamine control was also used (i.e. no plasmid DNA). 
The following day, the media was changed and cell lines incubated overnight at 37ºC.  
 
Utilising the antibiotic resistance marker relevant to each vector, an appropriate antibiotic 
was then added to each cell line for antibiotic-mediated selection of transfected cells (see 
Figures 3.2 and 3.3). G418 (500 μg/mL) was used for LOXL2 and FOXC2 over-expression 
lines, whilst puromycin (0.5 μg/mL) was used for LOXL2 sh-RNA lines. Once reaching 
80% confluency, each well containing treated cells was expanded into a T75 cm2 flask, 
and antibiotic selection maintained.  
 
General cell line care and maintenance was continued until cell growth was sufficient to 
permit freezing down of at least two cryovials to -80ºC for storage and the generation of a 
cell pellet. The cell pellets underwent cell lysis as per section 3.3.4, and the lysate used in 
Western blot to check for the presence of vector and relevant protein product. Over-
expression of LOXL2 was determined by probing for LOXL2 and Myc-Tag. LOXL2-
silencing was determined by probing for LOXL2 and tGFP.     
 
3.6 Cell biology & functional analysis 
3.6.1 Attachment-dependent growth  
For the measurement of attachment-dependent growth, cell lines were grown to 
approximately 80% confluency and then lifted from flasks with 0.075% trypsin. 10,000 cells 
per well were seeded into eight replicate 96-well plates in RPMI-1640- FCS-10% PS with 
antibiotic, and incubated overnight at 37ºC, 5% CO2. The following day, one plate was 
fixed in methylated spirit and stored at 4ºC. This process was repeated every 24 hours 
over the following 7 days.  
 
After all plates were fixed for a minimum of 24 hours, a sulforhodamine B (SRB) assay 
was used for cell density determination. Methylated spirit was discarded, and each plate 
was rinsed in 1 x PBS. Each well was stained with 50 μL of 0.4% SRB dye in 1% acetic 
acid and incubated at RT for 15 min. Each plate was then washed twice in 1% acetic acid. 
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100 μL of 10 mM Tris buffer was then added to each well and incubated at RT for 5 min. 
The optical density of each well at 564 nM was then determined with a Versamax™ 
microplate reader. 
 
3.6.2 Attachment-independent growth  
For the measurement of attachment-independent growth and colony-forming efficiency, 
12,000 cells per well were seeded into 6 well plates in 0.4% agar in RPMI-1640- FCS-10% 
PS on a bed of 0.8% agar in RPMI-1640 FCS-10% PS. The plates were incubated for 21 
days at 37ºC, 5% CO2. After 21 days, the number and size of any colonies was recorded 
with an inverted microscope.  
 
3.6.3 Clonogenicity  
To assess colony-forming efficiency, 100 cells per well were seeded into 6 well plates in 
RPMI-1640- FCS-10% PS and incubated for 14 days at 37ºC, 5% CO2. Media was then 
discarded and plates fixed in methanol at 4ºC for 24 hours. Methanol was then discarded, 
and each well was stained with 0.05% crystal violet and incubated at RT for 45 min. The 
staining solution was then discarded, the plates rinsed with water and allowed to air-dry 
overnight, and the colonies were then counted.  
 
3.6.4 Invasion  
Cell invasion properties were assessed using a Matrigel™ chamber invasion system. BD 
Biocoat™ Matrigel™ Invasion Chambers (BD Biosciences, California, USA) were prepared 
by thawing and rehydrating in media according to the manufacturer’s instructions. 100,000 
cells were seeded per chamber in RPMI-1640 FCS-10% PS (with three replicates) in a 24-
well plate and incubated for 24 hours at 37ºC, 5% CO2. The following day, the media was 
discarded and the upper surface of the chamber wiped with a PBS-soaked cotton-tip to 
remove cells on the surface that had not invaded through the membrane. The chambers 
were then fixed by immersion in methanol for 24 hours at 4ºC. The following day, the 
methanol was discarded and the chambers stained by immersion in 0.05% crystal violet in 
acetic acid for 2 min at RT. The chambers were then washed twice in Milli Q water and 
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then left to air-dry. Once dry, the membrane was imaged under a microscope and cells 
that had invaded through the membrane were counted.  
 
3.6.5 Migration  
To assess a cell’s migratory properties, a migration assay was performed using the 
IncuCyte™ ZOOM kinetic imaging system (Essen Bioscience, Michigan, USA). Cell lines 
were seeded onto 96-well ImageLock plates (Essen) to reach confluency following 
incubation at 37ºC, 5% CO2 overnight (between 750,000 and 1,500,000 cells per well). 
Once confluent, the plates were scratched using a 96-pin Essen Woundmaker™ as per 
the manufacturer’s instructions. The plates were then washed twice with RPMI-1640 FCS-
10% PS, and then 100 μL of media added. The plates were then incubated in the 
IncuCyte™ ZOOM kinetic imaging system at 37ºC, 5% CO2 and imaged at hourly intervals 
for 24 hours. IncuCyte™ ZOOM software was used to analyse wound width reduction over 
time.  
 
3.6.6 Morphology 
The morphology of each cell line was assessed and compared to corresponding vectored 
control. Each cell line was plated into a 6-well plate and incubated overnight at 37ºC, 5% 
CO2. Once cells reached approximately 60-75% confluency, plates were imaged with an 
inverted microscope.  
 
3.6.7 Tumourigenicity 
All animal work for this thesis was approved by the QIMR Animal Ethics Committee 
(Approval #: P343). Mice were utilised for studying tumourigenicity which were housed at 
the QIMR Berghofer animal holding facility. Mice were maintained on a twelve-hour 
light/dark cycle, and health monitored regularly. The pre-defined limit of tumour burden 
was 1000 mm3 total per mouse.  
 
To assess the tumourigenicity of cell lines in vivo, BALB/c nude mice were injected with a 
suspension of tumour cells and observed over 2-4 weeks for tumour growth. Following 
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trypsinisation, cell lines were resuspended in RPMI-1640 FCS-10% PS and counted. A 
stock containing 1-2 million cells/mL (depending on cell line growth characteristics) was 
then produced. 50 μL of each cell line was injected via intradermal route, bilaterally into 
the dorsum of two mice. Tumour growth was measured with calipers at least once a week. 
Tumour volume was calculated using the formula: Volume (mm3) = (length)2/width. Once 
the pre-defined limit of tumour burden was reached, the mice were euthanased using 
standard protocols. Tumours were dissected and placed in 10 mL of 10% formalin at 4ºC 
overnight. The following day, the formalin was discarded and replaced with 10 mL 70% 
ethanol for long-term storage at 4ºC. Formalin-fixed specimens were paraffin-processed 
and stained at the QIMR Berghofer Histology Unit with H&E and S100. S100 was used to 
assess for the presence of peri-tumoural incidental PNI. Tumours were also stained for the 
respective study gene/protein and S100 to identify PNI.  
 
3.7 Statistical analysis 
GraphPad Prism v6.0 was used for statistical analysis, with a p value ≤ 0.05 considered 
statistically significant. The strength of significance was denoted in figures when required 
with an asterix, where * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
Data was expressed as mean ± standard deviation when required and the statistical tests 
performed included t-test (two-tailed or Benjamini and Hochberg False Discovery Rate) 
and one-way ANOVA as indicated. Analysis of growth and migration curves for statistical 
significance was undertaken using software (Compare Groups of Growth Curves, 
http://bioinf.wehi.edu.au/software/compareCurves/index.html). This performs 5000 - 
10,000 permutation tests of differences between curves to calculate a p value, with p < 
0.05 deemed significant.  
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Chapter 4 
Discovery of markers of perineural spread of cutaneous SCC 
 
4.1 Introduction  
The molecular factors involved in PNS are unknown, and analysis of this disease using 
whole genome expression profiling had not been previously undertaken at the 
commencement of this study. In addition, no biomarkers to indicate prognosis or risk of 
disease progression have been identified. This study sought to define and compare the 
whole genome expression profiles of CSCCHN, CSCCHN with incidental PNI and 
CSCCHN with clinical PNI. The Whole-Genome DASL® HT Assay with hybridisation to the 
Illumina® HumanHT-12 v4.0 Expression BeadChip was used to assess and compare the 
expression profile of more than 47,000 transcripts within the patient tumour samples. 
Validation of significant findings was undertaken with IHC to identify those genes 
translated through to the protein level, adding further insight and weight to any role of 
differential gene expression in the disease process. 
 
4.2 Results 
4.2.1 RNA extraction and quantification 
FFPE tissue blocks were retrieved from pathology archives and assessed by an 
independent pathologist for both cutaneous SCC histology and the presence of PNI. A 
total of 68 cases were collected and processed for the extraction of RNA. 17 cases were of 
normal skin (12 taken from breast reduction surgery and 5 from donated neonatal foreskin 
tissue). There were 14 cases of CSCCHN, 13 cases of CSCCHN with incidental PNI and 
24 cases of clinical PNI from CSCCHN. The clinical PNI tissue specimens were from 
patients who underwent surgical resection of involved cranial nerve as treatment for 
recurrence of tumour into cranial nerve (i.e. the primary cutaneous tumour had been 
treated previously). Extraction of RNA from FFPE sections was performed as described in 
section 3.1.2.  
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Following extraction, the RNA concentration (A260) and protein contamination (A280) was 
calculated, with an A260:A280 ratio ≥ 1.7 accepted as adequate RNA purity from FFPE 
tissue. Patient samples above this purity threshold with sufficient concentration were 
further assessed with RT-PCR. The CT value from RT-PCR was used as a relative 
measure of RNA quantity and quality, and a CT value ≤ 28.5 was accepted as a strong 
positive reaction. In total, quality RNA was extracted in 42.65% (29/68) of FFPE samples. 
Only one sample in the normal skin group reached this threshold and this group was 
therefore not included in the profiling analysis. In the remaining 3 groups, 12 cases of 
CSCCHN, 8 cases of incidental PNI and 9 cases of clinical PNI had sufficient RNA quality 
and quantity. 
 
4.2.2 Microarray data analysis 
Patient characteristics and RNA qualification data of the 24 samples included in the 
microarray are summarised in Table 4.1. This initially comprised 8 patient samples per 
group. However, review of patient histology prior to RNA amplification and hybridisation 
demonstrated that one CSCCHN sample was misclassified in the incidental PNI group. 
Therefore, the final group allocations were 9 samples of CSCCHN, 7 samples of incidental 
PNI and 8 samples of clinical PNI.  
 
Normalised data from the microarray is graphically represented in Figure 4.1. This 
demonstrates high and low gene expression levels in each sample on a log scale. In total, 
27,607 transcripts from 19,770 genes were expressed in at least one sample across the 
entire cohort. Analysis with one-way ANOVA demonstrated 6917 genes with significantly 
different expression pattern between the groups (p ≤ 0.05). Hierarchical clustering was 
used to illustrate these patterns. As seen in Figure 4.2, many genes that were down-
regulated in CSCCHN were up-regulated in clinical PNI, whilst those up-regulated in 
CSCCHN were down-regulated in clinical PNI. A spectrum of progression from CSCCHN 
to incidental PNI to clinical PNI was visually apparent, with increasing gene up-regulation 
and down-regulation between the groups for certain genes (see Figure 4.2).  
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Table 4.1 Microarray patient characteristics and RNA pre-qualification. 
Group  Age Gender Diff Primary site PNI PNI site A260: A280 
Conc 
(ng/μL) Ct 
SCC 68 M Mod Ear no n/a 2.04 121.01 25.45 
SCC 78 M Mod Forehead no n/a 2.09 636.37 27.11 
SCC 87 M Mod Ear no n/a 1.99 56.49 27.66 
SCC 66 M Mod Cheek no n/a 1.99 74.96 27.44 
SCC 76 M Mod Cheek  no n/a 2.04 294.23 25.32 
SCC 82 F Mod Neck no n/a 2.07 112.27 25.75 
SCC 71 M Mod Scalp no n/a 2.04 238.09 25.64 
SCC 79 M Mod Temple no n/a 2.04 143.61 28.35 
SCC 87 M Mod Scalp no n/a 2.01 55.5 27.95 
SCC + 
iPNI 71 M Mod Neck incidental peritumoural 1.71 107.67 27.4 
SCC + 
iPNI 53 M Mod Cheek  incidental peritumoural 2.03 93.98 26.69 
SCC + 
iPNI 70 M Mod Temple incidental peritumoural 2 75.33 27.74 
SCC + 
iPNI 68 F Well Nose incidental peritumoural 2.03 105.59 26.07 
SCC + 
iPNI 79 M Poor Cheek incidental peritumoural 1.96 52.68 28.2 
SCC + 
iPNI 77 M Mod Cheek incidental peritumoural 1.92 79.92 27.32 
SCC + 
iPNI 70 M Poor Neck incidental peritumoural 1.99 88.52 26.35 
SCC + 
cPNI 72 M Mod Cheek  clinical VII 1.95 86.41 26.4 
SCC + 
cPNI 63 M Mod Cheek clinical VII 1.96 143.49 25.98 
SCC + 
cPNI 52 M Well Cheek clinical V3 & VII 1.99 69.15 26.56 
SCC + 
cPNI 62 M Poor Cheek  clinical VII 1.93 44.19 27.57 
SCC + 
cPNI 73 M Mod Cheek clinical V3 & VII 1.97 251.36 26.96 
SCC + 
cPNI 55 M Poor Preauricular clinical VII 1.98 37.69 27.45 
SCC + 
cPNI 71 F Mod Cheek  clinical V2 2.03 24.09 27.75 
SCC + 
cPNI 77 M Poor Cheek clinical V2 1.89 196.54 26.74 
Abbreviations: Conc concentration; Ct cycling time; PNI perineural invasion; iPNI, incidental PNI; cPNI 
clinical PNI; Diff tumour differentiation; Mod moderate. 
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Figure 4.1. Normalisation of data from microarray expression profiling. Patient samples in 
groups are represented on the x-axis. Above 0 represents increased gene expression, 
below 0 represents decreased gene expression across the dataset. 
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                                        Figure 4.2(a)                  Figure 4.2(b) 
 
Figure 4.2. Microarray demonstrated differences in gene expression between clinical PNI 
(cPNI), incidental PNI (iPNI) and CSCCHN (SCC). (a) Hierarchical clustering of 6917 
genes with statistically significant different expression patterns between the three groups is 
shown (p ≤ 0.05). Genes are represented on the y-axis, and patient samples (in groups) 
on the x-axis. Gene expression pattern was depicted by a colour spectrum, with green 
shading signifying up-regulation, red shading signifying down-regulation and black 
signifying no difference in expression. (b) Venn diagram demonstrating pair-wise 
comparisons between clinical PNI, incidental PNI and CSCCHN statistically significant 
different gene expression (p ≤ 0.05).  
 
SCC   iPNI  cPNI 
Downregulated 
Upregulated 
6917 
genes 
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Condensed lists of the significant up-regulated genes with the highest fold change when 
groups were compared on pairwise analysis are included in Supplementary Tables 4.1 - 
4.4 in Appendix (t-test with Benjamini and Hochberg False Discovery Rate; p ≤ 0.05). 
Comparison between clinical PNI and incidental PNI demonstrated 342 genes with 
significantly different expression. When clinical PNI and SCC were compared, 7793 
significantly different genes were identified. Comparison between incidental PNI and SCC 
showed 2412 genes with significantly different expression. There was considerable 
overlap of gene expression between each pairwise analysis, as demonstrated in Figure 
4.2b.  
 
4.2.3 Pathway analysis 
Selected canonical pathways from the pathway analysis are listed in Tables 4.2 - 4.4. In 
summary, the common significant pathways in the dataset involved cellular processes 
(mitochondrial dysfunction and oxidative phosphorylation), cancer signalling pathways 
(Ephrin receptors, ERK/MAPK, mTOR pathways), EMT regulators and cell adhesion 
mediators (integrins, epithelial adherens), neuronal growth and axonal guidance molecules 
(reelin, NGF, neuregulin, netrins, neurotrophins), immune mediators (IL6, NFκB and TGF-
β) and general molecular mechanisms of cancer. The relevant factors within each 
significant pathway were then correlated with microarray data in order to narrow the 
search for gene targets.  
 
 
 
 
 
 
 
 
 
 127 
Table 4.2. Significant canonical pathways when clinical PNI genomic expression was 
compared to CSCCHN.  
Canonical pathway Log p-value Ratio 
Mitochondrial Dysfunction 5.45E+00 4.42E-01 
mTOR Signalling 4.36E+00 5.12E-01 
ERK/MAPK Signalling 3.83E+00 5.12E-01 
Oxidative Phosphorylation 3.72E+00 4.92E-01 
Integrin Signalling 3.67E+00 5.38E-01 
RhoA Signalling 3.60E+00 5.77E-01 
Molecular Mechanisms of Cancer 3.54E+00 4.72E-01 
PI3K/AKT Signalling 3.12E+00 4.74E-01 
Tight Junction Signalling 2.52E+00 5.15E-01 
STAT3 Pathway 2.47E+00 5.62E-01 
Neuregulin Signalling 2.11E+00 4.81E-01 
Ephrin Receptor Signalling 1.93E+00 4.43E-01 
NGF Signalling 1.93E+00 4.92E-01 
Remodelling of Epithelial Adherens Junctions 1.92E+00 4.14E-01 
Epithelial Adherens Junction Signalling 1.73E+00 5.06E-01 
IL-6 Signalling 1.18E+00 4.92E-01 
UVB-Induced MAPK Signalling 6.97E-01 4.66E-01 
TGF-β Signalling 6.10E-01 4.57E-01 
Neurotrophin/TRK Signalling 5.35E-01 4.34E-01 
Axonal Guidance Signalling 4.56E-01 4.02E-01 
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Table 4.3. Significant canonical pathways when clinical PNI genomic expression was 
compared to incidental PNI. 
Canonical pathway Log p-value Ratio 
ERK/MAPK Signaling 3.47E+00 2.56E-01 
Molecular Mechanisms of Cancer 3.35E+00 2.27E-01 
Ephrin A Signaling 3.18E+00 3.52E-01 
IL-6 Signaling 2.98E+00 2.90E-01 
UVB-Induced MAPK Signaling 2.29E+00 3.10E-01 
Integrin Signaling 2.25E+00 2.45E-01 
Wnt/β-catenin Signaling 2.21E+00 2.57E-01 
Reelin Signaling in Neurons 2.05E+00 2.82E-01 
Mitochondrial Dysfunction 1.78E+00 1.81E-01 
Ephrin Receptor Signaling 1.77E+00 2.10E-01 
Oxidative Phosphorylation 1.75E+00 2.17E-01 
NF-κB Signaling 1.72E+00 2.32E-01 
Regulation of the EMT Pathway 1.71E+00 2.30E-01 
TGF-β Signaling 1.54E+00 2.55E-01 
Neurotrophin/TRK Signalling 1.43E+00 2.50E-01 
PI3K/AKT Signalling 1.25E+00 1.97E-01 
mTOR Signalling 1.22E+00 2.02E-01 
Epithelial Adherens Junction Signalling 7.63E-01 2.08E-01 
Neuregulin Signalling 4.82E-01 1.73E-01 
Netrin Signalling 3.40E-01 1.38E-01 
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Table 4.4. Significant canonical pathways when incidental PNI genomic expression was 
compared to CSCCHN. 
Canonical pathway Log p-value Ratio 
Molecular Mechanisms of Cancer 6.22E+00 3.69E-01 
Oxidative Phosphorylation 4.69E+00 3.92E-01 
Mitochondrial Dysfunction 4.66E+00 3.21E-01 
mTOR Signalling 4.29E+00 3.76E-01 
ERK/MAPK Signalling 2.88E+00 3.55E-01 
Integrin Signalling 2.63E+00 3.70E-01 
UVB-Induced MAPK Signalling 2.31E+00 4.31E-01 
Ephrin Receptor Signalling 2.28E+00 3.24E-01 
Cell Cycle: G1/S Checkpoint Regulation 1.95E+00 3.89E-01 
Neurotrophin/TRK Signalling 1.82E+00 3.82E-01 
TGF-β Signalling 1.33E+00 3.62E-01 
Neuregulin Signalling 1.27E+00 3.17E-01 
IL-6 Signalling 6.30E-01 3.15E-01 
NF-κB Signalling 6.17E-01 2.98E-01 
Reelin Signalling in Neurons 5.99E-01 3.18E-01 
Tight Junction Signalling 5.94E-01 2.99E-01 
Sphingosine-1-phosphate Signalling 5.77E-01 2.93E-01 
Axonal Guidance Signalling 5.69E-01 2.75E-01 
Epithelial Adherens Junction Signalling 5.47E-01 3.05E-01 
Netrin Signalling 4.10E-01 2.24E-01 
 
 
4.3 Identifying gene targets 
A shortlist of promising genes for further investigation was generated using the following 
criteria: (i) at least 5-fold up-regulation in clinical PNI compared to incidental PNI and 
CSCCHN; and (ii) the gene was known or proposed to be associated with tumour 
proliferation, spread or neurotropism in other cancers based on pathway analysis and/or 
literature review. Ten genes meeting these criteria were selected for validation at the 
protein level with IHC, and they are summarised in Table 4.5. Genes excluded from the 
overall list included genes for salivary gland differentiation and function, which likely 
originated from tissue within clinical PNI samples that contained adjacent parotid tissue. A 
summary of the function of each of the candidate genes in the shortlist is listed below. 
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Table 4.5. Candidate gene shortlist. 
Gene 
Symbol 
Entrez 
Gene 
ID 
Name 
Fold 
change 
cPNI v 
iPNI 
Fold 
change 
cPNI v 
SCC  
Fold 
change 
iPNI v 
SCC 
IL6 3569 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 15.80 4.14 -3.81 
FOXC2 2303 
Homo sapiens forkhead box C2 
(MFH-1, mesenchyme forkhead 1) 
(FOXC2), mRNA. 
10.15 11.12 1.10 
ATF3 467 
Homo sapiens activating transcription 
factor 3 (ATF3), transcript variant 4, 
mRNA. 
9.46 11.82 1.25 
SPHK1 8877 Homo sapiens sphingosine kinase 1 (SPHK1), transcript variant 2, mRNA. 7.72 -1.70 -4.70 
CXCL9 4283 Homo sapiens chemokine (C-X-C motif) ligand 9 (CXCL9), mRNA. 7.32 ns ns 
MDK 4192 
Homo sapiens midkine (neurite 
growth-promoting factor 2) (MDK), 
transcript variant 1, mRNA. 
6.65 14.43 2.17 
LOXL2 4017 Homo sapiens lysyl oxidase-like 2 (LOXL2), mRNA. 6.21 5.64 -1.10 
EPHA3 2042 Homo sapiens EPH receptor A3 (EPHA3), transcript variant 2, mRNA. 5.87 6.31 1.07 
ESM1 11082 Homo sapiens endothelial cell-specific molecule 1 (ESM1), mRNA. 5.61 6.71 1.20 
FN1 2335 Homo sapiens fibronectin 1 (FN1), transcript variant 7, mRNA. 5.05 9.16 1.82 
 
 
4.3.1 LOXL2 
Lysyl oxidase-like 2 (LOXL2) is a copper amine oxidase that catalyses the crosslinking of 
collagen and elastin in the extracellular matrix for connective tissue formation and 
repair.199 It is encoded by the LOXL2 gene located on chromosome 8. It has been 
proposed to be involved in the EMT cascade, the process whereby a cell transitions from a 
static epithelial phenotype with strong cell-cell adhesions to being mesenchymal and 
possibly metastatic through weak cell-cell adhesions.180 This function of LOXL2 is believed 
to be through the stabilisation of SNAI1/Snail, resulting in mesenchymal marker 
upregulation and epithelial marker downregulation.200 Increased expression of LOXL2 has 
been demonstrated in many cancers including pancreatic, colon and breast cancers and 
noted to correlate with tumour grade, disease progression and reduced survival.201 
 
 131 
4.3.2 FOXC2 
FOXC2 is located on chromosome 16 and encodes Forkhead box C2, a member of a 
family of transcription factors involved in the regulation of genes for cell growth, 
proliferation and differentiation. It is also thought to be involved in the regulation of EMT, 
possibly during tumour metastasis.202,203 High FOXC2 expression is associated with 
metastasis in murine models of basal-like breast cancers.202 Increased FOXC2 expression 
has also been shown to correlate with lymph node metastases in colorectal cancer.204 In 
addition, high expression is associated with advanced oesophageal SCC disease through 
with lymph node metastases, lymphatic invasion and worse prognosis.205  
 
4.3.3 EPHA3 
EPH receptor A3 (EPHA3) belongs to a large family of receptor tyrosine kinases that bind 
ephrin ligands.206 The EPH signalling system is important in neural and vascular 
development, participating in axon guidance and EMT processes for normal heart 
formation.207,208 Although theorised to be a tumour suppressor gene, it is well recognised 
for its role in cancer with somatic mutations possibly disrupting its normal function.206,208,209 
Indeed, EPHA3 somatic mutations have been recognised in a variety of cancers such as 
mucosal head and neck SCC, haematological malignancies, melanoma and colorectal 
cancer.206,209,210 High expression of EPHA3 has been shown to be associated with 
metastatic melanoma (when compared to normal melanocytes) and also poor outcomes in 
patients with colorectal cancer.211,212   
 
4.3.4 ATF3 
Activating transcription factor 3 (ATF3) is from the ATF/cyclic AMP response element-
binding family of transcription factors.213 It is an adaptive response gene that regulates cell 
proliferation and cellular stress responses.214 ATF3 is also involved in the neuronal 
response to peripheral nerve injury and inflammation, with high expression apparent in 
peripheral regenerating neurons.214 ATF3 has been shown to be associated with 
cutaneous SCC, and may indirectly promote tumour formation through the suppression of 
p53.110 In prostate cancer, ATF3 over-expression in cell lines was associated with 
increased proliferation and high expression was seen in malignant prostate cancer 
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tissues.215 High ATF3 expression has also been shown in breast cancer tissue, and over-
expression induced metastatic features associated with up-regulation of fibronectin-1 
(FN1) and EMT regulators (Slug/SNA12 and TWIST).216 However, evidence exists of the 
converse role for ATF3 as a tumour suppressor through an increase in apoptosis 
suggesting its function may be tumour or cell dependent.216  
 
4.3.5 FN1 
The FN1 gene encodes fibronectin-1, an ECM glycoprotein that is involved in cell 
adhesion and migration, and evidence points to a role in tumour metastasis.217 It is also a 
component of the basement membrane that surrounds perineural cells.53 Increased 
expression of fibronectin has also been associated with EMT, and it is increased when 
other EMT markers are present (e.g. low E-Cadherin, increased vimentin and delta-EF1) in 
mucosal head and neck SCC cells with EMT phenotype.218,219 FN1 has also been shown 
to be up-regulated in breast cancer tissues.220  
 
4.3.6 ESM1 
Endothelial cell-specific molecule-1 (ESM1 or endocan) is a secreted proteoglycan, found 
mainly in endothelial cells in lung and kidney tissue where it may play a role in 
angiogenesis.221 Increased expression of ESM1 is noted in clear cell renal carcinoma, and 
associated with disease progression in hepatocellular carcinoma, and poor prognosis in 
breast cancer and non-small cell lung cancer.222-225 It has also been shown to be 
associated with melanoma cell lines with aggressive phenotype.226 
 
4.3.7 SPHK1 
Sphingosine kinase 1, the protein encoded by the SPHK1 gene, is an enzyme which 
phosphorylates sphingosine to sphingosine-1-phosphate (S1P), a lipid mediator.227 It 
regulates cell proliferation and survival following activation of a G protein-coupled receptor. 
This protein and its product S1P play key roles in TNF-alpha signalling and the NFκB 
activation pathway important in immune and inflammatory processes, anti-apoptotic 
mechanisms and also tumour formation.227 Increased expression has been associated 
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with oesophageal carcinoma metastasis, and over-expression of this protein can cause 
de-differentiation to a progenitor or stem cell phenotype.228  
 
4.3.8 MDK 
Midkine (neurite growth-promoting factor 2) is a growth factor that promotes angiogenesis, 
neurite outgrowth, and cell migration and growth.229, 230 High expression of midkine has 
been described in many cancers, such as prostate, pancreas, colorectal and breast.229,230 
In addition, high midkine expression within tumour cells has been shown to be associated 
with poor prognosis.230  
 
4.3.9 CXCL9 
Chemokine (C-X-C motif) ligand 9 (CXCL9) is a chemokine ligand for the CXCR3 receptor.  
It has been shown at high levels to be associated with migration of metastatic melanoma 
cells.231 Other chemokines associated with pancreatic cancer and PNI have also been 
described.23,232   
 
4.3.10 IL6 
Interleukin 6 (interferon, beta 2, IL6)  is an inflammatory cytokine that assists B cell 
maturation.233 Increased levels have been found in breast cancer tissue and cell lines, and 
may have prognostic implications.234 In addition, increased levels of IL6 have been shown 
in patients with colon cancer, with levels correlating with tumour size and metastases.235  
 
4.4 IHC validation 
A further independent set of 82 FFPE tissue blocks (none from the original samples used 
in the expression profiling) were collected from the pathology archives. In total, 21 samples 
of CSCCHN, 30 samples of incidental PNI and 29 samples of clinical PNI were collected 
and subjected to IHC with one section for each antibody (see Table 3.1 for antibodies 
used). One independent non-blinded histopathologist assessed all slides and a H-score of 
staining intensity was calculated for each section (as defined in section 3.2).198  
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LOXL2 staining strongly validated the microarray results with a significantly different 
staining pattern between the groups. The highest staining was evident in clinical PNI, 
followed by intermediate staining in incidental PNI and low staining in CSCCHN (p = 
0.0049 on ANOVA, see Figure 4.3). The significant difference was maintained when 
CSCCHN was compared to clinical PNI (p = 0.0032) and when incidental PNI was 
compared to clinical PNI (p = 0.03), yet not present when CSCCHN was compared to 
incidental PNI (p = 0.27).  
 
FOXC2 did not demonstrate significantly different staining between the groups on ANOVA 
(p = 0.22), yet a trend towards significance was evident when clinical PNI was compared 
to CSCCHN (p = 0.12). In addition, an overall trend between the groups was evident 
visually (see Figure 4.4).  
 
ESM1 showed a trend towards significance when clinical PNI was compared to CSCCHN, 
although there were very few positive cases (p = 0.08; see Figure 4.5). EPHA3 did not 
stain clinical PNI samples. This result was not consistent with the microarray findings of 
EPHA3 up-regulation in clinical PNI (see Figure 4.6). When the groups were compared, 
there was significantly different results between all groups (p = 0.02 on ANOVA) and this 
significance was evident when incidental PNI was compared to clinical PNI (p = 0.01).  
 
ATF3 staining did not demonstrate any significant differences between the groups (p = 
0.16 on ANOVA), yet a weak trend was observed when CSCCHN was compared to 
incidental PNI (p = 0.13) and clinical PNI (p = 0.1). However, the staining pattern was not 
consistent with the microarray data (see Figure 4.7). Low numbers of positively staining 
samples were seen with FN1 and SPHK1, with no significant difference between the 
groups (p = 0.92, see Figure 4.8; p = 0.27; see Figure 4.9, respectively). Little or no 
staining was seen with MDK, CXCL9 and IL6 (data not shown).  
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Figure 4.3. LOXL2 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). For each group, a representative slide for positive and 
negative staining is shown. Each stain was given a H-score by calculating the product of 
the staining intensity and the percentage of tumour cells with positive staining. One-way 
ANOVA demonstrated significant differences with high staining in clinical PNI, intermediate 
staining in incidental PNI and low staining in CSCCHN (p = 0.0049). 
 
Figure 4.4. FOXC2 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). This demonstrated a trend towards significance 
between clinical PNI and CSCCHN (p = 0.12). For each group, a representative slide for 
high staining and negative/low staining is shown. Graphic representation of H-score 
comparison is also included.  
 136 
 
Figure 4.5. ESM1 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). This demonstrated a trend towards significance 
between clinical PNI and CSCCHN (p = 0.08). For each group, a representative slide for 
high staining and nil/low staining is shown. Graphic representation of H-score comparison 
is also included.   
 
Figure 4.6. EPHA3 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). Staining was negative in clinical PNI samples. A 
significant difference was evident between the groups (p = 0.02) and between clinical PNI 
and incidental PNI on pair-wise analysis (p = 0.01). For each group, a representative slide 
for high staining and nil/low staining is shown. Graphic representation of H-score 
comparison is also included.   
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Figure 4.7. ATF3 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). This demonstrated a trend towards significance on pair-
wise analysis between CSCCHN and clinical PNI (p = 0.1), and CSCCHN and incidental 
PNI (p = 0.13). There was no significant difference between all three groups on ANOVA (p 
= 0.16) For each group, a representative slide for high staining and nil/low staining is 
shown. Graphic representation of H-score comparison is also included.    
 
Figure 4.8. FN1 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI (iPNI) 
and CSCCHN (SCC; x100). This demonstrated sparse staining in few samples with no 
significant differences between the groups (p = 0.92). For each group, a representative 
slide for high staining and nil/low staining is shown. Graphic representation of H-score 
comparison is also included.    
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Figure 4.9. SPHK1 immunohistochemistry comparing clinical PNI (cPNI), incidental PNI 
(iPNI) and CSCCHN (SCC; x100). This demonstrated sparse staining in few samples with 
no significant differences between the groups (p = 0.27). For each group, a representative 
slide for high staining and nil/low staining is shown. Graphic representation of H-score 
comparison is also included.   
 
In summary, DASL® whole genome microarray to screen for genomic expression 
differences followed by IHC in an independent set of tumour samples to validate at the 
protein level has shown one significant target gene in LOXL2, while FOXC2 proved an 
additional target with a trend towards significance. The other genes selected in the 
preliminary list for validation did not show IHC results that were concordant with the 
microarray, limiting them from further assessment in this study.  
 
4.5 Discussion 
This work has demonstrated the expression profiles of a small sample of CSCCHN, 
CSCCHN with incidental PNI and CSCCHN with clinical PNI. Many significantly different 
gene expression patterns were noted between the study groups, and based on this novel 
target genes were identified. The microarray as depicted in the hierarchical cluster 
diagram in Figure 4.2a suggests a spectrum of disease may exist, with disease 
progression from CSCCHN, CSCCHN with incidental PNI to CSCCHN with clinical PNI. 
We identified ten candidate genes, and one gene was further validated on IHC. At the time 
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this study was performed, no other assessment of CSCCHN with clinical PNI had been 
performed. Recently, a study has been published profiling incidental PNI from 
CSCCHN.178 An additional study has investigated the mutation profile of aggressive SCCs 
with whole exome sequencing, but did not include gene expression differences.85 The 
study described here still represents the only expression study of clinical PNI to our 
knowledge.  
 
Genomic expression profiling demonstrated 6917 genes with a significantly different 
expression pattern between the study groups. The search for key genes was narrowed to 
further investigate genes involved in tumour proliferation, spread and/or neurotropism with 
at least five-fold upregulation in clinical PNI. This criteria was used to maintain a broad 
approach to the dataset. No genes associated with axonal guidance or neurotrophins were 
identified within the dataset. It is possible that significant key genes in the disease process 
were selected out and further investigation of the dataset with bioinformatics will be 
needed. Indeed, it is most likely that a multitude of factors from tumour cells, local nerve 
fibres and the stromal microenvironment are involved in a complex interplay and that this 
process is not dependent on a single gene.172  
 
Interpretation of the microarray data is limited due to small numbers assessed in each 
group amidst the constraints of a pilot study. Also, there are likely factors that induce the 
development of incidental PNI from a given CSSCHN that may not have been identifiable 
from the representative CSCCHN specimens used in this study. Comparing a primary 
tumour to the perineural cranial nerve tumour in the same patient, or through the use of 
animal models in a more longitudinal study could be worthwhile.  
 
Key genes were correlated with the major pathways identified on pathway analysis to 
further narrow the search. Many pathways associated with tumour spread and progression 
was identified within the microarray dataset. Pathways involved in EMT, cell adhesion and 
signalling, axonal guidance, nerve growth factors, neurotrophins and cytokine signalling 
were shown to be significant. Whilst the mechanisms underlying PNI are unknown, these 
molecular factors have been proposed as possible contributors to this disease process in 
other tissues such as pancreas and prostate.172   
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Several limitations with this study are recognised. Given that no viable RNA was extracted 
from neonatal foreskin tissue, this group was not pursued further. Neonatal foreskin tissue 
is a commonly used control tissue and is readily available for skin research, however the 
impact of the clear age difference and development level of the tissue may restrict its 
applicability as a control tissue. Although normal skin from the head and neck is an ideal 
control tissue, results could have been confounded by a ‘field change’ effect from local sun 
and UV exposure. In addition, availability of normal skin from the head and neck for 
research purposes is limited. However, it would be ideal to compare expression profiles of 
normal skin and CSCCHN to further investigate SCC tumourigenesis.  
 
The tumour specimens were taken from different locations from different patients and this 
could be considered a confounding factor. The patients with clinical PNI presented as 
tumour recurrence, having had prior treatment to the skin for the primary skin neoplasm. In 
addition, any previous treatment with radiotherapy could have had an influence on gene 
expression and thus introduce bias. This could form the basis of future investigation. 
Clinical PNI specimens were taken from cranial nerve specimens (not from the skin), whilst 
incidental PNI and CSCCHN specimens were taken at the primary site within the skin. 
Clinical PNI patients typically present years after primary tumour treatment, and can 
present with clinical PNI from an unknown primary in almost 1 in 4 patients as described 
above (see section 2.2.4.2). 
 
Tumour was harvested from FFPE histological sections using a scalpel, guided by a H&E 
reference slide. Another method of tumour harvesting from FFPE sections is via laser 
capture, which can be more precise yet costly and time consuming.236 It is possible that 
adjacent non-pathological tissue was included in the RNA extraction and subsequent 
microarray, such as normal cranial nerve and salivary gland tissue (i.e. parotid gland 
resected with VII nerve specimens). We therefore filtered out any significant genes that 
correlated with normal local tissue, such as salivary gland. Conversely, it is also possible 
that local stromal factors were also included with the scalpel harvesting approach, and this 
has permitted a more complete tumour microenvironment profile to be generated.  
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The extraction of viable RNA from FFPE tissue blocks can be a difficult process with 
recognised limitations.237,238 Nucleic acids can fragment and degrade due to the formalin 
fixation process which results in crosslinks between nucleic acids and other local 
molecules.238 In addition, poor storage and handling conditions limit RNA viability, which is 
particularly pertinent in non-pathological tissues such as neonatal foreskin. The rate of 
success in this study using the techniques described was reasonable at 42.65%.  
 
We utilised commercially available antibodies for the IHC validation process. Only one 
section was able to be analysed for each antibody and this was due to limited tissue 
sections being available. The quality of these antibodies is highly variable and poor quality 
antibody binding could account for the limited validation observed in this study. 
Alternatively, the IHC results here could indicate an additional layer of gene modulation, 
possibly via aberrant microRNAs (miRNAs) that interfere prior to the level of protein 
translation.239 It has been suggested that certain miRNAs are key players in cancer 
processes, possibly in the tumour microenvironment where these short transcripts regulate 
protein expression via translation inhibition or mRNA degradation.239,240  
 
The current theories of the mechanism of PNI revolve around interplay between the 
tumour and nerve within the tumour microenvironment. LOXL2 and FOXC2 both drew 
attention due to their apparent role in EMT, which could trigger the cellular migration, 
invasion and spread seen in clinical PNI. LOXL2 appears to function both extracellularly to 
regulate the ECM, and also intracellularly via EMT induction.201 A key feature in EMT is the 
repression of E-Cadherin transcription, which is partly mediated by SNAI1/Snail and 
SNAI2/Slug transcription factors.241 LOXL2 has been shown to stabilise SNA1/Snail, and is 
considered a key factor in the repression of E-Cadherin for EMT induction (see Figure 
4.10).180,241 FOXC2 has been shown to be involved in tumour progression potentially via 
the EMT pathway.202 It is believed to promote cytoplasmic localisation of E-Cadherin, 
inducing mesenchymal differentiation (see Figure 4.11).242  
 
In this study, a target gene/protein (LOXL2) was validated as being more highly expressed 
at the mRNA and protein level in CSCCHN with clinical PNI compared to incidental or 
CSCCHN without PNI. Previous work has demonstrated LOXL2 up-regulation in mucosal 
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head and neck SCCs, with higher expression associated with poorer prognosis.243 It has 
also been shown to be associated with tumour progression in a mouse model of 
cutaneous SCC, and increased expression was associated with reduced survival in 
laryngeal SCC.244 LOXL2 expression correlates with increased metastatic potential and 
reduced survival in aggressive breast cancer.245 Higher expression was also shown to be 
associated with disease progression in human oesophageal and colon tumours.246,247 
LOXL2 has also become a novel target and a LOXL2 specific monoclonal antibody 
(AB0023) may find clinical application in cancer, inflammation and fibrosis.248  
 
 
 
Figure 4.10. Epithelial mesenchymal transition pathway involving LOXL2 (Image taken 
from Thiery 2009).180  
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Figure 4.11. Epithelial mesenchymal transition pathway involving FOXC2 to induce a 
mesenchymal phenotype (Image taken from Yang & Weinberg 2008).242  
 
 
LOXL2 may be exerting its actions intracellularly via induction of an EMT phenotype.249 
Conversely, LOXL2 may also be exercising its tumour promoting function extracellularly 
through modulation of the tumour microenvironment. Increased extracellular matrix 
deposition and ‘stiffening’ of the local tissues is proposed to contribute to tumour 
progression.250 LOXL2 may be secreted by stromal cancer-associated fibroblasts or 
tumour cells.247,251 LOXL2 secreted by tumour cells has also been shown to activate 
stromal fibroblasts and cause local desmoplasia (fibrosis), possibly via FAK (focal 
adhesion kinase) signalling.199 Increased expression of LOXL2 in stromal fibroblasts has 
also been shown to be associated with aggressiveness in gastric cancer.251 LOXL2 
silencing or inhibition using the LOXL2 inhibitor AB0023 reduced cell invasiveness both in 
vitro and in vivo, and this effect was possibly via a reduction in activated fibroblasts within 
the tumour microenvironment.252,253  
 
Although FOXC2 did not reach statistical significance on IHC validation, it showed an 
apparent trend on staining as being more highly expressed in CSCCHN with clinical PNI, 
and a significant effect could develop with higher sample numbers. FOXC2 has recently 
been shown to promote growth and migration of pancreatic adenocarcinoma cell lines, and 
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demonstrates higher expression within pancreatic adenocarcinoma tissues.254 One recent 
study also found FOXC2 was highly expressed and correlated with poor prognosis in colon 
cancer tumour samples.255  
 
Given this background and the validation results, LOXL2 and FOXC2 were both selected 
for functional analysis. The aim was to assess the impact of modulation of gene 
expression of LOXL2 and FOXC2 in the role of PNI. The following chapter will describe 
these studies.   
 145 
Chapter 5 
Functional analysis of LOXL2 and FOXC2 in cutaneous SCC 
with perineural spread 
 
5.1 Introduction 
In order to characterise the significance of differences in gene expression at the cellular 
level, two key genes of interest from the microarray analysis were selected for functional 
studies. These genes were chosen based on the strength of microarray findings, IHC 
validation and apparent role in tumour biology. In particular, genes that function to promote 
or facilitate tumour spread were targeted. LOXL2 and FOXC2 were selected given their 
proposed roles in EMT, a process thought to be involved in tumour spread and metastasis, 
and therefore potentially PNS.180 With regards to FOXC2, despite not reaching statistical 
significance on IHC validation, a trend consistent with the microarray result was evident, 
and this effect may have been more pronounced with greater sample numbers.  
 
The development of a primary perineural cell line was attempted. In addition, cell lines 
representative of CSCCHN were assessed for their native expression levels of the genes 
of interest. Depending on this, the cell lines were then transfected to overexpress and/or 
silence these genes, followed by Western blot to confirm vector presence and expression 
of, or knock-down of the gene of interest. Functional assays were then undertaken to 
assess the phenotypic changes of transfected cell lines when compared to a 
corresponding transfected control cell line. Assessment of growth, invasion, migration, 
colony-forming ability, morphology and tumourigenicity in mice was undertaken. This 
provided insight into whether a potentially significant phenotype change was induced by 
the over-expression or silencing of a candidate gene.  
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5.2 Results: Cell lines 
5.2.1 Primary perineural cell line 
Using fresh human tissue samples of CSCCHN with clinical PNI harvested at surgery, 
eight attempts at culturing a primary perineural cell line were made. Despite various 
methods (described in section 3.4), no immortal cell growth was achievable. Whilst in 
some instances cell colonies formed in culture, this was temporary and did not survive 
passage. There was no clear pattern as to an ideal culture medium. In most plates, tumour 
cells were overgrown by CAFs with time. These fibroblasts were harvested and stored at -
80°C for future investigation into their significance. In addition, no in vivo tumour growth 
was seen following injection of these fibroblasts into a NOD-SCID mouse after three 
months of observation (results not shown).  
 
5.2.2 Cell line selection  
Given the inability to generate a primary perineural cell line, commercially available 
representative cell lines were used for gene transfection and assessed with functional 
assays. The cell lines selected were A431 (tumourigenic SCC line), Colo16 (tumourigenic 
SCC line), HaCat (non-tumourigenic keratinocyte line) and KJD (non-tumourigenic 
keratinocyte cell line).  
 
All parental cell lines were assessed by Western blot for LOXL2 and FOXC2 baseline 
protein expression (for antibodies utilised see Table 3.1). This result was used to guide 
transfection planning and determine if the gene altered cell phenotype to being more 
aggressive, metastatic and/or invasive compared to transfected control. As illustrated in 
Figure 5.1, some LOXL2 protein expression was evident in A431, HaCat and KJD lines, 
yet not in Colo16. Therefore, gene transfection to induce LOXL2 over-expression in all 
lines was planned. In addition, LOXL2 gene silencing with sh-RNA was proposed for 
A431, HaCat and KJD lines. FOXC2 protein expression was not evident in any of the cell 
lines, and therefore over-expression of this gene in all cell lines was attempted (see Figure 
5.2).      
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Figure 5.1. Baseline protein expression of LOXL2 and FOXC2 in SCC (A431, Colo16) and 
keratinocyte (HaCat, KJD) cell lines. Based on this result, LOXL2 was to be over-
expressed by vector in all cell lines, and silenced by shRNA in A431, HaCat and KJD lines. 
FOXC2 was to be over-expressed in all cell lines. Dilutions of primary and secondary 
antibodies are shown.  
 
5.2.3 Plasmid preparation 
Plasmid DNA quality and quantity was confirmed with restriction enzyme digestion and gel 
electrophoresis. Four HuSH pGFP-V-RS plasmid vector constructs with LOXL2 short-
hairpin (sh)-RNA and two control vectors were provided by the manufacturer as sequence-
verified. However, sequencing verification of the LOXL2 and FOXC2 over-expression 
vectors and the Entry Vector control was required. This demonstrated a sequence match 
between each target gene and the respective vector cassette (LOXL2, FOXC2 and Entry 
Vector; sequencing data not shown).  
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Figure 5.2(a)   Figure 5.2(b) 
 
 
             Figure 5.2(c)            Figure 5.2(d) 
Figure 5.2. Western blot of cell lines following transfection of LOXL2 and FOXC2 cDNA 
vectors. LOXL2 over-expression was successful yet FOXC2 was not. (a) A431, (b) HaCat, 
(c) Colo16, (d) KJD. Myc-Tag expression confirmed vector presence at the corresponding 
band size for either LOXL2 or FOXC2. LOXL2 expression was confirmed to be over-
expressed when compared to control in A431, HaCat and Colo16. Dilutions of primary and 
secondary antibodies are shown. Image stitched for illustrative purposes. 
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5.2.4 Cell line transfection 
As seen in Figure 5.2, LOXL2 over-expression was successful in three cell lines following 
triplicate experiments with corresponding transfected control (A431, Colo16 and HaCat). 
KJD was not successfully transfected. Probing for LOXL2 confirmed target gene over-
expression compared to the empty vector control, and Myc-Tag expression confirmed the 
presence and expression of the tagged version of LOXL2 from the vector in over-
expressed lines. Myc-Tag expression was not detected in control cell lines. This was likely 
due to its small size (approximately 2 kDa) not being detectable on standard Western blot.  
 
The transfection of FOXC2 cDNA vector to induce gene over-expression into all cell lines 
was unsuccessful after triplicate attempts. The vector was not detected after probing for 
Myc-Tag on Western blot (see Figure 5.3). Therefore, no functional assays were carried 
out and FOXC2 was no longer pursued as a candidate gene in this study. This could 
possibly be due to cell toxicity generated by FOXC2 (see discussion below).  
 
LOXL2 silencing was attempted using four different shRNA constructs and this was 
successful in A431 and KJD cell lines after triplicate experiments. This was evidenced by 
positive turbo (t)GFP expression, and the degree of LOXL2 silencing was variable (see 
Figure 5.3). Negative (empty vector) and scrambled shRNA controls were also generated 
for each cell line. Two LOXL2 silencing constructs were selected for further assessment 
with functional assays by comparison to negative and scrambled controls (constructs KO-
89 and KO-92; see below section 5.3). Silencing in HaCat cell lines was not successful 
following triplicate experiments (data not shown).  
 
5.2.5 LOXL2-EMT pathway  
Further Western blots were undertaken to determine whether the over-expression and 
silencing of LOXL2 induced changes in cellular expression of downstream proteins known 
to be involved in the EMT pathway (see Figure 4.10). SNAI1/Snail and SNAI2/Slug are 
both downstream effector proteins, potentially stimulated by LOXL2. E-Cadherin was used 
as a marker of epithelial cell state (deactivated by LOXL2), whilst N-Cadherin was used as 
a marker of mesenchymal cell state (stimulated by LOXL2).  
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Figure 5.3 (a) 
 
Figure 5.3(b) 
Figure 5.3. Western blot demonstrating LOXL2 silencing in: (a) A431; and (b) KJD cells. 
Presence of vector was confirmed with tGFP expression. LOXL2 expression was 
compared to control to confirm silencing. Dilutions of primary and secondary antibodies 
are shown. 
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Western blot demonstrated increased expression of Slug protein in A431 and HaCat 
LOXL2 over-expressed cell lines compared to control, consistent with possible activation 
by LOXL2 (see Figure 5.4). Slug protein expression was relatively stable in A431 LOXL2 
silenced cells compared to control, yet did appear reduced in one KJD LOXL2 silenced 
construct (KO-89), compared to scrambled control (see Figure 5.5). No SNAI1/Snail 
protein expression was detected in any cell lines. E-Cadherin expression was stable, with 
no evidence of either reduced expression with LOXL2 over-expression or increased 
expression with LOXL2 silencing. N-Cadherin expression was not increased with LOXL2 
over-expression. The subtle increase in Colo16 lines with LOXL2 over-expression possibly 
represents loading error.   
 
 
 
Figure 5.4. Western blot demonstrating expression of molecules downstream of LOXL2 in 
the epithelial mesenchymal transition pathway in LOXL2 over-expressed cell lines 
compared to control (EVC). E-Cad (E-Cadherin), N-Cad (N-Cadherin). Antibody dilutions 
are described in Table 3.1. Image stitched for illustrative purposes.  
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Figure 5.5. Western blot demonstrating expression of molecules downstream of LOXL2 in 
the epithelial mesenchymal transition pathway in LOXL2 silenced cell lines (KO) compared 
to control (scrambled and negative controls). E-Cad (E-Cadherin), N-Cad (N-Cadherin). 
See Figure 5.3 for LOXL2 and tGFP expression. Antibody dilutions are described in Table 
3.1.  
 
5.3 Results: Functional assays 
5.3.1 LOXL2 over-expression  
5.3.1.1 Attachment-dependent growth 
When LOXL2 was over-expressed in A431 and HaCat cell lines, there was no significant 
change in growth pattern when compared to control cells containing the empty vector (see 
Figure 5.6a-b). LOXL2 over-expressed in Colo16 cells initially demonstrated a slower 
proliferation rate over time compared to control, reflected by significantly slower 
proliferation at Day 5 (p = 0.005; see Figure 5.6c). However, overall this was not significant 
with similar growth being observed by Day 7 (p = 0.01).  
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5.3.1.2 Attachment-independent growth 
Assessment of attachment-independent growth was undertaken in soft agar. No cell 
growth or colony-formation was evident in any cell line. This was undertaken in triplicate 
(data not shown).  
 
5.3.1.3 Migration 
The migratory properties of each cell line were assessed using a scratch/migration assay. 
When LOXL2 was over-expressed in A431 cells, an obvious trend towards slower 
migration compared to control was witnessed at 16 hours (p = 0.07; see Figure 5.6a). Yet 
over the total assay this was not significant, possibly due to variability between 
experiments performed in duplicate (p = 0.33). In addition, the A431 LOXL2-over-
expressed cells appeared to form colonies prior to migrating across the generated wound, 
leading to slower migration and variation amongst replicate wells. Given this cell line had 
similar growth patterns on the growth assay, this effect may be independent of proliferative 
properties alone. LOXL2 over-expression in HaCat did not significantly alter the cell 
migratory properties overall, although a trend towards slower migration was evident (p 
0.08; see Figure 5.6b). This effect was most pronounced at 11 hours (p = 0.057). 
Conversely, LOXL2 over-expression in Colo16 cells demonstrated a trend towards 
significantly faster migration over time when compared to control in triplicate experiments 
(p = 0.08; see Figure 5.6c). This effect was most pronounced at 11 hours (p = 0.06).  
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Figure 5.6(a) 
 
 
Figure 5.6(b) 
 
 
Figure 5.6(c) 
Figure 5.6. Functional assays assessing LOXL2 over-expression (OE) with attachment-
dependent growth (triplicate) and migration assays compared to control (duplicate, 
baseline-corrected wound width): (a) A431; (b) HaCat; (c) Colo16  
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5.3.1.4 Clonogenicity 
The clonogenicity (colony-forming ability) of each cell line was compared to control in 
triplicate experiments. Both A431 and HaCat cells did not display differences in colony 
count when LOXL2 over-expressed cells were compared to control (see Figure 5.7a), and 
cell morphology was similar. LOXL2 over-expression in Colo16 cells showed significantly 
lower colony counts with distinctly smaller colonies (see Figure 5.7a; p < 0.0001).  
 
5.3.1.5 Invasion 
The invasive capacity of each cell line was assessed with Matrigel chamber invasion 
assays performed in duplicate. In LOXL2 over-expressed cell lines, Colo16 and HaCat did 
not display differences in invasion when compared to control (see Figure 5.7b). Colo16 is 
known to be a weakly tumourigenic cell line, whilst HaCat is a non-tumourigenic 
keratinocyte cell line, and altering LOXL2 expression did not change their invasive 
potential. The A431 cell line is known to be tumourigenic with native invasive potential.256 
Over-expressing LOXL2 significantly reduced this property (p < 0.001).  
 
 
Figure 5.7(a)      Figure 5.7(b) 
Figure 5.7. (a) Clonogenicity colony counts of cell lines with LOXL2 over-expression (OE); 
(b) Chamber invasion of LOXL2 over-expressed (OE) lines. Counts of cells invading 
through Matrigel-impregnated chambers is shown as a proportion of cells plated.  
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5.3.2 LOXL2 silencing 
5.3.2.1 Attachment-dependent growth 
LOXL2-silencing in A431 produced no difference in growth pattern when compared to 
control (see Figure 5.8a). When LOXL2 was silenced in KJD cells, a slower growth rate 
was apparent in one construct when compared to controls (KJD KO-89). Whilst this did not 
reach statistical significance overall, KJD KO-89 at Day 6 had significantly slower growth 
compared to negative control (see Figure 5.9a; p = 0.007).      
 
5.3.2.2 Attachment-independent growth 
Assessment of attachment-independent growth was undertaken in soft agar. No cell 
growth or colony-formation was evident in any cell line. This was undertaken in triplicate 
(data not shown).  
 
5.3.2.3 Migration 
When LOXL2 was silenced in A431 cells, there was a trend towards faster migration in 
one construct (KO-89) when compared to negative and scrambled control (p = 0.1), and 
this reached statistical significance at 15 hours (p = 0.03 and p = 0.003 respectively; see 
Figure 5.8b). Conversely, the remaining construct (KO-92) displayed a tendency towards 
slower migration when compared to negative and scrambled control (p = 0.1). This 
reached significance at 15 hours when compared to scrambled control (p = 0.004). In KJD 
cells with LOXL2 silencing, reduced migration compared to controls was apparent in one 
construct yet was not significant (KO-89; p = 0.12; see Figure 5.9b). However, significant 
differences were observed at 10 hours (p = 0.02). It was evident that LOXL2 silencing was 
evidently having differing effects on the various cell lines and constructs.  
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Figure 5.8(a)      Figure 5.8(b) 
 
 
Figure 5.8(c)      Figure 5.8(d) 
 
Figure 5.8. Functional assays assessing LOXL2 silencing (KO) in A431 cells. (a) 
attachment dependent growth assays (triplicate); (b) migration assay compared to control 
(triplicate; baseline-corrected for wound width); (c) clonogenicity demonstrating colony 
counts; and (d) chamber invasion: cells that invaded through Matrigel-impregnated 
chambers were counted, and the proportion of cells invaded per cells plated is shown.  
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Figure 5.9(a)     Figure 5.9(b) 
 
 
 
Figure 5.9(c)     Figure 5.9(d) 
 
Figure 5.9. Functional assays assessing LOXL2 silencing (KO) in KJD cells compared to 
control. (a) attachment dependent growth assays (triplicate); (b) migration assay compared 
to control (triplicate; baseline corrected for wound width); (c) clonogenicity demonstrating 
colony counts; and (d) chamber invasion: cells that invaded through Matrigel-impregnated 
chambers were counted, and the proportion of cells invaded per cells plated is shown. 
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5.3.2.4 Clonogenicity 
LOXL2 silencing had a variable effect on cell line colony count and morphology. A431 cells 
produced significantly higher colony counts when construct KO-89 was compared to 
negative control, and altered colony morphology was also evident (p < 0.0001; see Figure 
5.8c). In the A431 KO-89 silencing construct, larger colonies were evident. However, in the 
KO-92 construct smaller colonies were seen. LOXL2 silencing in KJD cells also altered 
colony count and morphology in one construct (KO-89), with significantly fewer colonies 
that were overall smaller in morphology (p < 0.001; see Figure 5.9c). 
 
5.3.2.5 Invasion 
LOXL2-silencing in A431 cells did not significantly increase invasiveness through Matrigel. 
However, there was a trend towards increased invasion when KO-89 and KO-92 
constructs were compared to negative control cells (p = 0.064 and p = 0.067, respectively; 
see Figure 5.8d). The invasive nature of KJD cells was significantly increased in one 
construct with LOXL2-silencing (p = 0.001; see Figure 5.9d). This effect was not seen in 
the KJD KO-92 construct.  
 
5.3.3 Cell line morphology 
The microscopic morphology of each cell line was compared to the respective transfected 
control cell line and the results are depicted in Figures 5.10 and 5.11. In summary, there 
were no obvious differences in morphology evident. The A431 control cell lines (Entry 
Vector and scrambled control) displayed differing morphology on comparison. This is 
potentially the result of cell line manipulation from transfection of different vectors.  
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Figure 5.10. Cell line morphology of LOXL2 over-expressed (OE) cell lines (A431, HaCat 
and Colo16) compared to respective Entry Vector control (EVC; x500).  
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Figure 5.11. Cell line morphology of LOXL2 silenced cell lines (KO) compared to control 
(x500). A431 with LOXL2 silencing (KO) compared to scrambled control and KJD with 
LOXL2 silencing (KO) compared to scrambled control.  
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5.3.4 Tumourigenicity 
Tumourigenicity experiments were undertaken with four replicate tumours per cell line. 
A431 and Colo16 cell lines with LOXL2 over-expression were selected for tumourigenicity 
comparison with respective control given their native tumourigenic potential. However, 
Colo16 is known to have weak tumourigenicity in mice, resulting in variable tumour 
growth.257,258 A431 with LOXL2 silencing was also selected for tumourigenicity 
assessment, with construct KO-89 compared with the A431 scrambled control.  
 
When LOXL2 was over-expressed in A431, there was no change in tumourigenicity in vivo 
(see Figure 5.12). In Colo16 cells with LOXL2 over-expression, no tumour growth was 
observed. In addition, only two injection sites demonstrated tumour growth in the control 
cells (see Figure 5.13). This is reflective of the known weak tumourigenicity of this cell line 
and variable uptake following injection. Tumourigenicity was increased in A431 LOXL2 
silenced cells compared to scrambled control by Week 2, although not reaching statistical 
significance (p = 0.065; see Figure 5.14). This cell line grew rapidly during Week 2, 
necessitating animal sacrifice due to tumour burden 
 
 
 
 
 
 
 
 
Figure 5.12. Tumourigenicity in nude mice of LOXL2 over-expression in A431 cells 
compared to control. Tumour volume (mm3) was calculated using the formula: volume = 
(length)2/width. The mean and standard deviation of four replicate tumours per cell line is 
depicted. 
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Figure 5.13. Tumourigenicity in nude mice of LOXL2 over-expression in Colo16 cells 
compared to control. Tumour volume (mm3) was calculated using the formula: volume = 
(length)2/width. Single tumour volumes are depicted as only two tumours demonstrated 
growth.    
 
Histology was then performed on the tumours grown in mice from A431 cell lines with 
LOXL2 over-expression and silencing (and respective controls) with staining using H&E, 
LOXL2 and S100. This was not undertaken for Colo16, given only two control tumours 
demonstrated growth. H&E staining highlighted differences in the microscopic appearance 
of tumours. As seen in Figure 5.15, tumours from A431 cells with LOXL2 over-expression 
demonstrated increased cellular heterogeneity with variable cell size and shape, and 
increased amounts of central tumour necrosis. In tumours from LOXL2-silenced A431 
cells, the tumour was comprised of cells with variable size and shape and disordered 
growth pattern, which was distinct from the whorl pattern seen in the control (see Figure 
5.16). There was no difference in LOXL2 staining characteristics between the tumours 
generated from the cells lines and no evidence of PNI on S100 staining in any of the 
tumours for LOXL2 over-expression or silencing (see Figure 5.17 and 5.18, respectively). 
A summary of all functional assay results is included in Table 5.1, and this illustrates the 
heterogeneous results obtained.  
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Figure 5.14(a) 
 
Figure 5.14(b) 
Figure 5.14. Tumourigenicity in nude mice of LOXL2 silencing (KO) in A431 cells 
compared to negative control. (a) Tumour volume (mm3) was calculated using the formula: 
volume = (length)2/width. The mean and standard deviation of four replicate tumours per 
cell line is depicted; (b) Representative photo comparing A431 control and LOXL2 
silencing tumours.  
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Figure 5.15. Histology of tumours from tumourigenicity assays comparing A431 LOXL2 
over-expression (OE) and Entry Vector control (EVC). (a) control (H&E; x10); (b) control 
(H&E; x100); (c) LOXL2 over-expressed (H&E; x10); and (d) LOXL2 over-expressed (H&E; 
x100). Tumours from A431 cells with LOXL2 over-expression demonstrated increased 
cellular heterogeneity with variable cell size and shape, and increased amounts of central 
tumour necrosis.  
 166 
 
 
Figure 5.16. Histology of tumours from tumourigenicity assays comparing A431 cells with 
LOXL2 silencing and scrambled control. (a) control (H&E; x10); (b) control (H&E; x100); (c) 
LOXL2 silenced (H&E; x10); and (d) LOXL2 silenced (H&E; x100).  
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Figure 5.17. Histology of tumours from tumourigenicity assays comparing A431 LOXL2 
over-expression (OE) and Entry Vector control (EVC) staining with LOXL2 and S100 (to 
identify perineural invasion). (a) control (LOXL2) x100; (b) LOXL2 over-expressed (LOXL2) 
x100; (c) control (S100) x10; and (d) LOXL2 over-expressed (S100) x10. 
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Figure 5.18. Histology of tumours from tumourigenicity assays comparing A431 LOXL2 
silencing (KO 89) and scrambled control staining with LOXL2 and S100 (to identify 
perineural invasion). (a) control (LOXL2); x10; (b) LOXL2 silenced (LOXL2) x100; (c) 
control (S100) x10; and (d) LOXL2 silenced (S100) x10. 
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Table 5.1 Summary of functional assay results. The impact of LOXL2 silencing and over-
expression on cell line functional properties compared to relevant control.  
Cell Line Growth Migration Invasion Clonogenicity Tumourigenicity Morphology 
KJD-LOXL2 
silenced  
 
 
 
~ ~ n/a ~ 
A431-LOXL2 
silenced ~  ~   ~ 
A431-LOXL2 
over-
expressed 
~  *  ~ ~ 
Colo16-
LOXL2 over- 
expressed 
*  ~ *  ~ 
HaCat-LOXL2 
over- 
expressed 
~ ~ ~ ~ n/a ~ 
Key: *denotes statistically significant difference when compared to control p < 0.05;  reduced function;  increased 
function; ~ function unchanged; n/a not applicable. When a combination of symbols is used (i.e. ~), this represents a 
weak effect was noted. 
 
 
5.4 Discussion 
This work investigated the functional properties of two target genes at the cellular level 
identified from gene expression profiling as potential factors in CSCCHN with clinical PNI. 
Using commercially available cell lines to represent CSCCHN, cell line transfection was 
undertaken to attempt LOXL2 over-expression and silencing, and FOXC2 over-expression. 
LOXL2 over-expression and silencing was successful and further functional assessment 
carried out using both in vitro and in vivo techniques.  
 
Transfection with FOXC2 over-expression was unsuccessful after triplicate attempts. This 
gene was therefore not pursued further in this study. Epithelial cell toxicity from FOXC2 
 170 
over-expression has been reported, possibly by an abrupt change from an epithelial to a 
mesenchymal phenotype leading to cell death.202 The process of EMT likely requires 
multiple coordinated factors and it is possible that an abrupt switch through FOXC2 over-
expression may be detrimental to cell survival in the absence of other necessary factors.202 
Selection of antibiotic-resistant cells without vector could also have occurred.  
 
A primary perineural CSCCHN cell line was unable to be established. This may reflect 
suboptimal culture conditions such as the chosen media and additives. In addition, the 
volume of tumour harvested from an involved cranial nerve for culturing is limited. It is 
possible that tumour growth within each specimen is heterogeneous, and this can 
therefore be dependent on which sample is used for culture.259 Perineural tumours 
typically spread slowly, yet patients have presented with more rapid symptom onset and 
disease progression (as described in Section 2.2.4.3.1). Tumourigenicity in mice from 
injected SCC cell lines is also known to be variable, and a reliance on tumour growth in 
immune-suppressed mice is a further limitation.259,260 In future, this could be improved by 
sampling larger dermal tumour deposits (which can be present overlying the involved 
cranial nerve) rather than cranial nerve itself, and/or tumour sampling at the advancing 
tumour front. Also, in vivo implantation-explantation of fresh tumour tissue to culture 
perpetual cell growth was not attempted, and this would be worthwhile in future work. A 
recently developed explant model has shown promise as a method for studying cutaneous 
SCC.261  
 
The cell lines used were non-tumourigenic keratinocyte cell lines (HaCat and KJD), and 
SCC lines from vulval SCC (A431) and cutaneous SCC from the lower leg (Colo16). Whilst 
the selected commercially available cell lines are commonly used in cutaneous SCC 
research, a cell line more reflective of CSCCHN with PNS is ideal in future studies. The 
use of non-tumourigenic cell lines has inherent limitations, and LOXL2 transfection did not 
appear to change this property.   
 
Interestingly, the primary perineural cell line culture attempts resulted in the heavy growth 
of CAFs. It has been proposed that these cells have a role in tumour progression and 
spread through modulation of the tumour microenvironment.102 CAFs may be stimulated 
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by local tumour, other stromal factors or possibly even nerves, to enable tumour cell 
migration and spread potentially via an EMT process.102 It has been proposed that LOXL2 
may function to stimulate CAFs and thus modulate the ECM and tumour 
microenvironment.201,245 Alternatively, LOXL2 may be secreted by local CAFs to influence 
ECM composition, and this has been shown in gastric cancer cell lines to be associated 
with increased aggressiveness.251 In addition, increased LOXL2 expression in CAFs is 
associated with reduced OS and increased recurrence in colon cancer patients.247 The 
CAFs grown from this study will be investigated in future experimental work.  
 
The functional assays produced variable results with no clear pronounced effect induced 
by LOXL2. Overall, silencing of LOXL2 in KJD (non-tumourigenic) cells generated a less 
aggressive picture in one construct (KO-89) with reduced growth, colony formation and 
migration, yet invasiveness was increased. This may be the result of a reduction in 
LOXL2-induced connective tissue cross-linking in the ECM, which facilitates a more 
invasive phenotype. This result would be contrary to what was anticipated from the 
microarray analysis. Conversely, LOXL2 in A431 (tumourigenic) cells produced a counter-
intuitive result with silencing of LOXL2 giving one construct (KO-89) of this cell line overall 
more aggressive in vitro features including migration, colony formation and in vivo 
tumourigenicity. Also, over-expression of LOXL2 in A431 cells conversely appeared to 
make them either less aggressive (migration and invasiveness) or be unchanged (growth, 
colony formation and tumourigenicity). This may be via direct effects of LOXL2 to enhance 
the extracellular/Matrigel connective tissue paradoxically preventing invasion. With Colo16 
cells, over-expression of LOXL2 induced less aggressive features yet there was an 
apparent trend towards enhanced cell migration ability. In addition, LOXL2 expression 
changes did not alter the morphology of any of the cell lines. LOXL2 over-expression in 
A431 and Colo16 cells demonstrated higher expression of Slug protein, suggesting 
activation of the EMT pathway via LOXL2. However, this effect was inconsistent, with 
other EMT markers such as SNAI1/Snail not being activated.  
 
The control cell lines for A431 LOXL2 over-expression and silencing displayed different 
properties. These lines have each been independently manipulated by transfection and 
comparisons are limited. However, it is possible that the transfection process has altered 
the cell line’s functional capacity through an unknown mechanism.   
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The impact of LOXL2 on in vitro cell line functional properties was variable. These findings 
may not be reflective of the gene’s function in vivo, particularly given the potential role of 
the tumour microenvironment in this disease process. Whilst this cannot be accurately 
assessed in this model, future in vivo work is ideal. It is possible the reduced invasiveness 
and migration ability of A431 cells with LOXL2 over-expression is related to its impact on 
the ECM, even in the in vitro systems used here. The pattern seen in tumourigenicity with 
increased tumour growth with LOXL2 silencing in A431, and decreased tumour growth 
with LOXL2 over-expression in A431 is not consistent with the purported role of LOXL2 in 
cancer.201 It would be ideal to study these cell lines in an animal model of PNS to ascertain 
their neurotropic abilities. Whilst there are models of general PNS, such as a sciatic nerve 
model, there is a need for an animal model of PNS in the head and neck and preliminary 
work is underway (see section 6.1).169  
 
In summary, there was no conclusive, consistent functional impact of LOXL2 over-
expression and silencing on the cell lines studied. Further in vivo and in vitro studies are 
ideal using more closely representative cell lines in an animal model of this disease. Whilst 
the precise role and function of LOXL2 is yet to be elucidated and warrants further 
investigation, it is likely that PNS is not dependent on a specific single gene and that 
multiple coordinating factors are involved. 
 
 
 
 
 
 
 
 
 
 
 173 
Chapter 6 
Synthesis and future directions 
 
6.1 Synthesis  
CSCCHN with clinical PNI is a rare and unique form of tumour metastasis that can be 
associated with poor prognosis. Its rarity combined with the slowly progressive and often 
insidious nature of the clinical presentation contributes to the limited awareness of clinical 
PNI amongst clinicians and patients. This can lead to delays in presentation, diagnosis 
and appropriate treatment and associated poor outcomes.36,126,195  
 
This thesis has contributed significantly to the understanding of the disease process at 
both a clinical and molecular level and many of the findings have never been previously 
described. Detailed assessment of the epidemiology and natural history of the disease has 
not been previously undertaken using a clearly defined patient cohort. The analysis of a 
relatively homogenous series of patients has enabled the generation of clinically relevant 
and applicable outcome data that can guide management. The molecular work presented 
includes whole genome expression profiling of CSCCHN with clinical PNI that has not 
been previously reported. This demonstrated unique gene expression patterns in clinical 
PNI specimens and LOXL2 was identified as a target for further assessment into its role in 
PNI pathogenesis. The manipulation of LOXL2 expression with transfection did not 
demonstrate more aggressive properties in multiple functional assays however further 
investigation is ideal.  
 
6.1.1 Epidemiological features 
The definition of PNI utilised here reflects an updated understanding of the histology of the 
peripheral nerve and the histopathological features of clinical PNI.35 The typical patient 
with clinical PNI of CSCCHN is a middle-aged male with a history of skin cancers. In this 
series immunosuppression was not significantly associated with the presence of PNI. 
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Consistent with previous series of clinical PNI patients, the cheek was the most common 
primary location and the majority were moderate or poorly differentiated (> 80%).15,122-
124,139 This contrasts with the typical distribution of cutaneous SCCs being 53% well-
differentiated and 47% moderate or poorly differentiated.33 In addition, the primary tumours 
from patients with clinical PNI were typically of large size (mean 1.7 cm) and deeply 
invasive (mean 7.4 mm). Certain epidemiological features were similar to cutaneous SCC 
without PNI, such as patients typically being of male gender, middle age and having a 
history of skin cancer.63  
 
The importance of clear margins during treatment for the primary tumour is evident. Almost 
1 in 4 clinical PNI patients had involved primary tumour margins following surgical 
treatment. The use of PORT in the management of incidental PNI may be provided 
according to NCCN guidelines and the presence of high-risk features as detailed in Figure 
1.3.157 In this series 37.8% of patients with clinical PNI received PORT to the primary 
tumour yet still progressed to clinical PNI. Further longitudinal studies into incidental PNI 
treated with surgery and PORT is necessary to guide this aspect of management and 
determine its effectiveness at preventing clinical PNI.  
 
There were two major findings regarding the primary tumours from patients with CSCCHN 
and clinical PNI which have not been previously reported. Firstly, over 1 in 3 patients did 
not have incidental PNI detected in the primary tumour, and this could indicate that PNI 
was present yet not detected on histology. This reiterates the need for careful 
histopathological assessment of skin cancers and standardised pathology reporting. In 
addition, almost 1 in 4 patients had clinical PNI from an unknown primary tumour, possibly 
as a result of sub-clinical disease or immune-mediated tumour regression.192 These 
findings are important since they demonstrate that patients who present with a cranial 
nerve neuropathy could have clinical PNI even without a skin cancer history or known 
primary tumour in the region of interest. In addition, patients may not necessarily have had 
a history of incidental PNI in a previous skin cancer.  
 
Other important aspects of the disease natural history presented were the typical clinical 
features and the slowly progressive nature of the disease, with a median time from primary 
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tumour treatment until symptom onset being 16 months. Numbness, neuropathic pain, 
paraesthesia and partial facial palsy were the most common clinical features. In addition, 
complete facial palsy (when present) was progressive in onset in the majority of cases 
which helps differentiate it from Bell’s palsy.130 Despite typically being a slowly progressive 
disease process, patient management is time sensitive. Significant delays in diagnosis can 
occur with a median delay in diagnosis of 6 months demonstrated in this series. Zone 1 
patients have improved outcomes compared to patients with zone 2 or 3 disease, and this 
reiterates the need to limit diagnostic and treatment delays.126,195 
 
Single cranial or spinal nerve involvement (64%) occurred more frequently than multiple 
nerve involvement (36%). Consistent with previous reports, the V and VII nerves were the 
most frequently involved cranial nerves, with V2 being the most frequent V nerve division 
involved.34,117 Involvement of the great auricular nerve is noted to be rare with few reports 
in the literature and this was seen in two patients in this series.15,196,197 The most frequent 
pattern when multiple nerves were involved was simultaneous V3 and VII disease, 
reflecting their close anatomical relationship often with communication.191 
 
Nodal disease at presentation (5.8%) and nodal recurrence post-treatment (2%) were both 
uncommon and this is consistent with previous reports.13,125 This may reflect innate tumour 
biology and requires further investigation as it may have ramifications for management of 
the neck in CSCCHN with clinical PNI. Currently at our institution, there is generally no role 
for elective nodal dissection or irradiation in clinical PNI patients unless other high-risk 
primary tumour features are present.42 Other centres have previously advocated elective 
nodal irradiation without clear justifying data.123  
 
Previous series of clinical PNI patients have been restricted by variable terminology and 
the pooling of tumour types (i.e. SCC and BCC), treatment approaches and PNI subtypes 
(incidental and clinical PNI).12,13,47-49 Analysis of a cohort of patients with clinical PNI of 
CSCCHN treated with surgery and PORT has generated clear outcome data that can 
guide management and inform patients on prognosis. This complex disease necessitates 
multidisciplinary management in a specialised tertiary centre, with surgery and PORT 
being the mainstay of treatment. Reasonable outcomes are achievable with this approach, 
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as evidenced by 5-year DSS of 75% in this series with limited morbidity.120 Recurrence of 
disease was significantly associated with worse OS, and local recurrence was the most 
common mode of recurrence consistent with other series.34 The mean time to any 
recurrence was two years, which highlights the need for close follow-up and surveillance in 
this early period. In addition, 95% of recurrences occurred in the first five years post-
treatment, obviating the need for five years minimum follow-up.  
 
The importance of MRI neurography in diagnosis, treatment planning and ongoing 
surveillance has been highlighted in this study. Clinical PNI was detected using MRI 
neurography in up to 97% in this series consistent with previous work.118,132 The zonal 
classification on imaging is heavily relied upon to guide disease staging and treatment 
strategies and has been shown to correlate with outcomes.126,195 The staging of CSCCHN 
with clinical PNI using the AJCC staging system should reflect current clinical practice.10 
The 8th edition AJCC staging system to be released in 2018 has appropriately 
acknowledged the negative prognostic significance of PNI to include the impact of nerve 
diameter and depth of nerve invasion.156  
 
This body of work has detailed novel features in the epidemiology of patients with clinical 
PNI. These findings have enabled a greater understanding of many aspects of the disease 
process. This includes the characteristics of the primary tumours from patients who 
progressed to clinical PNI, the typical clinical, radiological and pathological features of 
clinical PNI, and the overall natural history timeline from the initial primary tumour through 
to post-treatment follow-up and modes of treatment failure. Clear outcomes that clarify the 
effectiveness of treatment with surgery and PORT for clinical PNI have been described. 
This will ideally contribute to improved awareness and understanding of CSCCHN with 
clinical PNI that can lead to improved patient management.   
 
6.1.2 Molecular features 
The molecular work presented in this thesis has demonstrated multiple genes potentially 
involved in the pathogenesis of clinical PNI. Genomic expression profiling was utilised to 
screen for gene expression differences in clinical PNI tumours that could be contributing to 
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PNI development and progression. Significantly different expression profiles were noted 
between CSCCHN, CSCCHN with incidental PNI and CSCCHN with clinical PNI and this 
has not been previously described. A spectrum of disease may be evident at the gene 
expression level.  
 
Despite the limitations of small sample numbers, the microarray has identified significant 
differences between study groups with validation of one key gene being achieved with 
LOXL2. Although the functional assays assessing LOXL2 failed to clearly identify any 
consistent impact of differential expression of LOXL2 on the neoplastic properties of the 
cell lines used, further work is ideal given the reported role of LOXL2 in other cancers.201 
The impact of LOXL2 on neurotropism was not assessed in this study. LOXL2 could be 
exerting its effects on the tumour microenvironment, and further work using PNI models is 
desirable. LOXL2 could also function through an EMT pathway, and activation of one EMT 
downstream effector protein was noted following LOXL2 over-expression on Western blot 
in two cell lines.180 However, this effect was not consistently demonstrated in all cell lines 
or with other downstream effectors.  
 
FOXC2 was unable to be assessed due to transfection failure. The microarray result 
combined with the strong interest in this gene’s role in other cancers and its possible role 
in EMT signifies that more investigation is warranted.203,254,262 This is also true of the other 
candidate genes identified in the microarray that subsequently failed to validate with IHC, 
and their significance should not be dismissed without further study.  
 
The microarray dataset analysis did not reveal specific genes associated with 
neurotrophins or axonal guidance molecules using the search criteria described. However, 
these factors were significant on pathway analysis and further assessment into the 
significance of these pathways in PNI would be ideal. Although the role of EMT in the 
pathogenesis of PNI remains uncertain, it continues to be a pathway of interest. Whilst a 
unique biomarker was not identified in this study, multiple genes within key cancer 
pathways were identified as potential targets. These findings are consistent with PNI being 
a multifactorial process and not related to a single gene or pathway. There remain many 
avenues for future molecular research stemming from this work. 
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6.2 Future directions 
Ongoing epidemiological analysis of patients is important to continue the characterisation 
of the disease. Ideally, a risk prediction model could be developed in future that identifies 
those patients at risk of PNS who may benefit from close follow-up based on their clinical 
profile and the primary tumour features. Increasing disease awareness amongst clinicians 
and patients is an important goal of this thesis and future research. This will assist in early 
identification of affected patients which can facilitate early management with improvement 
in outcomes 
 
There remain other attractive target genes identified on microarray that did not validate on 
IHC. These potential candidates and others within the microarray dataset were not able to 
be further pursued in this study due to time and cost constraints. Further work has been 
recently undertaken on the role of p53 and this has demonstrated that CSCCHN with 
clinical PNI is more likely to contain alterations in the p53 pathway compared to CSCCHN 
without PNI.263 Clinical PNI tissue specimens were more likely to show diffuse over-
expression of p53. DNA sequencing did not demonstrate any differences in mutation 
number or position, however differences in expression of regulators of p53 were noted.263 
Bioinformatics of the microarray data will also be necessary to identify other potential 
target genes or pathways embedded within this large dataset. This study focused on the 
genes that were significantly upregulated in CSCCHN with clinical PNI, and assessment of 
the genes demonstrated to be significantly downregulated is also worthwhile. The focus in 
future work could also be on the significant pathways rather than individual gene targets. 
Other transfection methods to be explored include the use of a lentiviral system in an 
attempt to prevent clonal selection, or an inducible system to permit relative control on 
timing of over-expression levels in functional studies. 
 
Further characterisation of the significance of the lymphocytic cell infiltrates in PNS is 
needed. Preliminary studies into the role of infiltrating lymphocytes in the disease 
pathogenesis has recently been undertaken.101 This work demonstrated that expression of 
galectin-1 in lymphocyte-rich regions of perineural tumour was associated with poor 
prognosis, and that galectin-1 may function to regulate the interaction between tumour 
cells and the host immune system.  
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The development of a perineural cell line will continue to be attempted, since this would be 
an ideal cell line for further in vitro and in vivo work. Future resources will also be directed 
towards the investigation of CAFs and their potential role in clinical PNI, ideally using a 
model that can simulate the tumour microenvironment. The co-culture model of PNI 
partially offers this for future in vitro studies as it enables the study of the tumour-nerve 
interface, yet is restricted by the absence of a realistic ECM.166 Pilot studies have been 
undertaken using LOXL2 and TGM3, the latter a gene demonstrated to be significantly 
downregulated on the microarray (see Figure 6.1).264 With the use of a culture plate with 
divider, mouse DRG tissue is harvested and then cultured adjacent to the test cell line. 
Once this divider is removed, interaction between the tumour cells and the DRG is 
assessed over time. The impact of various factors (such as neurotrophins) on the tumour 
microenvironment can then be further tested. The role of the tumour microenvironment in 
PNS remains unclear, yet it appears that complex signalling that culminates in nerve and 
tumour interaction and invasion may be occurring that warrants further 
investigation.92,100,172  
 
 
Figure 6.1. In vitro co-culture model of perineural invasion using mouse dorsal root 
ganglion (DRG) cultured with A431 cells transfected with either control or TGM3 silencing. 
* labels DRG tissue; red arrows indicate A431 cells surrounding DRG.  
 
An animal model of PNS is also ideal, and preliminary work is underway using a mouse 
trigeminal nerve model. In this model, the mouse trigeminal nerve and its divisions are 
surgically exposed with microscope guidance under general anaesthesia. This can permit 
 180 
implantation of tumour cell pellets within or adjacent to the trigeminal nerve to simulate 
PNS in an in vivo model. This may be more relevant to CSCCHN than the established 
sciatic nerve model.169  
 
Future research into PNS offers many opportunities and will need to be multi-faceted 
through ongoing epidemiological analysis, molecular studies and animal models. It is 
important for this to be led by the clinicians who diagnose and treat these patients, and for 
the experience of these patients to be harnessed. Prevention of skin cancer remains the 
ideal approach to preventing CSCCHN and clinical PNI. Ongoing investigation into the 
clinical and molecular features of both incidental and clinical PNI is necessary. This has 
the potential to significantly improve our understanding of the disease process and ideally 
lead to improved patient management and outcomes.     
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Appendix 
 
Supplementary Table 4.1 Selected gene list of significantly up-regulated gene transcripts 
between clinical PNI, incidental PNI and SCC on ANOVA.  
Entrez  
Gene 
ID 
Symbol Name Fold change cPNI v SCC 
Fold 
change 
iPNI v SCC 
p value 
5284 PIGR 
Homo sapiens polymeric 
immunoglobulin receptor (PIGR), 
mRNA. 
37.33 5.64 0.0083 
5554 PRH1 Homo sapiens proline-rich protein HaeIII subfamily 1 (PRH1), mRNA. 29.90 2.65 0.0004 
3346 HTN1 Homo sapiens histatin 1 (HTN1), mRNA. 27.03 1.07 0.0263 
5545 PRB4 Homo sapiens proline-rich protein BstNI subfamily 4 (PRB4), mRNA. 26.36 1.12 0.0227 
57158 JPH2 Homo sapiens junctophilin 2 (JPH2), transcript variant 2, mRNA. 25.16 4.24 0.0001 
10879 SMR3B 
Homo sapiens submaxillary gland 
androgen regulated protein 3B 
(SMR3B), mRNA. 
23.72 1.05 0.0258 
6779 STATH Homo sapiens statherin (STATH), transcript variant 2, mRNA. 20.71 -1.02 0.0390 
140458 ASB5 
Homo sapiens ankyrin repeat and 
SOCS box-containing 5 (ASB5), 
mRNA. 
20.64 2.84 0.0342 
5555 PRH2 Homo sapiens proline-rich protein HaeIII subfamily 2 (PRH2), mRNA. 20.49 1.21 0.0183 
10586 MAB21L2 
PREDICTED: Homo sapiens mab-21-
like 2 (C. elegans) (MAB21L2), mRNA. 18.44 2.24 0.0071 
3347 HTN3 Homo sapiens histatin 3 (HTN3), mRNA. 17.88 -1.21 0.0321 
401137 LOC401137 
Homo sapiens hypothetical 
LOC401137 (LOC401137), mRNA. 17.69 1.70 0.0475 
140458 ASB5 
Homo sapiens ankyrin repeat and 
SOCS box-containing 5 (ASB5), 
mRNA. 
17.42 2.60 0.0226 
5542 PRB1 
Homo sapiens proline-rich protein 
BstNI subfamily 1 (PRB1), transcript 
variant 2, mRNA. 
17.33 1.05 0.0266 
486 FXYD2 
Homo sapiens FXYD domain 
containing ion transport regulator 2 
(FXYD2), transcript variant a, mRNA. 
17.24 1.09 0.0010 
653247 PRB2 Homo sapiens proline-rich protein BstNI subfamily 2 (PRB2), mRNA. 16.47 1.04 0.0421 
5542 PRB1 
Homo sapiens proline-rich protein 
BstNI subfamily 1 (PRB1), transcript 
variant 3, mRNA. 
15.61 -1.03 0.0230 
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579 BAPX1 
Homo sapiens bagpipe homeobox 
homolog 1 (Drosophila) (BAPX1), 
mRNA. 
15.34 3.76 0.0008 
486 FXYD2 
Homo sapiens FXYD domain 
containing ion transport regulator 2 
(FXYD2), transcript variant b, mRNA. 
15.33 1.09 0.0010 
277 AMY1B Homo sapiens amylase, alpha 1B (salivary) (AMY1B), mRNA. 15.03 1.80 0.0068 
140683 C20orf70 Homo sapiens chromosome 20 open reading frame 70 (C20orf70), mRNA. 14.90 1.09 0.0293 
2139 EYA2 
Homo sapiens eyes absent homolog 2 
(Drosophila) (EYA2), transcript variant 
1, mRNA. 
14.85 2.38 0.0013 
4192 MDK 
Homo sapiens midkine (neurite 
growth-promoting factor 2) (MDK), 
transcript variant 1, mRNA. 
14.43 2.17 0.0041 
276 AMY1A 
Homo sapiens amylase, alpha 1A 
(salivary) (AMY1A), transcript variant 
1, mRNA. 
14.05 1.05 0.0327 
54959 ODAM 
Homo sapiens odontogenic, 
ameloblast associated (ODAM), 
mRNA. 
13.81 -1.00 0.0181 
1300 COL10A1 
Homo sapiens collagen, type X, alpha 
1 (COL10A1), mRNA. 13.63 -1.01 0.0010 
3164 NR4A1 
Homo sapiens nuclear receptor 
subfamily 4, group A, member 1 
(NR4A1), transcript variant 1, mRNA. 
13.41 1.67 0.0056 
491 ATP2B2 
Homo sapiens ATPase, Ca++ 
transporting, plasma membrane 2 
(ATP2B2), transcript variant 2, mRNA. 
12.91 1.41 0.0023 
4148 MATN3 Homo sapiens matrilin 3 (MATN3), mRNA. 12.60 1.85 0.0001 
27063 ANKRD1 Homo sapiens ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), mRNA. 12.22 2.65 0.0472 
467 ATF3 
Homo sapiens activating transcription 
factor 3 (ATF3), transcript variant 4, 
mRNA. 
11.82 1.25 0.0020 
6288 SAA1 Homo sapiens serum amyloid A1 (SAA1), transcript variant 1, mRNA. 11.19 2.61 0.0001 
2303 FOXC2 
Homo sapiens forkhead box C2 (MFH-
1, mesenchyme forkhead 1) (FOXC2), 
mRNA. 
11.12 1.10 0.0066 
10562 OLFM4 Homo sapiens olfactomedin 4 (OLFM4), mRNA. 10.77 7.53 0.0057 
1473 CST5 Homo sapiens cystatin D (CST5), mRNA. 10.64 1.45 0.0351 
3164 NR4A1 
Homo sapiens nuclear receptor 
subfamily 4, group A, member 1 
(NR4A1), transcript variant 2, mRNA. 
10.61 2.65 0.0080 
7292 TNFSF4 
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 4 (tax-
transcriptionally activated glycoprotein 
1, 34kDa) (TNFSF4), mRNA. 
10.03 1.39 0.0008 
1295 COL8A1 
Homo sapiens collagen, type VIII, 
alpha 1 (COL8A1), transcript variant 1, 
mRNA. 
9.68 1.87 0.00002 
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100302
181 MIR1294 
Homo sapiens microRNA 1294 
(MIR1294), microRNA. 9.59 3.45 0.0037 
720 C4A 
Homo sapiens complement 
component 4A (Rodgers blood group) 
(C4A), mRNA. 
9.48 2.02 0.0001 
114881 OSBPL7 
Homo sapiens oxysterol binding 
protein-like 7 (OSBPL7), transcript 
variant 1, mRNA. 
9.45 1.90 0.0075 
2335 FN1 Homo sapiens fibronectin 1 (FN1), transcript variant 7, mRNA. 9.16 1.82 0.0001 
3671 ISLR 
Homo sapiens immunoglobulin 
superfamily containing leucine-rich 
repeat (ISLR), transcript variant 2, 
mRNA. 
9.02 1.49 0.0055 
25817 FAM19A5 
Homo sapiens family with sequence 
similarity 19 (chemokine (C-C motif)-
like), member A5 (FAM19A5), 
transcript variant 1, mRNA. 
8.97 1.15 0.0014 
3053 SERPIND1 
Homo sapiens serpin peptidase 
inhibitor, clade D (heparin cofactor), 
member 1 (SERPIND1), mRNA. 
8.81 1.48 0.0024 
6271 S100A1 Homo sapiens S100 calcium binding protein A1 (S100A1), mRNA. 8.75 4.17 0.0017 
1831 TSC22D3 
Homo sapiens TSC22 domain family, 
member 3 (TSC22D3), transcript 
variant 2, mRNA. 
8.62 2.64 0.0001 
6424 SFRP4 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 8.49 1.57 0.0006 
1592 CYP26A1 
Homo sapiens cytochrome P450, 
family 26, subfamily A, polypeptide 1 
(CYP26A1), transcript variant 2, 
mRNA. 
8.36 -2.25 0.0248 
51280 GOLM1 
Homo sapiens golgi membrane protein 
1 (GOLM1), transcript variant 2, 
mRNA. 
8.30 2.80 0.0098 
27295 PDLIM3 Homo sapiens PDZ and LIM domain 3 (PDLIM3), mRNA. 8.23 2.17 0.0231 
55898 UNC45A 
Homo sapiens unc-45 homolog A (C. 
elegans) (UNC45A), transcript variant 
3, mRNA. 
8.23 1.46 0.0318 
4025 LPO Homo sapiens lactoperoxidase (LPO), mRNA. 8.19 -1.75 0.0499 
10234 LRRC17 
Homo sapiens leucine rich repeat 
containing 17 (LRRC17), transcript 
variant 1, mRNA. 
7.83 1.06 0.0018 
4504 MT3 Homo sapiens metallothionein 3 (MT3), mRNA. 7.82 2.08 0.0321 
27295 PDLIM3 Homo sapiens PDZ and LIM domain 3 (PDLIM3), mRNA. 7.74 1.79 0.0019 
677840 SNORA71D 
Homo sapiens small nucleolar RNA, 
H/ACA box 71D (SNORA71D), small 
nucleolar RNA. 
7.66 5.04 0.0006 
1187 CLCNKA 
Homo sapiens chloride channel Ka 
(CLCNKA), transcript variant 1, 
mRNA. 
7.65 2.82 0.0043 
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81099 OR4F17 
Homo sapiens olfactory receptor, 
family 4, subfamily F, member 17 
(OR4F17), mRNA. 
7.56 1.68 0.0089 
222389 BEND7 
Homo sapiens BEN domain containing 
7 (BEND7), transcript variant 1, 
mRNA. 
7.54 1.27 0.0258 
167 CRISP1 
Homo sapiens cysteine-rich secretory 
protein 1 (CRISP1), transcript variant 
1, mRNA. 
7.53 2.58 0.0167 
339778 C2orf70 Homo sapiens chromosome 2 open reading frame 70 (C2orf70), mRNA. 7.50 1.27 0.0292 
23764 MAFF 
Homo sapiens v-maf 
musculoaponeurotic fibrosarcoma 
oncogene homolog F (avian) (MAFF), 
transcript variant 2, mRNA. 
7.35 2.73 0.0010 
1470 CST2 Homo sapiens cystatin SA (CST2), mRNA. 7.29 -1.02 0.0122 
3778 KCNMA1 
Homo sapiens potassium large 
conductance calcium-activated 
channel, subfamily M, alpha member 1 
(KCNMA1), transcript variant 1, 
mRNA. 
7.14 3.12 0.0061 
10085 EDIL3 
Homo sapiens EGF-like repeats and 
discoidin I-like domains 3 (EDIL3), 
mRNA. 
7.11 2.66 0.0003 
1756 DMD Homo sapiens dystrophin (DMD), transcript variant Dp427m, mRNA. 6.96 3.99 0.0346 
8708 B3GALT1 
Homo sapiens UDP-Gal:betaGlcNAc 
beta 1,3-galactosyltransferase, 
polypeptide 1 (B3GALT1), mRNA. 
6.91 2.63 0.0005 
91828 C14orf73 Homo sapiens chromosome 14 open reading frame 73 (C14orf73), mRNA. 6.88 1.99 0.0042 
  
BP873537 Sugano cDNA library, 
embryonal kidney Homo sapiens 
cDNA clone HKR13896, mRNA 
sequence 
6.87 2.03 0.00001 
2669 GEM 
Homo sapiens GTP binding protein 
overexpressed in skeletal muscle 
(GEM), transcript variant 1, mRNA. 
6.82 2.18 0.0060 
4837 NNMT Homo sapiens nicotinamide N-methyltransferase (NNMT), mRNA. 6.79 1.55 0.0027 
54557 SGTB 
Homo sapiens small glutamine-rich 
tetratricopeptide repeat (TPR)-
containing, beta (SGTB), mRNA. 
6.78 -1.62 0.0170 
11082 ESM1 Homo sapiens endothelial cell-specific molecule 1 (ESM1), mRNA. 6.71 1.20 0.0001 
7003 TEAD1 
Homo sapiens TEA domain family 
member 1 (SV40 transcriptional 
enhancer factor) (TEAD1), mRNA. 
6.71 5.25 0.0008 
7052 TGM2 
Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-
gamma-glutamyltransferase) (TGM2), 
transcript variant 2, mRNA. 
6.70 -1.02 0.0068 
114899 C1QTNF3 
Homo sapiens C1q and tumor 
necrosis factor related protein 3 
(C1QTNF3), transcript variant 2, 
mRNA. 
6.65 1.91 0.0083 
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51339 DACT1 
Homo sapiens dapper, antagonist of 
beta-catenin, homolog 1 (Xenopus 
laevis) (DACT1), transcript variant 1, 
mRNA. 
6.63 2.80 0.0071 
6779 STATH Homo sapiens statherin (STATH), transcript variant 1, mRNA. 6.62 -1.01 0.0330 
149954 C20orf186 
Homo sapiens chromosome 20 open 
reading frame 186 (C20orf186), 
mRNA. 
6.59 -2.31 0.0461 
467 ATF3 
Homo sapiens activating transcription 
factor 3 (ATF3), transcript variant 4, 
mRNA. 
6.58 1.99 0.0014 
3108 HLA-DMA 
Homo sapiens major histocompatibility 
complex, class II, DM alpha (HLA-
DMA), mRNA. 
6.56 2.73 0.0013 
3784 KCNQ1 
Homo sapiens potassium voltage-
gated channel, KQT-like subfamily, 
member 1 (KCNQ1), transcript variant 
1, mRNA. 
6.55 2.00 0.0045 
340075 ARSI Homo sapiens arylsulfatase family, member I (ARSI), mRNA. 6.55 -1.09 0.0161 
285126 DNAJC5G 
Homo sapiens DnaJ (Hsp40) 
homolog, subfamily C, member 5 
gamma (DNAJC5G), mRNA. 
6.46 2.08 0.0137 
10841 FTCD 
Homo sapiens formiminotransferase 
cyclodeaminase (FTCD), transcript 
variant A, mRNA. 
6.44 2.57 0.0359 
4241 MFI2 
Homo sapiens antigen p97 (melanoma 
associated) identified by monoclonal 
antibodies 133.2 and 96.5 (MFI2), 
transcript variant 1, mRNA. 
6.42 -1.65 0.0180 
2042 EPHA3 Homo sapiens EPH receptor A3 (EPHA3), transcript variant 2, mRNA. 6.31 1.07 0.0014 
1301 COL11A1 
Homo sapiens collagen, type XI, alpha 
1 (COL11A1), transcript variant B, 
mRNA. 
6.28 -1.16 0.0010 
5915 RARB 
Homo sapiens retinoic acid receptor, 
beta (RARB), transcript variant 1, 
mRNA. 
6.27 1.83 0.0213 
10501 SEMA6B 
Homo sapiens sema domain, 
transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6B 
(SEMA6B), mRNA. 
6.27 4.51 0.0008 
26582 DUX3 Homo sapiens double homeobox, 3 (DUX3), mRNA. 6.22 -1.56 0.0009 
11105 PRDM7 
Homo sapiens PR domain containing 
7 (PRDM7), transcript variant 1, 
mRNA. 
6.19 -1.17 0.0047 
276 AMY1A 
Homo sapiens amylase, alpha 1A 
(salivary) (AMY1A), transcript variant 
2, mRNA. 
6.16 1.04 0.0307 
285033 LOC285033 
Homo sapiens hypothetical protein 
LOC285033 (LOC285033), mRNA. 6.14 1.05 0.0027 
339122 RAB43 Homo sapiens RAB43, member RAS oncogene family (RAB43), mRNA. 6.07 1.52 0.0145 
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93653 ST7OT1 
Homo sapiens ST7 overlapping 
transcript 1 (non-protein coding) 
(ST7OT1), antisense RNA. 
6.07 3.69 0.0016 
440073 IQSEC3 Homo sapiens IQ motif and Sec7 domain 3 (IQSEC3), mRNA. 6.04 2.01 0.0010 
7052 TGM2 
Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-
gamma-glutamyltransferase) (TGM2), 
transcript variant 2, mRNA. 
6.00 1.60 0.0024 
5339 PLEC1 
Homo sapiens plectin 1, intermediate 
filament binding protein 500kDa 
(PLEC1), transcript variant 3, mRNA. 
5.99 5.88 0.0290 
349136 WDR86 Homo sapiens WD repeat domain 86 (WDR86), mRNA. 5.98 1.79 0.00003 
53616 ADAM22 
Homo sapiens ADAM 
metallopeptidase domain 22 
(ADAM22), transcript variant 1, 
mRNA. 
5.97 2.87 0.0002 
8532 CPZ Homo sapiens carboxypeptidase Z (CPZ), transcript variant 1, mRNA. 5.93 2.04 0.0243 
81849 ST6GALNAC5 
Homo sapiens ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-galactosyl-1, 3)-
N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5 (ST6GALNAC5), 
mRNA. 
5.90 1.33 0.0402 
2905 GRIN2C 
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 2C 
(GRIN2C), mRNA. 
5.89 1.84 0.0204 
112 ADCY6 Homo sapiens adenylate cyclase 6 (ADCY6), transcript variant 2, mRNA. 5.88 3.39 0.0001 
440083 PRB2 Homo sapiens proline-rich protein BstNI subfamily 2 (PRB2), mRNA. 5.85 1.06 0.0382 
5890 RAD51L1 
Homo sapiens RAD51-like 1 (S. 
cerevisiae) (RAD51L1), transcript 
variant 3, mRNA. 
5.85 -1.13 0.0045 
7136 TNNI2 Homo sapiens troponin I type 2 (skeletal, fast) (TNNI2), mRNA. 5.81 4.02 0.0357 
146723 C17orf77 Homo sapiens chromosome 17 open reading frame 77 (C17orf77), mRNA. 5.80 -1.99 0.0297 
1301 COL11A1 
Homo sapiens collagen, type XI, alpha 
1 (COL11A1), transcript variant B, 
mRNA. 
5.70 -2.16 0.0014 
7005 TEAD3 Homo sapiens TEA domain family member 3 (TEAD3), mRNA. 5.69 3.56 0.0010 
3339 HSPG2 Homo sapiens heparan sulfate proteoglycan 2 (HSPG2), mRNA. 5.67 -1.07 0.0087 
54596 L1TD1 
Homo sapiens LINE-1 type 
transposase domain containing 1 
(L1TD1), mRNA. 
5.65 2.12 0.0042 
4170 MCL1 
Homo sapiens myeloid cell leukemia 
sequence 1 (BCL2-related) (MCL1), 
transcript variant 1, mRNA. 
5.65 2.10 0.0006 
4017 LOXL2 Homo sapiens lysyl oxidase-like 2 (LOXL2), mRNA. 5.64 -1.10 0.0087 
64061 TSPYL2 Homo sapiens TSPY-like 2 (TSPYL2), mRNA. 5.61 -1.37 0.00001 
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767562 SNORD113-2 
Homo sapiens small nucleolar RNA, 
C/D box 113-2 (SNORD113-2), small 
nucleolar RNA. 
5.60 2.92 0.00002 
5329 PLAUR 
Homo sapiens plasminogen activator, 
urokinase receptor (PLAUR), 
transcript variant 1, mRNA. 
5.59 1.63 0.0176 
407018 MIR27A Homo sapiens microRNA 27a (MIR27A), microRNA. 5.59 -1.08 0.0006 
1000 CDH2 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) (CDH2), mRNA. 5.54 1.36 0.0016 
115653 KIR3DL3 
Homo sapiens killer cell 
immunoglobulin-like receptor, three 
domains, long cytoplasmic tail, 3 
(KIR3DL3), mRNA. 
5.53 1.39 0.0038 
6876 TAGLN Homo sapiens transgelin (TAGLN), transcript variant 1, mRNA. 5.52 -1.00 0.0053 
767577 SNORD114-1 
Homo sapiens small nucleolar RNA, 
C/D box 114-1 (SNORD114-1), small 
nucleolar RNA. 
5.52 3.10 0.0008 
4969 OGN Homo sapiens osteoglycin (OGN), transcript variant 3, mRNA. 5.51 2.32 0.0018 
5318 PKP2 Homo sapiens plakophilin 2 (PKP2), transcript variant 2a, mRNA. 5.44 2.38 0.0231 
767563 SNORD113-3 
Homo sapiens small nucleolar RNA, 
C/D box 113-3 (SNORD113-3), small 
nucleolar RNA. 
5.43 2.86 0.0002 
23598 PATZ1 
Homo sapiens POZ (BTB) and AT 
hook containing zinc finger 1 (PATZ1), 
transcript variant 2, mRNA. 
5.43 1.17 0.0311 
9590 AKAP12 
Homo sapiens A kinase (PRKA) 
anchor protein (gravin) 12 (AKAP12), 
transcript variant 2, mRNA. 
5.42 2.43 0.0001 
4739 NEDD9 
Homo sapiens neural precursor cell 
expressed, developmentally down-
regulated 9 (NEDD9), transcript 
variant 2, mRNA. 
5.41 2.06 0.0015 
8600 TNFSF11 
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 11 
(TNFSF11), transcript variant 1, 
mRNA. 
5.41 2.45 0.0004 
343450 KCNT2 
Homo sapiens potassium channel, 
subfamily T, member 2 (KCNT2), 
mRNA. 
5.39 2.91 0.0004 
3164 NR4A1 
Homo sapiens nuclear receptor 
subfamily 4, group A, member 1 
(NR4A1), transcript variant 3, mRNA. 
5.38 -1.98 0.0191 
677766 SCARNA2 
Homo sapiens small Cajal body-
specific RNA 2 (SCARNA2), guide 
RNA. 
5.36 2.09 0.0006 
2752 GLUL 
Homo sapiens glutamate-ammonia 
ligase (glutamine synthetase) (GLUL), 
transcript variant 1, mRNA. 
5.36 -1.05 0.0008 
861 RUNX1 
Homo sapiens runt-related 
transcription factor 1 (acute myeloid 
leukemia 1; aml1 oncogene) (RUNX1), 
transcript variant 2, mRNA. 
5.35 2.45 0.0015 
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1806 DPYD 
Homo sapiens dihydropyrimidine 
dehydrogenase (DPYD), transcript 
variant 1, mRNA. 
5.34 2.64 0.00002 
10406 WFDC2 
Homo sapiens WAP four-disulfide core 
domain 2 (WFDC2), transcript variant 
5, mRNA. 
5.32 1.08 0.0055 
653604 LOC653604 
PREDICTED: Homo sapiens similar to 
H3 histone, family 2 isoform 2 
(LOC653604), mRNA. 
5.32 2.28 0.0018 
767568 SNORD113-8 
Homo sapiens small nucleolar RNA, 
C/D box 113-8 (SNORD113-8), small 
nucleolar RNA. 
5.32 2.60 0.0002 
8013 NR4A3 
Homo sapiens nuclear receptor 
subfamily 4, group A, member 3 
(NR4A3), transcript variant 2, mRNA. 
5.32 1.53 0.0006 
53942 CNTN5 Homo sapiens contactin 5 (CNTN5), transcript variant 2, mRNA. 5.30 1.20 0.0109 
11030 RBPMS 
Homo sapiens RNA binding protein 
with multiple splicing (RBPMS), 
transcript variant 1, mRNA. 
5.27 2.56 0.0005 
57467 HHATL Homo sapiens hedgehog acyltransferase-like (HHATL), mRNA. 5.27 3.78 0.0081 
5101 PCDH9 Homo sapiens protocadherin 9 (PCDH9), transcript variant 1, mRNA. 5.24 2.16 0.0003 
26022 TMEM98 
Homo sapiens transmembrane protein 
98 (TMEM98), transcript variant 1, 
mRNA. 
5.22 1.74 0.0228 
23034 SAMD4A 
Homo sapiens sterile alpha motif 
domain containing 4A (SAMD4A), 
mRNA. 
5.22 -1.23 0.0138 
3754 KCNF1 
Homo sapiens potassium voltage-
gated channel, subfamily F, member 1 
(KCNF1), mRNA. 
5.22 1.57 0.0393 
55365 TMEM176A 
Homo sapiens transmembrane protein 
176A (TMEM176A), mRNA. 5.18 4.13 0.0039 
83953 FCAMR Homo sapiens Fc receptor, IgA, IgM, high affinity (FCAMR), mRNA. 5.18 -1.24 0.0156 
84456 L3MBTL3 
Homo sapiens l(3)mbt-like 3 
(Drosophila) (L3MBTL3), transcript 
variant 2, mRNA. 
5.17 1.25 0.0067 
22808 MRAS 
Homo sapiens muscle RAS oncogene 
homolog (MRAS), transcript variant 1, 
mRNA. 
5.17 3.24 0.0056 
140766 ADAMTS14 
Homo sapiens ADAM 
metallopeptidase with thrombospondin 
type 1 motif, 14 (ADAMTS14), 
transcript variant 2, mRNA. 
5.15 1.25 0.0308 
6001 RGS10 
Homo sapiens regulator of G-protein 
signaling 10 (RGS10), transcript 
variant 2, mRNA. 
5.14 1.66 0.0158 
9892 SNAP91 
Homo sapiens synaptosomal-
associated protein, 91kDa homolog 
(mouse) (SNAP91), mRNA. 
5.13 2.36 0.0120 
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692053 SNORD9 
Homo sapiens small nucleolar RNA, 
C/D box 9 (SNORD9), small nucleolar 
RNA. 
5.08 3.48 0.0002 
6424 SFRP4 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 5.05 2.03 0.0018 
284114 TMEM102 
Homo sapiens transmembrane protein 
102 (TMEM102), mRNA. 5.05 -1.22 0.0471 
6853 SYN1 Homo sapiens synapsin I (SYN1), transcript variant Ia, mRNA. 5.04 1.96 0.0351 
55568 GALNT10 
Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 
(GalNAc-T10) (GALNT10), transcript 
variant 1, mRNA. 
5.04 2.77 0.0018 
5250 SLC25A3 
Homo sapiens solute carrier family 25 
(mitochondrial carrier; phosphate 
carrier), member 3 (SLC25A3), 
nuclear gene encoding mitochondrial 
protein, transcript variant 3, mRNA. 
5.00 2.06 0.0234 
1610 DAO Homo sapiens D-amino-acid oxidase (DAO), mRNA. 5.00 -1.09 0.0017 
8828 NRP2 Homo sapiens neuropilin 2 (NRP2), transcript variant 1, mRNA. 5.00 2.78 0.0005 
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Supplementary Table 4.2 Selected gene list of significantly up-regulated gene transcripts 
between clinical PNI and incidental PNI on pairwise analysis. 
Entrez 
Gene  ID Symbol Name Fold change p value 
6779 STATH Homo sapiens statherin (STATH), transcript variant 2, mRNA. 21.21 0.0151 
1592 CYP26A1 
Homo sapiens cytochrome P450, family 26, 
subfamily A, polypeptide 1 (CYP26A1), transcript 
variant 2, mRNA. 
18.83 0.0055 
5542 PRB1 Homo sapiens proline-rich protein BstNI subfamily 1 (PRB1), transcript variant 3, mRNA. 16.07 0.0151 
486 FXYD2 
Homo sapiens FXYD domain containing ion 
transport regulator 2 (FXYD2), transcript variant a, 
mRNA. 
15.84 0.0038 
3569 IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 15.80 0.0078 
149954 C20orf186 Homo sapiens chromosome 20 open reading frame 186 (C20orf186), mRNA. 15.22 0.0078 
486 FXYD2 
Homo sapiens FXYD domain containing ion 
transport regulator 2 (FXYD2), transcript variant b, 
mRNA. 
14.07 0.0038 
54959 ODAM Homo sapiens odontogenic, ameloblast associated (ODAM), mRNA. 13.86 0.0279 
1300 COL10A1 Homo sapiens collagen, type X, alpha 1 (COL10A1), mRNA. 13.75 0.0026 
1469 CST1 Homo sapiens cystatin SN (CST1), mRNA. 12.70 0.0151 
54504 CPVL Homo sapiens carboxypeptidase, vitellogenic-like (CPVL), transcript variant 1, mRNA. 12.46 0.0206 
1301 COL11A1 Homo sapiens collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA. 12.34 0.0012 
146723 C17orf77 Homo sapiens chromosome 17 open reading frame 77 (C17orf77), mRNA. 11.54 0.0491 
5554 PRH1 Homo sapiens proline-rich protein HaeIII subfamily 1 (PRH1), mRNA. 11.30 0.0026 
5924 RASGRF2 Homo sapiens Ras protein-specific guanine nucleotide-releasing factor 2 (RASGRF2), mRNA. 11.12 0.0109 
3036 HAS1 Homo sapiens hyaluronan synthase 1 (HAS1), mRNA. 10.99 0.0078 
54557 SGTB Homo sapiens small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta (SGTB), mRNA. 10.96 0.0206 
3164 NR4A1 Homo sapiens nuclear receptor subfamily 4, group A, member 1 (NR4A1), transcript variant 3, mRNA. 10.66 0.0078 
4241 MFI2 
Homo sapiens antigen p97 (melanoma associated) 
identified by monoclonal antibodies 133.2 and 96.5 
(MFI2), transcript variant 1, mRNA. 
10.57 0.0206 
56164 STK31 Homo sapiens serine/threonine kinase 31 (STK31), transcript variant 2, mRNA. 10.39 0.0151 
2303 FOXC2 Homo sapiens forkhead box C2 (MFH-1, mesenchyme forkhead 1) (FOXC2), mRNA. 10.15 0.0078 
4973 OLR1 Homo sapiens oxidized low density lipoprotein (lectin-like) receptor 1 (OLR1), mRNA. 10.01 0.0018 
26582 DUX3 Homo sapiens double homeobox, 3 (DUX3), mRNA. 9.69 0.0109 
467 ATF3 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 4, mRNA. 9.46 0.0109 
1757 SARDH Homo sapiens sarcosine dehydrogenase (SARDH), mRNA. 9.22 0.0055 
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491 ATP2B2 Homo sapiens ATPase, Ca++ transporting, plasma membrane 2 (ATP2B2), transcript variant 2, mRNA. 9.19 0.0151 
2922 GRP Homo sapiens gastrin-releasing peptide (GRP), transcript variant 3, mRNA. 9.04 0.0151 
3208 HPCA Homo sapiens hippocalcin (HPCA), mRNA. 8.94 0.0018 
57537 SORCS2 Homo sapiens sortilin-related VPS10 domain containing receptor 2 (SORCS2), mRNA. 8.77 0.0078 
203260 CCDC107 Homo sapiens coiled-coil domain containing 107 (CCDC107), mRNA. 8.74 0.0026 
80028 FBXL18 Homo sapiens F-box and leucine-rich repeat protein 18 (FBXL18), mRNA. 8.71 0.0012 
152195 LOC152195 Homo sapiens hypothetical protein LOC152195 (LOC152195), mRNA. 8.40 0.0012 
5810 RAD1 Homo sapiens RAD1 homolog (S. pombe) (RAD1), transcript variant 3, mRNA. 8.34 0.0109 
10586 MAB21L2 PREDICTED: Homo sapiens mab-21-like 2 (C. elegans) (MAB21L2), mRNA. 8.23 0.0026 
3164 NR4A1 Homo sapiens nuclear receptor subfamily 4, group A, member 1 (NR4A1), transcript variant 1, mRNA. 8.05 0.0151 
10312 TCIRG1 
Homo sapiens T-cell, immune regulator 1, ATPase, 
H+ transporting, lysosomal V0 subunit A3 (TCIRG1), 
transcript variant 2, mRNA. 
7.91 0.0038 
25817 FAM19A5 
Homo sapiens family with sequence similarity 19 
(chemokine (C-C motif)-like), member A5 
(FAM19A5), transcript variant 1, mRNA. 
7.79 0.0018 
440138 ALG11 
Homo sapiens asparagine-linked glycosylation 11, 
alpha-1,2-mannosyltransferase homolog (yeast) 
(ALG11), mRNA. 
7.79 0.0055 
8877 SPHK1 Homo sapiens sphingosine kinase 1 (SPHK1), transcript variant 2, mRNA. 7.72 0.0078 
64061 TSPYL2 Homo sapiens TSPY-like 2 (TSPYL2), mRNA. 7.68 0.0012 
124857 WFIKKN2 
Homo sapiens WAP, follistatin/kazal, 
immunoglobulin, kunitz and netrin domain containing 
2 (WFIKKN2), mRNA. 
7.55 0.0026 
5996 RGS1 Homo sapiens regulator of G-protein signaling 1 (RGS1), mRNA. 7.48 0.0012 
57168 ASPHD2 Homo sapiens aspartate beta-hydroxylase domain containing 2 (ASPHD2), mRNA. 7.48 0.0078 
1470 CST2 Homo sapiens cystatin SA (CST2), mRNA. 7.47 0.0151 
10234 LRRC17 Homo sapiens leucine rich repeat containing 17 (LRRC17), transcript variant 1, mRNA. 7.41 0.0026 
4283 CXCL9 Homo sapiens chemokine (C-X-C motif) ligand 9 (CXCL9), mRNA. 7.32 0.0279 
1301 COL11A1 Homo sapiens collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA. 7.30 0.0026 
11105 PRDM7 Homo sapiens PR domain containing 7 (PRDM7), transcript variant 1, mRNA. 7.25 0.0078 
7292 TNFSF4 
Homo sapiens tumor necrosis factor (ligand) 
superfamily, member 4 (tax-transcriptionally 
activated glycoprotein 1, 34kDa) (TNFSF4), mRNA. 
7.22 0.0038 
6004 RGS16 Homo sapiens regulator of G-protein signalling 16 (RGS16), mRNA. 7.22 0.0109 
8013 NR4A3 Homo sapiens nuclear receptor subfamily 4, group A, member 3 (NR4A3), transcript variant 1, mRNA. 7.20 0.0206 
340075 ARSI Homo sapiens arylsulfatase family, member I (ARSI), mRNA. 7.11 0.0026 
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11282 MGAT4B 
Homo sapiens mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-acetylglucosaminyltransferase, isozyme 
B (MGAT4B), transcript variant 1, mRNA. 
6.99 0.0491 
5551 PRF1 Homo sapiens perforin 1 (pore forming protein) (PRF1), transcript variant 1, mRNA. 6.98 0.0151 
7052 TGM2 
Homo sapiens transglutaminase 2 (C polypeptide, 
protein-glutamine-gamma-glutamyltransferase) 
(TGM2), transcript variant 2, mRNA. 
6.84 0.0018 
4148 MATN3 Homo sapiens matrilin 3 (MATN3), mRNA. 6.81 0.0012 
441362 REXO1L2P 
Homo sapiens REX1, RNA exonuclease 1 homolog 
(S. cerevisiae)-like 2 (pseudogene) (REXO1L2P), 
non-coding RNA. 
6.80 0.0206 
253982 ASPHD1 Homo sapiens aspartate beta-hydroxylase domain containing 1 (ASPHD1), mRNA. 6.76 0.0026 
4192 MDK Homo sapiens midkine (neurite growth-promoting factor 2) (MDK), transcript variant 1, mRNA. 6.65 0.0151 
5890 RAD51L1 Homo sapiens RAD51-like 1 (S. cerevisiae) (RAD51L1), transcript variant 3, mRNA. 6.63 0.0026 
65975 STK33 Homo sapiens serine/threonine kinase 33 (STK33), mRNA. 6.57 0.0109 
83953 FCAMR Homo sapiens Fc receptor, IgA, IgM, high affinity (FCAMR), mRNA. 6.45 0.0206 
7376 NR1H2 Homo sapiens nuclear receptor subfamily 1, group H, member 2 (NR1H2), mRNA. 6.44 0.0109 
23034 SAMD4A Homo sapiens sterile alpha motif domain containing 4A (SAMD4A), mRNA. 6.42 0.0078 
2918 GRM8 Homo sapiens glutamate receptor, metabotropic 8 (GRM8), mRNA. 6.36 0.0109 
27303 RBMS3 
Homo sapiens RNA binding motif, single stranded 
interacting protein (RBMS3), transcript variant 1, 
mRNA. 
6.35 0.0109 
11272 PRR4 Homo sapiens proline rich 4 (lacrimal) (PRR4), transcript variant 1, mRNA. 6.32 0.0206 
84910 TMEM87B Homo sapiens transmembrane protein 87B (TMEM87B), mRNA. 6.27 0.0078 
2139 EYA2 Homo sapiens eyes absent homolog 2 (Drosophila) (EYA2), transcript variant 1, mRNA. 6.25 0.0151 
415116 PIM3 Homo sapiens pim-3 oncogene (PIM3), mRNA. 6.24 0.0055 
4017 LOXL2 Homo sapiens lysyl oxidase-like 2 (LOXL2), mRNA. 6.21 0.0279 
7186 TRAF2 Homo sapiens TNF receptor-associated factor 2 (TRAF2), mRNA. 6.15 0.0151 
117289 TAGAP 
Homo sapiens T-cell activation RhoGTPase 
activating protein (TAGAP), transcript variant 3, 
mRNA. 
6.14 0.0151 
399474 TMEM200B Homo sapiens transmembrane protein 200B (TMEM200B), mRNA. 6.10 0.0038 
25956 SEC31B Homo sapiens SEC31 homolog B (S. cerevisiae) (SEC31B), mRNA. 6.08 0.0109 
3671 ISLR 
Homo sapiens immunoglobulin superfamily 
containing leucine-rich repeat (ISLR), transcript 
variant 2, mRNA. 
6.07 0.0026 
407018 MIR27A Homo sapiens microRNA 27a (MIR27A), microRNA. 6.06 0.0055 
3339 HSPG2 Homo sapiens heparan sulfate proteoglycan 2 (HSPG2), mRNA. 6.04 0.0018 
8771 TNFRSF6B 
Homo sapiens tumor necrosis factor receptor 
superfamily, member 6b, decoy (TNFRSF6B), 
transcript variant M68C, mRNA. 
6.02 0.0151 
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3053 SERPIND1 Homo sapiens serpin peptidase inhibitor, clade D (heparin cofactor), member 1 (SERPIND1), mRNA. 5.96 0.0078 
222389 BEND7 Homo sapiens BEN domain containing 7 (BEND7), transcript variant 1, mRNA. 5.94 0.0372 
57158 JPH2 Homo sapiens junctophilin 2 (JPH2), transcript variant 2, mRNA. 5.93 0.0012 
339778 C2orf70 Homo sapiens chromosome 2 open reading frame 70 (C2orf70), mRNA. 5.93 0.0151 
286527 MGC39900 Homo sapiens hypothetical protein MGC39900 (MGC39900), mRNA. 5.91 0.0109 
51339 DACT1 
Homo sapiens dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis) (DACT1), transcript 
variant 1, mRNA. 
5.91 0.0018 
338069 ST7OT4 Homo sapiens ST7 overlapping transcript 4 (non-protein coding) (ST7OT4), non-coding RNA. 5.88 0.0151 
5573 PRKAR1A 
Homo sapiens protein kinase, cAMP-dependent, 
regulatory, type I, alpha (tissue specific extinguisher 
1) (PRKAR1A), transcript variant 2, mRNA. 
5.88 0.0372 
9590 AKAP12 Homo sapiens A kinase (PRKA) anchor protein (gravin) 12 (AKAP12), transcript variant 1, mRNA. 5.88 0.0038 
2042 EPHA3 Homo sapiens EPH receptor A3 (EPHA3), transcript variant 2, mRNA. 5.87 0.0078 
285033 LOC285033 Homo sapiens hypothetical protein LOC285033 (LOC285033), mRNA. 5.85 0.0055 
10572 SIVA Homo sapiens CD27-binding (Siva) protein (SIVA), transcript variant 1, mRNA. 5.70 0.0206 
11082 ESM1 Homo sapiens endothelial cell-specific molecule 1 (ESM1), mRNA. 5.61 0.0026 
2752 GLUL Homo sapiens glutamate-ammonia ligase (glutamine synthetase) (GLUL), transcript variant 1, mRNA. 5.61 0.0026 
11341 SCRG1 Homo sapiens scrapie responsive protein 1 (SCRG1), mRNA. 5.61 0.0038 
8904 CPNE1 Homo sapiens copine I (CPNE1), transcript variant 8, mRNA. 5.56 0.0038 
6876 TAGLN Homo sapiens transgelin (TAGLN), transcript variant 1, mRNA. 5.53 0.0109 
8795 TNFRSF10B 
Homo sapiens tumor necrosis factor receptor 
superfamily, member 10b (TNFRSF10B), transcript 
variant 1, mRNA. 
5.50 0.0012 
29015 SLC43A3 Homo sapiens solute carrier family 43, member 3 (SLC43A3), mRNA. 5.49 0.0206 
2581 GALC Homo sapiens galactosylceramidase (GALC), transcript variant 2, mRNA. 5.47 0.0206 
91544 UBXN11 Homo sapiens UBX domain protein 11 (UBXN11), transcript variant 2, mRNA. 5.47 0.0279 
1295 COL8A1 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 2, mRNA. 5.47 0.0055 
6299 SALL1 Homo sapiens sal-like 1 (Drosophila) (SALL1), transcript variant 1, mRNA. 5.46 0.0206 
1610 DAO Homo sapiens D-amino-acid oxidase (DAO), mRNA. 5.45 0.0055 
6424 SFRP4 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 5.42 0.0038 
84623 KIRREL3 Homo sapiens kin of IRRE like 3 (Drosophila) (KIRREL3), mRNA. 5.39 0.0109 
5644 PRSS1 Homo sapiens protease, serine, 1 (trypsin 1) (PRSS1), mRNA. 5.31 0.0109 
79674 VEPH1 Homo sapiens ventricular zone expressed PH domain homolog 1 (zebrafish) (VEPH1), mRNA. 5.28 0.0279 
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6356 CCL11 Homo sapiens chemokine (C-C motif) ligand 11 (CCL11), mRNA. 5.28 0.0372 
118611 C10orf90 Homo sapiens chromosome 10 open reading frame 90 (C10orf90), mRNA. 5.22 0.0206 
25789 C19orf4 Homo sapiens chromosome 19 open reading frame 4 (C19orf4), mRNA. 5.20 0.0038 
610 HCN2 
Homo sapiens hyperpolarization activated cyclic 
nucleotide-gated potassium channel 2 (HCN2), 
mRNA. 
5.19 0.0491 
4499 MT1M Homo sapiens metallothionein 1M (MT1M), mRNA. 5.19 0.0372 
1295 COL8A1 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 1, mRNA. 5.18 0.0012 
10572 SIVA1 Homo sapiens SIVA1, apoptosis-inducing factor (SIVA1), transcript variant 1, mRNA. 5.18 0.0151 
56286 DAD1L Homo sapiens defender against cell death 1-like (DAD1L), non-coding RNA. 5.15 0.0491 
54436 SH3TC1 Homo sapiens SH3 domain and tetratricopeptide repeats 1 (SH3TC1), mRNA. 5.13 0.0372 
92949 ADAMTSL1 Homo sapiens ADAMTS-like 1 (ADAMTSL1), transcript variant 2, mRNA. 5.12 0.0055 
51339 DACT1 Homo sapiens dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) (DACT1), mRNA. 5.12 0.0038 
348180 CTU2 
Homo sapiens cytosolic thiouridylase subunit 2 
homolog (S. pombe) (CTU2), transcript variant 2, 
mRNA. 
5.11 0.0109 
56975 FAM20C Homo sapiens family with sequence similarity 20, member C (FAM20C), mRNA. 5.09 0.0151 
56850 GRIPAP1 Homo sapiens GRIP1 associated protein 1 (GRIPAP1), transcript variant 1, mRNA. 5.09 0.0206 
2335 FN1 Homo sapiens fibronectin 1 (FN1), transcript variant 7, mRNA. 5.05 0.0012 
8013 NR4A3 Homo sapiens nuclear receptor subfamily 4, group A, member 3 (NR4A3), transcript variant 4, mRNA. 5.03 0.0491 
90427 BMF Homo sapiens Bcl2 modifying factor (BMF), transcript variant 2, mRNA. 5.02 0.0078 
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Supplementary Table 4.3 Selected gene list of significantly up-regulated gene transcripts 
between clinical PNI and SCC on pairwise analysis. 
Entrez  
Gene ID Symbol Name 
Fold 
change p value 
5284 PIGR Homo sapiens polymeric immunoglobulin receptor (PIGR), mRNA. 37.33 0.0008 
5554 PRH1 Homo sapiens proline-rich protein HaeIII subfamily 1 (PRH1), mRNA. 29.90 0.0005 
5545 PRB4 Homo sapiens proline-rich protein BstNI subfamily 4 (PRB4), mRNA. 26.36 0.0053 
57158 JPH2 Homo sapiens junctophilin 2 (JPH2), transcript variant 2, mRNA. 25.16 0.0005 
6779 STATH Homo sapiens statherin (STATH), transcript variant 2, mRNA. 20.71 0.0094 
140458 ASB5 Homo sapiens ankyrin repeat and SOCS box-containing 5 (ASB5), mRNA. 20.64 0.0053 
5555 PRH2 Homo sapiens proline-rich protein HaeIII subfamily 2 (PRH2), mRNA. 20.49 0.0343 
10586 MAB21L2 PREDICTED: Homo sapiens mab-21-like 2 (C. elegans) (MAB21L2), mRNA. 18.44 0.0011 
140458 ASB5 Homo sapiens ankyrin repeat and SOCS box-containing 5 (ASB5), mRNA. 17.42 0.0029 
486 FXYD2 
Homo sapiens FXYD domain containing 
ion transport regulator 2 (FXYD2), 
transcript variant a, mRNA. 
17.24 0.0021 
5542 PRB1 
Homo sapiens proline-rich protein BstNI 
subfamily 1 (PRB1), transcript variant 3, 
mRNA. 
15.61 0.0269 
579 BAPX1 Homo sapiens bagpipe homeobox homolog 1 (Drosophila) (BAPX1), mRNA. 15.34 0.0005 
486 FXYD2 
Homo sapiens FXYD domain containing 
ion transport regulator 2 (FXYD2), 
transcript variant b, mRNA. 
15.33 0.0029 
277 AMY1B Homo sapiens amylase, alpha 1B (salivary) (AMY1B), mRNA. 15.03 0.0011 
140683 C20orf70 Homo sapiens chromosome 20 open reading frame 70 (C20orf70), mRNA. 14.90 0.0343 
2139 EYA2 
Homo sapiens eyes absent homolog 2 
(Drosophila) (EYA2), transcript variant 1, 
mRNA. 
14.85 0.0005 
4192 MDK 
Homo sapiens midkine (neurite growth-
promoting factor 2) (MDK), transcript 
variant 1, mRNA. 
14.43 0.0005 
5544 PRB3 Homo sapiens proline-rich protein BstNI subfamily 3 (PRB3), mRNA. 14.34 0.0433 
54959 ODAM Homo sapiens odontogenic, ameloblast associated (ODAM), mRNA. 13.81 0.0209 
1300 COL10A1 Homo sapiens collagen, type X, alpha 1 (COL10A1), mRNA. 13.63 0.0011 
3164 NR4A1 
Homo sapiens nuclear receptor subfamily 
4, group A, member 1 (NR4A1), transcript 
variant 1, mRNA. 
13.41 0.0005 
491 ATP2B2 
Homo sapiens ATPase, Ca++ 
transporting, plasma membrane 2 
(ATP2B2), transcript variant 2, mRNA. 
12.91 0.0005 
4148 MATN3 Homo sapiens matrilin 3 (MATN3), mRNA. 12.60 0.0005 
27063 ANKRD1 Homo sapiens ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), mRNA. 12.22 0.0029 
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467 ATF3 
Homo sapiens activating transcription 
factor 3 (ATF3), transcript variant 4, 
mRNA. 
11.82 0.0008 
1469 CST1 Homo sapiens cystatin SN (CST1), mRNA. 11.69 0.0161 
6288 SAA1 Homo sapiens serum amyloid A1 (SAA1), transcript variant 1, mRNA. 11.19 0.0005 
2303 FOXC2 
Homo sapiens forkhead box C2 (MFH-1, 
mesenchyme forkhead 1) (FOXC2), 
mRNA. 
11.12 0.0015 
1755 DMBT1 
Homo sapiens deleted in malignant brain 
tumors 1 (DMBT1), transcript variant 2, 
mRNA. 
11.06 0.0124 
10562 OLFM4 Homo sapiens olfactomedin 4 (OLFM4), mRNA. 10.77 0.0029 
3164 NR4A1 
Homo sapiens nuclear receptor subfamily 
4, group A, member 1 (NR4A1), transcript 
variant 2, mRNA. 
10.61 0.0053 
4620 MYH2 
Homo sapiens myosin, heavy chain 2, 
skeletal muscle, adult (MYH2), transcript 
variant 1, mRNA. 
10.43 0.0161 
7292 TNFSF4 
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 4 (tax-
transcriptionally activated glycoprotein 1, 
34kDa) (TNFSF4), mRNA. 
10.03 0.0005 
1295 COL8A1 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 1, mRNA. 9.68 0.0005 
100302181 MIR1294 Homo sapiens microRNA 1294 (MIR1294), microRNA. 9.59 0.0021 
720 C4A Homo sapiens complement component 4A (Rodgers blood group) (C4A), mRNA. 9.48 0.0005 
114881 OSBPL7 
Homo sapiens oxysterol binding protein-
like 7 (OSBPL7), transcript variant 1, 
mRNA. 
9.45 0.0005 
7140 TNNT3 
Homo sapiens troponin T type 3 (skeletal, 
fast) (TNNT3), transcript variant 1, 
mRNA. 
9.18 0.0094 
2335 FN1 Homo sapiens fibronectin 1 (FN1), transcript variant 7, mRNA. 9.16 0.0005 
3671 ISLR 
Homo sapiens immunoglobulin 
superfamily containing leucine-rich repeat 
(ISLR), transcript variant 2, mRNA. 
9.02 0.0008 
25817 FAM19A5 
Homo sapiens family with sequence 
similarity 19 (chemokine (C-C motif)-like), 
member A5 (FAM19A5), transcript variant 
1, mRNA. 
8.97 0.0008 
3053 SERPIND1 
Homo sapiens serpin peptidase inhibitor, 
clade D (heparin cofactor), member 1 
(SERPIND1), mRNA. 
8.81 0.0011 
6271 S100A1 Homo sapiens S100 calcium binding protein A1 (S100A1), mRNA. 8.75 0.0011 
1831 TSC22D3 
Homo sapiens TSC22 domain family, 
member 3 (TSC22D3), transcript variant 
2, mRNA. 
8.62 0.0005 
6424 SFRP4 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 8.49 0.0008 
1592 CYP26A1 
Homo sapiens cytochrome P450, family 
26, subfamily A, polypeptide 1 
(CYP26A1), transcript variant 2, mRNA. 
8.36 0.0269 
51280 GOLM1 Homo sapiens golgi membrane protein 1 (GOLM1), transcript variant 2, mRNA. 8.30 0.0008 
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27295 PDLIM3 Homo sapiens PDZ and LIM domain 3 (PDLIM3), mRNA. 8.23 0.0015 
55898 UNC45A 
Homo sapiens unc-45 homolog A (C. 
elegans) (UNC45A), transcript variant 3, 
mRNA. 
8.23 0.0094 
5573 PRKAR1A 
Homo sapiens protein kinase, cAMP-
dependent, regulatory, type I, alpha 
(tissue specific extinguisher 1) 
(PRKAR1A), transcript variant 2, mRNA. 
7.96 0.0094 
10234 LRRC17 
Homo sapiens leucine rich repeat 
containing 17 (LRRC17), transcript 
variant 1, mRNA. 
7.83 0.0005 
4504 MT3 Homo sapiens metallothionein 3 (MT3), mRNA. 7.82 0.0161 
27295 PDLIM3 Homo sapiens PDZ and LIM domain 3 (PDLIM3), mRNA. 7.74 0.0008 
677840 SNORA71D 
Homo sapiens small nucleolar RNA, 
H/ACA box 71D (SNORA71D), small 
nucleolar RNA. 
7.66 0.0005 
1187 CLCNKA Homo sapiens chloride channel Ka (CLCNKA), transcript variant 1, mRNA. 7.65 0.0039 
81099 OR4F17 
Homo sapiens olfactory receptor, family 
4, subfamily F, member 17 (OR4F17), 
mRNA. 
7.56 0.0039 
222389 BEND7 Homo sapiens BEN domain containing 7 (BEND7), transcript variant 1, mRNA. 7.54 0.0015 
167 CRISP1 
Homo sapiens cysteine-rich secretory 
protein 1 (CRISP1), transcript variant 1, 
mRNA. 
7.53 0.0029 
339778 C2orf70 Homo sapiens chromosome 2 open reading frame 70 (C2orf70), mRNA. 7.50 0.0053 
23764 MAFF 
Homo sapiens v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog F 
(avian) (MAFF), transcript variant 2, 
mRNA. 
7.35 0.0008 
1470 CST2 Homo sapiens cystatin SA (CST2), mRNA. 7.29 0.0029 
3778 KCNMA1 
Homo sapiens potassium large 
conductance calcium-activated channel, 
subfamily M, alpha member 1 (KCNMA1), 
transcript variant 1, mRNA. 
7.14 0.0005 
10085 EDIL3 
Homo sapiens EGF-like repeats and 
discoidin I-like domains 3 (EDIL3), 
mRNA. 
7.11 0.0005 
1756 DMD Homo sapiens dystrophin (DMD), transcript variant Dp427m, mRNA. 6.96 0.0039 
8708 B3GALT1 
Homo sapiens UDP-Gal:betaGlcNAc beta 
1,3-galactosyltransferase, polypeptide 1 
(B3GALT1), mRNA. 
6.91 0.0005 
91828 C14orf73 Homo sapiens chromosome 14 open reading frame 73 (C14orf73), mRNA. 6.88 0.0015 
  
BP873537 Sugano cDNA library, 
embryonal kidney Homo sapiens cDNA 
clone HKR13896, mRNA sequence 
6.87 0.0005 
2669 GEM 
Homo sapiens GTP binding protein 
overexpressed in skeletal muscle (GEM), 
transcript variant 1, mRNA. 
6.82 0.0005 
4837 NNMT Homo sapiens nicotinamide N-methyltransferase (NNMT), mRNA. 6.79 0.0005 
54557 SGTB 
Homo sapiens small glutamine-rich 
tetratricopeptide repeat (TPR)-containing, 
beta (SGTB), mRNA. 
6.78 0.0124 
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11082 ESM1 Homo sapiens endothelial cell-specific molecule 1 (ESM1), mRNA. 6.71 0.0011 
7003 TEAD1 
Homo sapiens TEA domain family 
member 1 (SV40 transcriptional enhancer 
factor) (TEAD1), mRNA. 
6.71 0.0008 
7052 TGM2 
Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), transcript 
variant 2, mRNA. 
6.70 0.0015 
114899 C1QTNF3 
Homo sapiens C1q and tumor necrosis 
factor related protein 3 (C1QTNF3), 
transcript variant 2, mRNA. 
6.65 0.0053 
761 CA3 Homo sapiens carbonic anhydrase III, muscle specific (CA3), mRNA. 6.64 0.0209 
51339 DACT1 
Homo sapiens dapper, antagonist of 
beta-catenin, homolog 1 (Xenopus laevis) 
(DACT1), transcript variant 1, mRNA. 
6.63 0.0015 
126364 LRRC25 Homo sapiens leucine rich repeat containing 25 (LRRC25), mRNA. 6.61 0.0433 
467 ATF3 
Homo sapiens activating transcription 
factor 3 (ATF3), transcript variant 4, 
mRNA. 
6.58 0.0021 
3108 HLA-DMA 
Homo sapiens major histocompatibility 
complex, class II, DM alpha (HLA-DMA), 
mRNA. 
6.56 0.0011 
3784 KCNQ1 
Homo sapiens potassium voltage-gated 
channel, KQT-like subfamily, member 1 
(KCNQ1), transcript variant 1, mRNA. 
6.55 0.0015 
340075 ARSI Homo sapiens arylsulfatase family, member I (ARSI), mRNA. 6.55 0.0053 
285126 DNAJC5G 
Homo sapiens DnaJ (Hsp40) homolog, 
subfamily C, member 5 gamma 
(DNAJC5G), mRNA. 
6.46 0.0021 
10841 FTCD 
Homo sapiens formiminotransferase 
cyclodeaminase (FTCD), transcript 
variant A, mRNA. 
6.44 0.0071 
4241 MFI2 
Homo sapiens antigen p97 (melanoma 
associated) identified by monoclonal 
antibodies 133.2 and 96.5 (MFI2), 
transcript variant 1, mRNA. 
6.42 0.0021 
2042 EPHA3 Homo sapiens EPH receptor A3 (EPHA3), transcript variant 2, mRNA. 6.31 0.0011 
1301 COL11A1 Homo sapiens collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA. 6.28 0.0015 
5915 RARB Homo sapiens retinoic acid receptor, beta (RARB), transcript variant 1, mRNA. 6.27 0.0039 
10501 SEMA6B 
Homo sapiens sema domain, 
transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6B 
(SEMA6B), mRNA. 
6.27 0.0011 
26582 DUX3 Homo sapiens double homeobox, 3 (DUX3), mRNA. 6.22 0.0053 
11105 PRDM7 Homo sapiens PR domain containing 7 (PRDM7), transcript variant 1, mRNA. 6.19 0.0021 
276 AMY1A 
Homo sapiens amylase, alpha 1A 
(salivary) (AMY1A), transcript variant 2, 
mRNA. 
6.16 0.0071 
285033 LOC285033 Homo sapiens hypothetical protein LOC285033 (LOC285033), mRNA. 6.14 0.0005 
339122 RAB43 Homo sapiens RAB43, member RAS oncogene family (RAB43), mRNA. 6.07 0.0011 
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93653 ST7OT1 
Homo sapiens ST7 overlapping transcript 
1 (non-protein coding) (ST7OT1), 
antisense RNA. 
6.07 0.0011 
440073 IQSEC3 Homo sapiens IQ motif and Sec7 domain 3 (IQSEC3), mRNA. 6.04 0.0005 
7052 TGM2 
Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), transcript 
variant 2, mRNA. 
6.00 0.0021 
60468 BACH2 
Homo sapiens BTB and CNC homology 
1, basic leucine zipper transcription factor 
2 (BACH2), mRNA. 
6.00 0.0094 
5339 PLEC1 
Homo sapiens plectin 1, intermediate 
filament binding protein 500kDa (PLEC1), 
transcript variant 3, mRNA. 
5.99 0.0071 
349136 WDR86 Homo sapiens WD repeat domain 86 (WDR86), mRNA. 5.98 0.0005 
53616 ADAM22 
Homo sapiens ADAM metallopeptidase 
domain 22 (ADAM22), transcript variant 
1, mRNA. 
5.97 0.0008 
8532 CPZ Homo sapiens carboxypeptidase Z (CPZ), transcript variant 1, mRNA. 5.93 0.0071 
7169 TPM2 Homo sapiens tropomyosin 2 (beta) (TPM2), transcript variant 1, mRNA. 5.92 0.0039 
8048 CSRP3 
Homo sapiens cysteine and glycine-rich 
protein 3 (cardiac LIM protein) (CSRP3), 
mRNA. 
5.91 0.0161 
81849 ST6GALNAC5 
Homo sapiens ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-galactosyl-1, 3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 5 (ST6GALNAC5), 
mRNA. 
5.90 0.0053 
2905 GRIN2C 
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 2C 
(GRIN2C), mRNA. 
5.89 0.0053 
112 ADCY6 Homo sapiens adenylate cyclase 6 (ADCY6), transcript variant 2, mRNA. 5.88 0.0005 
440083 PRB2 Homo sapiens proline-rich protein BstNI subfamily 2 (PRB2), mRNA. 5.85 0.0433 
6588 SLN Homo sapiens sarcolipin (SLN), mRNA. 5.85 0.0124 
5890 RAD51L1 
Homo sapiens RAD51-like 1 (S. 
cerevisiae) (RAD51L1), transcript variant 
3, mRNA. 
5.85 0.0005 
7136 TNNI2 Homo sapiens troponin I type 2 (skeletal, fast) (TNNI2), mRNA. 5.81 0.0053 
4327 MMP19 Homo sapiens matrix metallopeptidase 19 (MMP19), transcript variant 2, mRNA. 5.79 0.0209 
3090 HIC1 Homo sapiens hypermethylated in cancer 1 (HIC1), transcript variant 2, mRNA. 5.73 0.0094 
1301 COL11A1 Homo sapiens collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA. 5.70 0.0029 
7005 TEAD3 Homo sapiens TEA domain family member 3 (TEAD3), mRNA. 5.69 0.0011 
3339 HSPG2 Homo sapiens heparan sulfate proteoglycan 2 (HSPG2), mRNA. 5.67 0.0005 
54596 L1TD1 Homo sapiens LINE-1 type transposase domain containing 1 (L1TD1), mRNA. 5.65 0.0015 
4170 MCL1 
Homo sapiens myeloid cell leukemia 
sequence 1 (BCL2-related) (MCL1), 
transcript variant 1, mRNA. 
5.65 0.0008 
4017 LOXL2 Homo sapiens lysyl oxidase-like 2 5.64 0.0124 
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(LOXL2), mRNA. 
64061 TSPYL2 Homo sapiens TSPY-like 2 (TSPYL2), mRNA. 5.61 0.0005 
767562 SNORD113-2 
Homo sapiens small nucleolar RNA, C/D 
box 113-2 (SNORD113-2), small 
nucleolar RNA. 
5.60 0.0005 
84935 C13orf33 Homo sapiens chromosome 13 open reading frame 33 (C13orf33), mRNA. 5.60 0.0071 
5329 PLAUR 
Homo sapiens plasminogen activator, 
urokinase receptor (PLAUR), transcript 
variant 1, mRNA. 
5.59 0.0015 
407018 MIR27A Homo sapiens microRNA 27a (MIR27A), microRNA. 5.59 0.0053 
727936 GXYLT2 Homo sapiens glucoside xylosyltransferase 2 (GXYLT2), mRNA. 5.59 0.0161 
1000 CDH2 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) (CDH2), mRNA. 5.54 0.0021 
115653 KIR3DL3 
Homo sapiens killer cell immunoglobulin-
like receptor, three domains, long 
cytoplasmic tail, 3 (KIR3DL3), mRNA. 
5.53 0.0039 
6876 TAGLN Homo sapiens transgelin (TAGLN), transcript variant 1, mRNA. 5.52 0.0039 
767577 SNORD114-1 
Homo sapiens small nucleolar RNA, C/D 
box 114-1 (SNORD114-1), small 
nucleolar RNA. 
5.52 0.0008 
10580 SORBS1 
Homo sapiens sorbin and SH3 domain 
containing 1 (SORBS1), transcript variant 
3, mRNA. 
5.52 0.0124 
4969 OGN Homo sapiens osteoglycin (OGN), transcript variant 3, mRNA. 5.51 0.0008 
5318 PKP2 Homo sapiens plakophilin 2 (PKP2), transcript variant 2a, mRNA. 5.44 0.0029 
767563 SNORD113-3 
Homo sapiens small nucleolar RNA, C/D 
box 113-3 (SNORD113-3), small 
nucleolar RNA. 
5.43 0.0005 
23598 PATZ1 
Homo sapiens POZ (BTB) and AT hook 
containing zinc finger 1 (PATZ1), 
transcript variant 2, mRNA. 
5.43 0.0005 
4606 MYBPC2 Homo sapiens myosin binding protein C, fast type (MYBPC2), mRNA. 5.42 0.0094 
9590 AKAP12 
Homo sapiens A kinase (PRKA) anchor 
protein (gravin) 12 (AKAP12), transcript 
variant 2, mRNA. 
5.42 0.0005 
4739 NEDD9 
Homo sapiens neural precursor cell 
expressed, developmentally down-
regulated 9 (NEDD9), transcript variant 2, 
mRNA. 
5.41 0.0005 
8600 TNFSF11 
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 11 
(TNFSF11), transcript variant 1, mRNA. 
5.41 0.0008 
8643 PTCH2 Homo sapiens patched homolog 2 (Drosophila) (PTCH2), mRNA. 5.40 0.0433 
343450 KCNT2 Homo sapiens potassium channel, subfamily T, member 2 (KCNT2), mRNA. 5.39 0.0008 
3164 NR4A1 
Homo sapiens nuclear receptor subfamily 
4, group A, member 1 (NR4A1), transcript 
variant 3, mRNA. 
5.38 0.0039 
677766 SCARNA2 Homo sapiens small Cajal body-specific RNA 2 (SCARNA2), guide RNA. 5.36 0.0005 
2752 GLUL 
Homo sapiens glutamate-ammonia ligase 
(glutamine synthetase) (GLUL), transcript 
variant 1, mRNA. 
5.36 0.0005 
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861 RUNX1 
Homo sapiens runt-related transcription 
factor 1 (acute myeloid leukemia 1; aml1 
oncogene) (RUNX1), transcript variant 2, 
mRNA. 
5.35 0.0011 
1806 DPYD 
Homo sapiens dihydropyrimidine 
dehydrogenase (DPYD), transcript 
variant 1, mRNA. 
5.34 0.0005 
92747 C20orf114 Homo sapiens chromosome 20 open reading frame 114 (C20orf114), mRNA. 5.33 0.0124 
10406 WFDC2 
Homo sapiens WAP four-disulfide core 
domain 2 (WFDC2), transcript variant 5, 
mRNA. 
5.32 0.0029 
653604 LOC653604 
PREDICTED: Homo sapiens similar to 
H3 histone, family 2 isoform 2 
(LOC653604), mRNA. 
5.32 0.0008 
767568 SNORD113-8 
Homo sapiens small nucleolar RNA, C/D 
box 113-8 (SNORD113-8), small 
nucleolar RNA. 
5.32 0.0005 
8013 NR4A3 
Homo sapiens nuclear receptor subfamily 
4, group A, member 3 (NR4A3), transcript 
variant 2, mRNA. 
5.32 0.0005 
53942 CNTN5 Homo sapiens contactin 5 (CNTN5), transcript variant 2, mRNA. 5.30 0.0161 
94025 MUC16 Homo sapiens mucin 16, cell surface associated (MUC16), mRNA. 5.29 0.0343 
11030 RBPMS 
Homo sapiens RNA binding protein with 
multiple splicing (RBPMS), transcript 
variant 1, mRNA. 
5.27 0.0008 
57467 HHATL Homo sapiens hedgehog acyltransferase-like (HHATL), mRNA. 5.27 0.0015 
5101 PCDH9 Homo sapiens protocadherin 9 (PCDH9), transcript variant 1, mRNA. 5.24 0.0005 
26022 TMEM98 Homo sapiens transmembrane protein 98 (TMEM98), transcript variant 1, mRNA. 5.22 0.0005 
23034 SAMD4A Homo sapiens sterile alpha motif domain containing 4A (SAMD4A), mRNA. 5.22 0.0011 
3754 KCNF1 
Homo sapiens potassium voltage-gated 
channel, subfamily F, member 1 
(KCNF1), mRNA. 
5.22 0.0094 
55365 TMEM176A Homo sapiens transmembrane protein 176A (TMEM176A), mRNA. 5.18 0.0015 
83953 FCAMR Homo sapiens Fc receptor, IgA, IgM, high affinity (FCAMR), mRNA. 5.18 0.0269 
84456 L3MBTL3 Homo sapiens l(3)mbt-like 3 (Drosophila) (L3MBTL3), transcript variant 2, mRNA. 5.17 0.0011 
22808 MRAS 
Homo sapiens muscle RAS oncogene 
homolog (MRAS), transcript variant 1, 
mRNA. 
5.17 0.0021 
6299 SALL1 Homo sapiens sal-like 1 (Drosophila) (SALL1), transcript variant 1, mRNA. 5.17 0.0071 
140766 ADAMTS14 
Homo sapiens ADAM metallopeptidase 
with thrombospondin type 1 motif, 14 
(ADAMTS14), transcript variant 2, mRNA. 
5.15 0.0053 
6001 RGS10 
Homo sapiens regulator of G-protein 
signaling 10 (RGS10), transcript variant 
2, mRNA. 
5.14 0.0015 
9892 SNAP91 
Homo sapiens synaptosomal-associated 
protein, 91kDa homolog (mouse) 
(SNAP91), mRNA. 
5.13 0.0011 
692053 SNORD9 Homo sapiens small nucleolar RNA, C/D box 9 (SNORD9), small nucleolar RNA. 5.08 0.0008 
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6424 SFRP4 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 5.05 0.0005 
284114 TMEM102 Homo sapiens transmembrane protein 102 (TMEM102), mRNA. 5.05 0.0433 
6853 SYN1 Homo sapiens synapsin I (SYN1), transcript variant Ia, mRNA. 5.04 0.0071 
55568 GALNT10 
Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 
(GalNAc-T10) (GALNT10), transcript 
variant 1, mRNA. 
5.04 0.0005 
117283 IHPK3 Homo sapiens inositol hexaphosphate kinase 3 (IHPK3), mRNA. 5.01 0.0269 
5250 SLC25A3 
Homo sapiens solute carrier family 25 
(mitochondrial carrier; phosphate carrier), 
member 3 (SLC25A3), nuclear gene 
encoding mitochondrial protein, transcript 
variant 3, mRNA. 
5.00 0.0029 
1610 DAO Homo sapiens D-amino-acid oxidase (DAO), mRNA. 5.00 0.0039 
8828 NRP2 Homo sapiens neuropilin 2 (NRP2), transcript variant 1, mRNA. 5.00 0.0005 
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Supplementary Table 4.4 Selected gene list of significantly up-regulated gene transcripts 
between incidental PNI and SCC on pairwise analysis. 
Entrez 
Gene  ID Symbol Name 
Fold 
change p value 
126364 LRRC25 Homo sapiens leucine rich repeat containing 25 (LRRC25), mRNA. 7.60 0.0229 
10562 OLFM4 Homo sapiens olfactomedin 4 (OLFM4), mRNA. 7.53 0.0026 
56651 C18orf2 Homo sapiens chromosome 18 open reading frame 2 (C18orf2), transcript variant 4, non-coding RNA. 5.93 0.0229 
5339 PLEC1 Homo sapiens plectin 1, intermediate filament binding protein 500kDa (PLEC1), transcript variant 3, mRNA. 5.88 0.0009 
7106 TSPAN4 Homo sapiens tetraspanin 4 (TSPAN4), transcript variant 6, mRNA. 5.67 0.0129 
5284 PIGR Homo sapiens polymeric immunoglobulin receptor (PIGR), mRNA. 5.64 0.0390 
7003 TEAD1 Homo sapiens TEA domain family member 1 (SV40 transcriptional enhancer factor) (TEAD1), mRNA. 5.25 0.0012 
6258 RXRG Homo sapiens retinoid X receptor, gamma (RXRG), transcript variant 1, mRNA. 5.22 0.0018 
677840 SNORA71D Homo sapiens small nucleolar RNA, H/ACA box 71D (SNORA71D), small nucleolar RNA. 5.04 0.0009 
3670 ISL1 Homo sapiens ISL1 transcription factor, LIM/homeodomain, (islet-1) (ISL1), mRNA. 4.99 0.0095 
3816 KLK1 Homo sapiens kallikrein 1 (KLK1), mRNA. 4.88 0.0095 
4232 MEST Homo sapiens mesoderm specific transcript homolog (mouse) (MEST), transcript variant 1, mRNA. 4.81 0.0036 
8578 SCARF1 Homo sapiens scavenger receptor class F, member 1 (SCARF1), transcript variant 3, mRNA. 4.77 0.0095 
22905 EPN2 Homo sapiens epsin 2 (EPN2), transcript variant 2, mRNA. 4.77 0.0070 
487 ATP2A1 
Homo sapiens ATPase, Ca++ transporting, cardiac 
muscle, fast twitch 1 (ATP2A1), transcript variant a, 
mRNA. 
4.75 0.0300 
114905 C1QTNF7 Homo sapiens C1q and tumor necrosis factor related protein 7 (C1QTNF7), mRNA. 4.72 0.0012 
212 ALAS2 
Homo sapiens aminolevulinate, delta-, synthase 2 
(ALAS2), nuclear gene encoding mitochondrial protein, 
transcript variant 3, mRNA. 
4.57 0.0390 
150084 IGSF5 Homo sapiens immunoglobulin superfamily, member 5 (IGSF5), mRNA. 4.55 0.0009 
10501 SEMA6B 
Homo sapiens sema domain, transmembrane domain 
(TM), and cytoplasmic domain, (semaphorin) 6B 
(SEMA6B), mRNA. 
4.51 0.0036 
166348 KBTBD12 Homo sapiens kelch repeat and BTB (POZ) domain containing 12 (KBTBD12), mRNA. 4.44 0.0172 
100313914 MIR548J Homo sapiens microRNA 548j (MIR548J), microRNA. 4.32 0.0050 
25803 SPDEF Homo sapiens SAM pointed domain containing ets transcription factor (SPDEF), mRNA. 4.31 0.0300 
54869 EPS8L1 Homo sapiens EPS8-like 1 (EPS8L1), transcript variant 1, mRNA. 4.25 0.0070 
57158 JPH2 Homo sapiens junctophilin 2 (JPH2), transcript variant 2, mRNA. 4.24 0.0229 
353189 SLCO4C1 Homo sapiens solute carrier organic anion transporter family, member 4C1 (SLCO4C1), mRNA. 4.21 0.0026 
60439 TTTY2 Homo sapiens testis-specific transcript, Y-linked 2 (TTTY2) on chromosome Y. 4.20 0.0300 
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157855 KCNU1 Homo sapiens potassium channel, subfamily U, member 1 (KCNU1), mRNA. 4.19 0.0095 
6271 S100A1 Homo sapiens S100 calcium binding protein A1 (S100A1), mRNA. 4.17 0.0129 
55365 TMEM176A Homo sapiens transmembrane protein 176A (TMEM176A), mRNA. 4.13 0.0095 
23415 KCNH4 Homo sapiens potassium voltage-gated channel, subfamily H (eag-related), member 4 (KCNH4), mRNA. 4.12 0.0036 
64081 PBLD Homo sapiens phenazine biosynthesis-like protein domain containing (PBLD), transcript variant 2, mRNA. 4.07 0.0036 
796 CALCA Homo sapiens calcitonin-related polypeptide alpha (CALCA), transcript variant 3, mRNA. 4.05 0.0050 
54578 UGT1A6 Homo sapiens UDP glucuronosyltransferase 1 family, polypeptide A6 (UGT1A6), transcript variant 1, mRNA. 4.03 0.0229 
7136 TNNI2 Homo sapiens troponin I type 2 (skeletal, fast) (TNNI2), mRNA. 4.02 0.0390 
50617 ATP6V0A4 Homo sapiens ATPase, H+ transporting, lysosomal V0 subunit a4 (ATP6V0A4), transcript variant 1, mRNA. 4.02 0.0229 
2934 GSN Homo sapiens gelsolin (amyloidosis, Finnish type) (GSN), transcript variant 1, mRNA. 4.00 0.0070 
4916 NTRK3 Homo sapiens neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), transcript variant 2, mRNA. 3.91 0.0070 
677837 SNORA60 Homo sapiens small nucleolar RNA, H/ACA box 60 (SNORA60), small nucleolar RNA. 3.89 0.0021 
55901 THSD1 Homo sapiens thrombospondin, type I, domain containing 1 (THSD1), transcript variant 2, mRNA. 3.86 0.0300 
57582 KCNT1 Homo sapiens potassium channel, subfamily T, member 1 (KCNT1), mRNA. 3.84 0.0129 
 
 
 
 
